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Nanomaterials are becoming attractive for a variety of medical applications with over 250 
nanotechnology-based products in U.S. pharmaceutical pipelines.  Nanoparticle-based targeting 
has the potential to improve upon the limitations of conventional pharmaceuticals and increase 
the efficacy of drug delivery, therapy and imaging systems while reducing the side effects to 
healthy tissues.  Due to the unique properties at nanometer scale, metallic nanomaterials have 
increasingly garnered interest as potential agents for selective molecular targeting, imaging, 
therapy, drug delivery and therapeutic applications.  Research efforts that initially focused on 
rational design of passively delivered therapeutic system have recently progressed to the 
development of  “second-generation” systems that can actively seek out cell markers and specific 
organs or cells based on over-expressed surface markers such as antigens expressed on cancer 
cells.  This thesis reports on the development of second-generation targeted metallic-based 
therapy and diagnostic agents for potential heat-induced therapy and for magnetic resonance-
based (MR) imaging. 
Here, we have developed selectively targeted metallic nanostructures that are conjugated 
to antibodies and have demonstrated their uses in molecular targeting, multimodal imaging, and 
in thermotherapy (photothermal therapy) applications both using in vitro as well as in animal 
  
models.  Initially, we have synthesized and designed iron oxide-gold hybrid nanoparticles 
(HNPs) to make stabile water-soluble particles with suitable end functional groups that allow 
attachment of targeting antibodies.  Next, the HNPs have been tested for cytotoxicity using 
targeted colorectal cancer cell lines.  Further experiments were used to test the potential uses of 
these hybrid nanoparticles for dual functions for photothermal therapy as well as for MRI. 
 On the basis of promising in vitro results, HNPs were tested in xenograft mice to 
illuminate the ability to achieve localized particle delivery following systemic injection.  Particle 
localization was visualized by optimal fluorescence imaging and corroborated by non-invasive 
MR imaging and by histological tissue staining.  After local particle delivery, effective 
photothermal therapy application has been demonstrated where tumor damage was observed 
posttreatment.  Gold nanorods have become attractive for deep tissue in vivo photothermal 
therapy applications. We have demonstrated a novel method of coating with polyacrylate, 
resulting in stabile water-soluble nanorods.  Further, the heating capacity of nanorods solution 
and selective in vitro photothermal therapy applications has been demonstrated. 
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1.1. Introduction 
When the size of a material is reduced to the nanometer length scale (which is the length 
scale of the electronic motion that determines the material’s properties), its electronic and 
chemical properties change tremendously.  In metals, the larger surface-to-volume ratio that arise 
from size reduction makes the surface properties more dominant, giving rise to new nanoparticle 
properties.  In semiconductor nanoparticles, the property change results from quantum 
confinement of the electronic motion 1.  In noble metals the coherent collective oscillation of 
electrons in the conduction band induces large surface electric fields which significantly enhance 
the radiative properties of gold and silver nanoparticles when they interact with resonant 
electromagnetic radiation 2.  This makes the nanoparticles’ absorption crossection several orders 
of magnitude stronger than the strongest absorbing molecules 3 and the scattered light becomes 
orders of magnitude more intense than the fluorescence of organic dyes 4.  For transition metals 
such as iron oxide, the reduction of their size to nanometer scale drastically changes to material 
properties, resulting in superparamagnetic behavior.  Nanomaterials with these unique properties 
have found myriad of potential applications such as uses in catalysis owing to the high surface-
to-volume ratios 5,  uses for biochemical sensing  6,  and in making medical therapeutics 7.  This 
thesis will focus on the various biomedical applications specifically as it pertains to the uses of 
gold and iron oxide nanoparticles for imaging and therapy applications.  
Since the seventeenth century metallic nanomaterials, although not  well understood, 
have been used to decorate glass cathedrals windows giving rise to brilliant rose colors 
throughout Europe 8.  They were also used by ancient Chinese to color vases and other 
ornaments 9.  The first scientific preparation of nanoparticles is traced back to the nineteenth 
century where Faraday reported colloids of relatively monodispersed gold nanoparticles.  In past 
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several decades there has been an exponential worldwide growth of activities in this field driven 
by the excitement of understanding new science, the invention of powerful investigative tools 
such as the electron microscope, and by the potential industrial applications and the resulting 
economic impact.  Indeed, great research efforts have been devoted to the synthesis, 
characterization, and application of nanomaterials for various uses ranging from industrial-scale 
catalysis to the development of novel clinical medical technologies.  In general, nanomaterials 
are classified into three groups which are: zero-dimensional materials (commonly referred to as 
nanoparticles), with variations in shape and diameter, one-dimensional materials, (e.g. nanorod 
and nanowire), and two-dimensional materials, (e.g. nanodisks, nanobelts, and films, 
nanosheets).  The focus of this review will be on the one-dimensional materials, specifically on 
metallic nanoparticles (NPs) and their potential medical applications. 
 
1.2. Noble  Metallic Nanoparticles 
Noble metals, particularly gold, have been considered to be mystical material for its 
supposed ancient medicinal value and for its ornamental values for centuries now 10.  “Red-gold” 
used to stain glass was known to medieval artisans to be “finely-divided” gold dispersed in plain 
glass 11.  In recent decades, nanoscale gold particles have generated great excitement due to the 
potential uses in medical diagnostics, as tracers, and other biological and biomedical 
applications.  For instance, the intriguing colors and properties of gold NPs are derived from 
their unique chemical and electronic properties arising from the high surface-to-volume ratio and 
the separation in the electronic energy levels.  These properties at the nanoscale, compared to 
their bulk counterparts, not only arise from the scaling factors but are also material-dependent 
properties that vary for different materials.  In semiconductor NPs, these unique properties are 
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derived from the confinement electrons to smaller dimension to nanometer scale which is of the 
same order of magnitude as electron Bohr radius -which determines the material properties.  
Herein, several properties that make gold nanostructures unique for biomedical applications will 
be reviewed. 
 
 
1.3. Radiactive properties 
The intriguing optical properties of metal nanoparticles, as reflected by their intense 
color, are attributed to their unique interaction with incident visible light.  In the presence of the 
oscillating electromagnetic field of light, the conduction band electrons of a metal nanoparticle 
undergo a collective coherent oscillation in resonance with the frequency of light, which is 
known as surface Plasmon resonance (SPR) 12.  This oscillation induces a charge separation 
between the free electrons and the ionic metal core, which exerts a restoring Coulomb force to 
make the electrons oscillate back and forth on the particle surface resulting in a dipole oscillation 
(see Figure 1-1).  The SPR oscillation induces a strong absorption of light, as seen on the UV–vis 
spectrum, which is the origin of the intense color  in noble metal colloidal solution and was first 
explained by Mie theory 13.  Spherical gold, silver, and copper nanoparticles show a strong SPR 
band in the visible region while other metals such as iron oxide show broad and weak bands in 
the UV region 14, 15.  The origin of the red color of gold nanoparticles and surface plasmon 
resonance behavior of the spherical metal nanoparticles was first explained by Mie 13.  He solved 
Maxwell’s equation for an electromagnetic light wave interaction with a small sphere.  For 
nanoparticles much smaller than the wavelength (< 20 nm), only the dipole oscillation 
contributes significantly to the extinction cross section and thus Mie’s theory reduced to the 
following equation: 
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where V is the particle volume, x is the angular frequency of the exciting light, c is the speed of 
light, and εm and ε(ω) = ε1(ω) + i ε2(ω) are the dielectric functions of the surrounding 
medium and the material itself respectively.  The resonance condition is fulfilled when is ε1(ω) 
= -2 εm if ε2 is small or weakly dependent on ω.  But for larger nanoparticles, the light cannot 
polarize the nanoparticles homogeneously and retardation effects lead to the excitation of higher-
order modes 16.  From equation (1.1), it can be seen that the peak intensity and the position 
absorption band is dependent on the size and shape of the metal nanoparticles as well as the 
dielectric constants of the metals  and the medium surrounding the particles 17.  As the size 
increases, the absorption maximum is red shifted slightly (see Figure 1-2).  The bandwidth also 
changes when the size changes.  The intriguing colors of noble metals, reflected in the UV-Vis 
absorption spectrum, are related to their size and shape 18.  For example gold nanospheres that 
 
Figure 1-1:  A schematic illustration of the interaction of polarized light with gold nanospheres 
to form electronic coherent surface Plasmon resonance (SPR) oscillation.  The electric field (E) 
of incident light propagating along the K direction induces coherent collective oscillation of band 
electrons with respect to positively charged metallic core (ionic cluster). Gold nanospheres show 
one SPR band in the visible region [15]. 
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re 
10 nm in diameter have a maximum absorbance at 520 nm and appear red in color whereas 50-
nm gold NPs with absorbance at 560 nm appear blue in color.  The fact that colloidal gold NPs 
present different shades of color that depends on the particle size and shape have not only created 
many aesthetical applications, but have more importantly generated great interest in applications 
where tunable optical properties are desirable.  
Further, Link and El-Sayed 3 have shown that the peak bandwidth decreases with 
increasing size when the particles are less than 20 nm in diameter while bandwidth increases 
with increasing nanoparticle size for  particles larger than 20 nm (Figure 1-3, left).  They also 
found that the absorption coefficient is linearly dependent on the volume of the nanoparticles 
 
Figure 1-2: Surface Plasmon absorption spectra (left) and TEM (right) of gold nanospheres 
of different sizes. The surface Plasmon absorption is maximum is weakly dependent on 
particle size. 
  
7 
 
which is in agreement with the Mie theory 13 . When the shape of the nanoparticles changes from 
nanosphere to nanorods, the surface plasmon absorption spectrum also changes.  In the case of 
gold nanorods, electron oscillation can occur in one of the two directions depending on the 
polarization of incident light: the short and long axes.   The excitation of the surface plasmon 
oscillation along the short axis induces an absorption band in the visible region at wavelength 
similar to that of gold nanospheres (referred to as transverse band) while excitation along the 
long axis induces a much stronger absorption band in the longer wavelength region (known as 
longitudinal band) (see Figure 1-4).   Figure 1-4 shows a typical absorption spectrum of 
nanorods.  The transverse band is insensitive to the size of nanorods and the longitudinal band is 
red-shifted from the visible to near-infrared region with increasing aspect ratio (length/width).  
This optical behavior has been explained by Gans theory 19 which  explains  the optical 
properties of ellipsoid particles based on a dipole approximation.  In 
 
Figure 1-3: Left: the relationship of the absorption bandwidth with the size of the 
nanoparticles; Right: the relationship of the absorption coeffiecient with the size of the 
nanoparticles]. The bandwidth increases with decreasing nanoparticle radius in the intrinsic 
size region and also with increasing radius in the entrinsic size region as predicted by Mie 
theory. The extinction coefficients of these gold nanoparticles against their volume show a 
linear dependence [3].  
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aqueous solution, the SPR absorption maximum (λmax) is linearly proportional to the aspect ratio 
(R) by the following relationship 20:  
   λmax  95  420                 (1.2) 
This provides a means of optically tuning gold nanorods by simply varying the aspect ratio of the 
particles.  The ability to tune the absorption of nanorods is different from nanospheres for which 
the SPR only slightly red-shifts with increasing particles.  Figure 1-5 shows how the absorption 
maximum of the nanorods shifts with varying aspect ratios.  As the aspect ratio increases, the 
absorption maximum of the longitudinal band is red-shifted.  The absorption difference of the 
 
Figure 1-4: Typical surface plasmon absorption spectrum of gold nanorods.  The strong long 
wavelength band in the near infrared region around  800 nm is due to the longitudinal 
oscillation of electrons while the weak short wavelength band in the visible region around 
520 nm is due to the transverse electron oscillation. 
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longitudinal band causes the color difference of the nanorod solution.  For short nanorods with 
the longitudinal maximum lower than 700 nm, the nanorods appear blue in color. When the 
longitudinal maximum is in the range 700-800 nm, the nanorod solution are gray-greenish  in 
color while a solution with longitudinal band longer than 800 nm appear pink-brownish in color.   
Biomedical medical application of Au nanostructures originate from their surface 
plasmon resonance (SPR) effect, a strong enhancement of absorption and scattering of light 
resonant with the SPR frequency, which has been utilized for photothermal ablation treatment 
and optical imaging.  It has been reported that the strongly absorbed radiation is converted 
efficiently into heat on a picosecond time domain due to electron-phonon and phonon-phonon 
processes 21.  Thus, upon the laser irradiation at the surface plasmon absorption band, the 
nanoparticles absorb photon energy and then immediately transfer into heat energy.  One of the 
 
Figure 1-5:  The absorption spectra of gold nanorods of different aspect ratios (left) and 
corresponding TEM images of the rods with aspect ratios (a.r.) at 3, 4 and 6. 
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potential applications is to selectively cause a sharp increase on the local temperature in 
biomolecules, cells or tissues and therefore causing heat-induced damage of the surrounding 
materials or cells.  This photothermal destruction can be used for disease treatment or cancer 
therapy.  The ability to tune the SPR wavelength of Au nanorods, nanoshells and nanocages to 
the NIR region, which is commonly regarded as a ‘clear window’ for deep tissue light 
penetration, have provided additional impetus to the use of gold nanostructures for in vivo 
medical applications.   In this thesis report, the use of gold nanorods will be explored as it relates 
to cancer therapy.  
 
1.4. Magnetic Nanoparticles 
In contrast to gold nanostructures with strong optical properties, transition metals such as 
iron, cobalt, gadolinium, and nickel have minimal absorption and SPR in the visible region but 
possess uniquely strong magnetic properties at the nanometer scale.  Compared to their 
counterparts in bulk, oxides of these metals display superparamagnetic behavior, a phenomenon 
that stems from presence of single magnetic domain when particle size is reduced to the 
nanometer scale.  In magnetic bulk materials such as ferromagnets and paramagnets, there exists 
multidomain structures that consist of regions of uniform magnetization separated by domain 
walls meant to minimizes the sum energy of external magnetic field (magnetostatic energy) and 
the energy of the domain walls (see Figure 1-6).  As the volume of magnetic particle decreases, 
the size of the domains and the width of the walls are reduced until the energy cost required to 
make a domain is greater than the corresponding reduction in magnetostatic energy.  
Consequently, the small magnetic nanoparticle is no longer divided into domains but instead 
exists in a single domain, which is referred to as superparamagnetism 22.  Ferromagnetic and 
superparamagnetic materials have shown potential for various applications because can be 
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magnetized in presence in an applied magnetic field.  For ferromagnets, when an external field is 
applied the initially un-magnetized sample (M = 0 at H = 0), gradually becomes magnetized as 
applied field (H).  This magnetization process is due to the motion and growth of the magnetic 
domains; areas with the same direction of the local magnetization (see Figure 1- 7 (a)).  When 
the sample is fully magnetized in the direction of M along H, a saturation point is reached, and 
magnetization curve will not retrace along the original dashed curved when the applied field (H) 
is reduced because the domain wall displacements are irreversible.  Instead, a degree of 
magnetization is retained as domains are still aligned in the original direction of applied 
magnetic field and this is known as remnant magnetization (Mr) shown on Figure 1-7 (a).  To 
reduce magnetization M back to zero (origin), a reverse field is required, known as coercive field 
or coercivity.  Superparamagnetic materials are similar to paramagnets except that their single 
domain allows reversible wall displacements (see Figure 1-7 (b)).  When applied field (H) is 
reduced, the materials becomes fully demagnetized (magnetization, M, comes back to zero) 
without expending extra coercivity energy; materials that display this characteristic have no 
coercivity and known to be superparamagnetic.  Superparamagnetism is a size-dependent 
phenomenon.  As particle size decreases the coercivity  decreases to reach a minimum at a 
 
Figure 1-6: Schematic Representation of the reorientation of domain walls and alignment of 
magnetic moments under an externally applied magnetic field. (Wikimedia Commons) 
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threshold particle size ( typical values are 15 and 35 nm for iron and cobalt metallic particles) 
which describes the transformation from multi domain structure to single domain nature 23.  
As consequent of this unique property, superparamagnetic nanoparticles have garnered 
interest for various applications because they have no remnant magnetic field once an external 
magnetic field is removed. While cobalt, manganese, and nickel nanoparticles exhibit good 
superparamagnetic properties, their use for bioapplication has been limited because they have 
shown poor biocompatibility. The superparamagnetic iron oxide nanoparticles (SPIONs) 
composed of iron oxides; magnetite (Fe3O4) and maghemite (γ-Fe2O3) are the commonly used 
magnetic materials because of their low toxicity and the advantage that our body is designed to 
process excess iron.  Hemoglobin in our blood, for example, is an iron complex and is magnetic 
in nature.  Biocompatible SPIONs have been widely used for in vivo biomedical applications 
 
 
Figure 1-7:  Hysteresis curves of (A) ferromagnetic; (B) superparamagnetic nanoparticles. 
Comparison shows the presence of coercivity or remnant magnetism for ferromagnetic 
after applied field is reduced to zero while superparamagnets such as iron oxide show no 
remnant coercivity. 
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including uses in magnetic resonance imaging (MRI) for contrast enhancement 24, 25, tissue 
specific release of therapeutic agents 26, hyperthermia, and magnetic field assisted  radionuclide 
therapy 27.  Since the pioneering of work of Freeman et al. on the use of external magnetic field 
coupled with magnetic carriers, a variety of magnetic SPIONs carriers have been employed for  
drug delivery to specific target sites 28, 29.  The optimization of these carriers continues today 
with the objectives (i) to reduce the amount of systemic distribution of the cytotoxic drug, thus 
reduce the associated side effects, and (ii) to reduce the dosage required for more efficacious and 
localized therapy. 
Besides uses as MRI contrast agents, SPIONs are commonly used for hyperthermia 
applications where they are used as heating agents to induce cell death in tumor cells.   The use 
of hyperthermia (heat) to treat malignant tumors is an old art that has been used since ancient 
times.  In cancer thermotherapy, when particles (SPIONs) are subjected to variable magnetic 
field heat is generated due to magnetic energy losses.  SPIONs embedded around a tumor site 
and placed within an oscillating magnetic field can heat up to a temperature dependent on the 
magnetic properties of the material, the strength of the magnetic field, and the frequency of 
oscillation and the cooling capacity of the blood flow in the tumor site.  Cancer cells are 
destroyed at temperature higher than 43oC, whereas the normal cells can survive at higher 
temperatures.  Heat could be generated applying an appropriate alternating magnetic field.  An 
applied magnetic field can provide the energy to repeatedly reorient particles’ magnetic moments 
which results in magnetic energy losses (due to Néel relaxation and Brownian motion 
relaxation).  These energy losses are converted to thermal energy.  For very small magnetic 
particles such as SPIONs, heating using alternating magnetic field is primarily due to magnetic 
moment relaxation effect (Néel relaxation) which is expressed by the following equation:  
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 where τ is magnetic relaxation time, *+ is remanence of particles not affected by relaxation.  
Because of superparamagnetic materials do not have hysteresis curve (losses), the power losses 
in SPIONs are only due to relaxation losses (both Brownian and Néel).  Néel relaxation, 
magnetic relaxation time is determined by the ratio of anisotropy energy KV (K is magnetic 
anisotropy energy density, V is volume of magnetic particle core) to thermal energy kT (k is the 
Boltzmann’s constant and T is absolute temperature and is expressed as:  
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where fo (frequency factor) ~ 109 s-1.  Néel relaxation is due to the reorientation of the magnetic 
moment inside a particle while Brownian relaxation is due to reorientation of magnetic particle 
itself in the fluid.  The Néel relaxation time is controlled by the anisotropy barrier while 
Brownian’s relaxation is determined by viscous friction.  
The use of SPIONs for hyperthermia  have been shown to enhance cytotoxicity  of 
radiation and drug treatment  with brain tumor cell lines, which were then confirmed in 
hyperthermia studies in rat, rabbits and dogs 30.   Hyperthermia treatment has become common 
for the treatment of the insidious brain tumors such as glioblastoma multiforme whose feasibility 
was recently demonstrated in a phase II clinical study.  The therapy was shown to promote 
uptake of nanoparticles with no adverse effects  resulting from the therapy 31.  
    In addition to the two applications already discussed, SPIONs have found widespread 
biomedical applications.  Figure 1- 8  shows a maze of potential SPIONs uses which span areas 
in diagnosis, therapeutic, and cell and biomolecule magnetic labeling.  For these applications, 
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SPIONs are rationally designed to exhibit desired size and properties and then functionalized 
with various types of biomolecules, making them suitable for the intended applications.  While 
the focus of the thesis review dwells on the SPIONs MR imaging application, they can be easily 
designed for other applications as illustrated on Figure 1- 8.  
 
1.5. Heterofunctional Nanoparticles 
In recent years, combining SPIONs with Au to form composite multifunctional 
nanoparticles has attracted considerable attention for making platforms of therapy and 
 
Figure 1- 8:  Recent diagnostic and therapeutic applications of SPIONs [76] 
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diagnostics (theranostics) application.  The efforts were originally mostly focused on coating 
iron oxide particles with thin layer of Au, where the Au shell not only provides convenient 
anchorage sites for functionalization of biomolecules through well-established Au-thiol 
conjugation procedure but also protects SPIONs from dissolution and aggregation 32.  However, 
using this approach makes it difficult to tune the SPR wavelengths to the near-IR region which 
would limit their uses in vivo.  Reported core/shell particles usually have their SPR in the visible 
light range (from 500 to 600 nm) which limits their optical functions for in vivo applications 33.  
More recent efforts have included the rational design of dumbbell-like heterofunctional 
nanoparticles with ability to tune the properties of the individual nanoparticles where the SPR 
absorption can be tuned by changing the size and shape of Au.  Examples of bifunctional 
nanocomposites include CdSe rods surrounded by Au nanoparticles (to form CdSe-Au) which 
have been used for catalysis.  Another example is iron oxide (SPION) nanoparticle surrounded 
by size-tunable Au NPs, forming SPIONs-Au with strong magnetic and optical properties.  
These dumbbell-like SPIONs-Au nanoparticles have great potential for dual applications for MR 
imaging as well as for tunable photothermal therapy that may include in vivo therapy 
applications 34.  Other efforts have also included syntheses of individual nanoparticles followed 
by chemical conjugations to form bifunctional nanocomposites such as the formation of Au 
nanorods coated with SPIONs 35.  Figure 1-9 illustrates bifunctional SPION-Au nanoparticles 
that combine the MR imaging and photothermal therapy functions in a single device for 
theranostic applications.  Additional chemical covalent conjugations to the bifunctional particle 
composites have also been used to make dual functional particles.  For instance, the corona of 
SPIONs have been conjugated to radionuclides (18F and 11C) and used for combined 
thermotherapy and radiotherapy of recurrent and deadly glioblastoma multiforme brain 
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malignancy 36.  Other research efforts have included the attachment of near-IR fluorescent 
molecules (dye or quantum dots) to make dual imaging probes for MR and NIR imaging (MR 
imaging and optical properties).  The conjugation of molecular specific targeting agents to 
nanoparticle surface  are now ubiquitous and used to make the particle as molecular probes that 
target specific cells.  
 
 
 
 
 
 
Figure 1-9:  Bifunctional nanoparticles illustrating the preparation of multifunctional probes 
that encompass uses in MR Imaging, molecular targeting, radiotherapy, photothermal therapy 
and for X-ray based CT imaging. 
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1.6. Cancer 
Cancer is the second killer in the United States under the age of 85, only behind heart 
disease in 2010 37.  Currently, one in four deaths in the United States is due to cancer.  Nearly 
half of all men and a little over one third of all women in the United States will develop cancer 
during their lifetime. Cancer can strike people of any age; although about 77% of all cancers are 
diagnosed in people age of 55 and older 37.  Cancer arises as a result of DNA mutation or change 
which alters the normal cell replication cycles and functions. Most of the time when DNA 
becomes damaged, the body is able to repair it.  In cancer cells, the damaged DNA is not 
repaired 38.  People can inherit damaged DNA, which accounts for inherited cancers.  More 
often, though, a person’s DNA becomes damaged due to exposure to carcinogenic toxins through 
ingestion or repeated contact with toxins.  Cancer usually forms as a tumor, however, some 
cancer such as leukemia, does not form solid tumors.  Instead these cancer cells involve blood 
and blood-forming organs and circulate through other tissues where they grow.  Benign (non-
malignant) tumors are considered the least deadly form of cancer as they do not spread 
(metastasize) to other parts of the body while malignant (cancerous) tumors are metastized tumor 
cells that have entered the blood stream.  Cancer develops when cells in the body begin to grow 
out of control.  Although there are many kinds of cancers, they all start because of the out-of-
control growth of abnormal cells.  Under normal physiological conditions, cells divide and grow 
in an orderly and controlled fashion.  Instead of dying as part of a normal cell cycle, they outlive 
normal cells and continue to form new abnormal cells 39. 
 
1.7. Colorectal cancer 
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Colorectal cancer is the third most common cancer in the United States and the second 
cause of cancer death 40.  The incidence in the United States is approximately 130,000 cases per 
year and over 50,000 deaths per year result; both incidence and outcome in Europe are similar 41.  
Approximately one in every four patients is diagnosed with metastatic disease while the rest are 
treated surgically to remove benign tumors.  However even with complete tumor resection, 50% 
of all cases will develop recurrence after treatment and die within 5 years of diagnosis.  Standard 
therapies for metastatic colorectal cancer is by chemotherapy using fluororacil modulated by 
calcium folinate which prolongs the survival time between 10-14 months 42.  Colorectal 
carcinoma cells have shown high resistance to conventional therapies and as a result the 
development of novel therapies remains an active area of research.  Recent advances in the 
understanding of the molecular mechanisms underlying the development and progression of 
cancer have resulted in the discovery of new therapeutic interventions that target specific 
molecular abnormalities. The development of novel and more efficacious technologies to better 
treat metastatic colorectal cancer are currently underway.   In fact several targeted therapies 
using humanized, less immunogenic antibodies that selectively target surface biomarkers 
expressed on the cancer cells are currently under clinical testing 43, 44.   Some examples of  these 
novel therapies currently in clinical trials include:  murine IgG2a which targets Ep-CAM,  
humanized IgG1 which targets VEGF and chimeric IgG1 which targets EGFR 41.    Recent 
studies have shown that colorectal cancers express high expression of A33 antigen which is a 
transmembrane glycoprotein and a novel member of the immunoglobulin superfamily that is 
expressed in normal colonic and small bowel epithelium and in > 95% of human colon cancers.  
Immunohistochemical testing of normal and malignant tissues has shown A33 antigen 
expression to be restricted to the epithelia of the lower gastrointestinal tract and to carcinoma 
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lesions.  This antigen system has been selected as a target for clinical studies because the A33 is 
expressed homogeneously and at higher levels in 95% of metastatic colorectal cancer 45.  It is 
absent from most other human tissues and tumor types.  Owing to the fact the A33 antigen is 
primarily expressed and restricted human epithelial colon cancers, clinical efforts have identified 
A33 antigen as a potential biomarker for the selective targeting and treatment of colorectal 
cancer.  This thesis will focus on use of A33 antigen as the colorectal cancer biomarker and its 
targeting using A33 single chain antibody as used to design novel nanomaterial therapies. 
 
1.8. Cell Receptors and Targeting 
Signal transduction “talking” between cells is essential for cell growth.  The 
communication between two cells involves a molecular messenger (referred as a ligand) from the 
sender and a site (called a receptor) on the membrane surface of the cell receiving the signal.  
When the signal reaches the surface receptor, the message is passed along from the outer surface 
of the cell to the cell’s nucleus 46.  One of the most common signaling pathways involves 
receptor tyrosine kinases, which have three components: An extracellular ligand-binding domain 
receptor that is located on the cell surface and receives incoming signals; a transmembrane 
domain that crosses the cell membrane and conveys information across the cell membrane; an 
intracellular tyrosine kinase that phosphorylates (adds a phosphate group) to tyrosine 39.  In 
cancer targeting, the most important tyrosine kinase signaling networks is a group of receptors 
belonging to the “HER” family, also known as the ErbB signaling network 47.  The HER family 
of receptors consists of four main members commonly known as HER1/EGFR (ErbB1), HER2 
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4), which demonstrate homology in their kinase 
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domains, but diverge in their extracellular regions 48.  These receptors are widely expressed in all 
tissues where they regulate diverse functions such as mitogenesis, differentiation, and cell 
survival.   Different ligands and protein-protein interactions contribute to the diverse signaling 
networks that characterize each receptor which are involved, in some way, in the development of 
malignant tumors.  Some of these receptors are overexpressed and more involved than others in 
different cancers.  In all cells, some level of growth-signal transduction is normal and is part of 
the regular growth cycle.  The over-expression or activation of these signals leads to 
uncontrollable cell proliferation and thus leads to cancer.  For example, in the case of the HER2, 
over-expression results from a genetic alteration that generates multiple copies of a gene that 
encodes a growth receptor. For colorectal adenocarcinoma, A33 surface receptor is over-
expressed and thus has become important in the development of novel therapies.  
 
1.9. Antibodies (mAbs) in Cancer therapy 
Antibodies are important components of the immune system, yet they have also found 
applicability in the treatment of a number of diseases, including cancers.  In particular, 
monoclonal antibodies (mAbs) belong to a class of molecules that are specifically engineered to 
bind to targets of interest with high affinity.  Their specificity and the potential to preferentially 
bind to receptors over-expressed on tumor cells make them an attractive therapeutic approach.  
For many years, research efforts have focused on the identification of cell-surface antigens 
whose expressions are restricted to tumor cells and can be used as specific targets for 
engineering antibodies.  Originally, an ideal antigen was considered one that is preferentially 
expressed in high copies on the surface membrane of tumor cells, plays a causal role in tumor 
development, stable, and not shed or secreted to the bloodstream.   Now, recent efforts have 
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expanded to the development of antibodies that can attach to tumor vasculature by targeting 
antigens associated with the formation of new blood vessel, angiogenesis, which plays a major 
role in the development of tumors 41.   
The first mAbs engineering were derived from mouse but the immunoglobulin immune 
response in the majority of patients have limited their clinical applications. Alternative strategies 
of producing less immunogenic mAbs have been underway.  The chimeric mAbs engineered by 
replacing the mouse constast domains of the antibody with human constant domains was the 
second generation of mAbs.   Further improvement came with the creation of humanized 
antibodies that are derived from human cells or genetically engineered mice in which murine 
immunoglobulin genes have been replaced with human antibody genes 49.   The treatment 
colorectal carcinoma has benefited from the development of mAbs, many of which are currently 
in various stages of clinical testing (Table 1-1).  For instance, five antibodies are currently in 
different stages of development namely: edrecolomab (mAb 17-1A), bevacizumab (Avastin), 
cetuximab (IMC-C225), ABX-EGF and EMD 72000.   
Table 1-1:   Monoclonal antibodies as therapy for colorectal cancer [41] 
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Immunogenicity and the bulky sizes of antibodies are two main challenges with the use 
of mAbs for cancer therapy.  To overcome these drawbacks, recent efforts have expanded to the 
engineering of single chain antibodies (scFv), composed of variable heavy and light chains of 
immunoglobulin (IgG) linked by a peptide linker.  A typical molecular weight of scFv is Mr ~ 
27,000   and Mr ~ 150,000 for a whole IgG antibody.  The low molecular weight of scFv is 
advantageous because it results in rapid plasma clearance and faster tumor penetration, resulting 
in high tumor: blood ratios at early time points in animals and in humans.  The use of scFv could 
be lead to the  development of more efficacious therapies as compared to mAbs 50.  Example of 
the various scFv that have been developed for the targeting and treatment of colorectal 
carcinoma cells include: Anti-CEA scFv genetically engineered for use in radioimmunoguided 
surgery 51, and A33scFv which an analog of murine IgG2a (mAb3 A33)  currently in phase III 
trials 52.  We have recently prepared A33scFv using Pichia pastoris 53 in our Laboratory and have 
tested their efficacy for targeting in colorectal cancer cells both in vitro and recently in xenograft 
murine models. 
 
1.10. Nanotechnology in cancer Therapy 
The tremendous developments in nanotechnology have enabled the syntheses of a variety 
of nanostructures with different shapes and structures of different composites 54-56.  These 
nanostructures demonstrate unique electronic, photonic, catalytic, highly controlled and 
interesting properties as a consequence of size reduction from bulk to nanometer scale, as 
detailed in the following reviews 57, 58.  These nanoparticles exhibit similar size dimensions to 
many common biomolecules such as proteins and DNA, thus offer great possibilities for the 
integration of nanotechnology with biotechnology.  Typical applications include contrast agents 
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for disease diagnostics and therapies 58, biological labeling 59, optoelectronics 60,  and surface-
enhanced Raman scattering (SERS) 61.  The use of nanoparticles in medicine is currently one of 
most exciting developments in nanotechnology.  Their applications in drug delivery 62, 63, cancer 
cell diagnostics  64, 65 and therapeutics 66, 67 are active fields of research.  Advances in this field 
have further sparked interest in the development of multifunctional devices with combinatorial 
use for therapy and diagnostics which has been referred to as theranostics.  For instance, drug-
loaded iron oxide nanoparticles can be used as contrast agents for magnetic resonance imaging as 
well as drug delivery systems.   The applications of nanomaterials as it relates to various 
biotechnological uses geared towards improving the efficacy of disease diagnosis and therapy 
will be further reviewed in this thesis. 
 
1.11. Nanomaterials in Cancer Imaging 
1.11.1.  Magnetic resonance based Imaging 
Imaging plays a critical role in overall cancer management: in diagnostics, staging, radiation 
planning, and evaluation of treatment efficiency.  Standard clinical imaging modalities such as 
CT, MRI, and ultrasound are considered structural imaging modalities that can identify 
anatomical patterns and thus provide basic information regarding tumor localization, size, and 
spread based on endogenous contrast 68.  Magnetic resonance imaging (MRI) has become a 
valuable modality in cancer detection due to its high soft tissue contrast, spatial resolution and 
penetration depth.  It is a non-invasive technique that involves the disturbance of aligned nuclear 
protons spins in a strong magnetic field; and their realignment following an application strong 
magnetic field is used to create spatial image of soft tissue.  The MR image acquisition is 
performed by obtaining the relaxation times of sample classified as T1 or T2 relaxation times.  
Two types of relaxation times T1, or spin-lattice (longitudinal) and T2, or spin-spin (transverse), 
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determine the signal for a particular tissue.  T1-weighted images are a result of longitudinal 
relaxation time while T2-weighted images rely on the rate of transverse relaxation to give 
positive and negative contrast enhancement in the MR image, respectively 57.  MR imaging 
require the use contrast agents because the imaging modality alone is not efficient in detecting 
tumors and metastases that are smaller than 0.5 cm and they can barely distinguish between 
benign and cancerous tumors. 
Significant research in the field of medical MRI has focused on the development of 
contrast agents to improve imaging signal intensity and reduce noise.  Contrast agent research 
has focused on gadolinium (Gd)-based MRI agents due to their ability to decrease the T1 
relaxation time, thus increasing (brightening) the MR signal.  These Gd chelates are also referred 
to as T1 contrast agents because they shorten the proton relaxation time, resulting in bright 
images as compared to the surrounding tissues.  In fact there are several FDA approved products 
that are currently for medical imaging.  Some examples of FDA-approved gadolinium-based 
contrast agents for clinical applications include: gadodiamide (Omniscan®), gadobenic 
(Multihance®), and gadopentetic acid (Magnevist®). They have been utilized to enhance blood 
vessels in brain tumor imaging 69.  However, one potential drawback of using paramagnetic Gd 
chelates is that relatively high concentrations are needed to achieve a sufficient increase in 
contrast signal which increases chances of acute toxicity. 
Recent efforts have focused on developing superparamagnetic iron oxide (SPIONs) as 
alternative negative contrast enhancers for MRI due to their ability to shorten T2 relaxation 
times.  SPIONs are predominantly used as MR contrast agents because of their low toxic and 
good biocompatibility.  In fact, a number of SPIONs contrast agents are  used clinically such as 
Endorem (Feridex®), Resovist®, Sinerem®, and Combidex® which are all referred to as T2 
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contrast agents 70.  These contrast agents reduce the T2 signals of absorbing tissues, resulting in 
darker MR images.  With the aim of increasing the specificity and selectivity of these contrast 
agents, the emerging field in molecular imaging seeks to integrate various targeting agents 
(mAbs, scFv, aptamers) in order to design more selective molecular probes with a broader 
applications in medicine.  Research and the development of antibody-conjugated SPIONs are 
intended for imaging solid tumors  71, drug delivery 72, hyperthermia cancer treatment 73, and can  
also be used to monitor progression of disease treatment.  For example, targeted SPIONs have 
been used in therapeutic strategy to deliver siRNA and also to image the accumulation in the 
targeted tumors in vivo 74.  The assessment of the biocompatibility, bio-distribution and in vivo 
clearance of superparamagnetic iron oxide nanoparticles (SPIONs) are well documented 75-79.  
For example, dextran-coated SPIONs have no measurable cytotoxocity index LD50 in animal 
models 80.  In general, SPIONs are typically  synthesized  and coated in surfactants and are 
subsequently  functionalized to make them biocompatible and allow the encapsulation and/or 
attachment specific targeting or therapeutic  drug 81.  
 
1.11.2.  Fluorescence Imaging 
 
Fluorescence imaging involves the detection of light emitted from molecules or materials 
subsequent to their excitation at a specific wavelength.  Fluorescence imaging of cancerous 
tissue can be traced back to the mid 1900’s where fluorescein was used to improve the detection 
of brain tumors 82. More recent discoveries of near-infrared (NIR) fluorophore capable of 
penetrating into heterogeneous biological samples has helped improve limitations of fluorescent 
imaging and has led to an increase in biological applications of NIR fluorophores.  To allow 
biological cellular labeling and tracking, small fluorescent molecules (such as fluorophore dyes 
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and quantum dots) have been conjugated or encapsulated with metallic NPs to build 
multifunctional composites.  It has been shown that nanoparticle scaffolds allow the multivalent 
attachment of dyes to increase their effective local concentration. Some of these materials have 
found applications in multimodal imaging uses depending upon the particle composition or 
modification.  For example, iron oxide nanoparticle-NIR fluorophore conjugates have been 
shown to be useful in tumor imaging with the aid of targeting ligands such as plasma clotting 
peptides that lead to enhanced tumor uptake 83 and hepsin-targeted peptides for prostate cancer 
84
.  Quantum dots (QDs) are highly fluorescent particles that have found recent use in cancer 
imaging because of their versatility and brightness that can be easily tuned to different emission 
wavelengths 85.  Hybrid magnetic-fluorescent QD nanoparticles have been shown to detect 
tumors in mice by both MRI as well as fluorescent imaging allowing for enhanced resolution as 
well as anatomical information 86.  Fluorescence imaging has become increasingly popular over 
the past decade and is now a highly valuable resource in biological imaging. 
 
1.11.3.  X-ray based computed tomography (CT Imaging) 
The other imaging modality that has gained more interest for biomedical imaging is X-
ray based computed tomography (CT) imaging.  CT imaging is one of the most useful diagnostic 
tools in hospitals today in terms of availability, efficiency, and cost.  CT distinguishes between 
different tissues based on the fact that different tissues provide different degrees of X-ray 
attenuation, where the attenuation coefficient is determined by the atomic number and electron 
density of the tissue; the higher the atomic number and electron density, the higher the 
attenuation coefficient.  Currently, it is not molecular imaging modality since relevant targeted 
and molecular specific contrast agents have yet to be approved for clinical use.  Present CT 
contrast agents are predominantly based on iodine containing molecules, which are effective in 
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absorbing X-rays; however they are nonspecific because they cannot be conjugated to biological 
components or cancer markers and allow only very short imaging times due to rapid renal 
clearance 87.  Recent advances in nanotechnology-based CT imaging have demonstrated the 
feasibility of using gold nanoparticles to induce in vivo vascular contrast enhancement. The 
atomic number and electron density of gold (79 and 19.32 g/cm3, respectively) are much higher 
than those of the currently used iodine (53 and 4.9 g/cm3) and are  being developed as CT 
contrast agents. Gold provides about 2.7 times greater contrast per unit weight than iodide 88.  
Additionally, gold nanoparticles provide a high degree of flexibility in terms of functional groups 
for coating and attachment of specific targeting agents.  Additionally,  gold nanostructures have 
been shown to be nontoxic and biocompatible in vivo 89.  Most recent efforts on the development 
of targeted gold nanoparticles for molecular CT imaging have shown promising results. For 
example, in vitro proof of principle experiments using head and neck cancer have shown 5 times 
higher attenuation coefficient for targeted cells as compared to untargeted cancer cells or normal 
cells 87. Other hybrid nanoparticles such as PEG-coated nanoparticles, antibiofouling polymer-
coated gold nanoparticles, gadolinium-coated gold nanoparticles 90, and polymer-coated Bi2S3 
nanoparticles 91 are currently under investigation as vascular CT contrast agents.  
 Recently, Hainfeld et al and coworkers, demonstrated successful use of 1.9 nm gold 
nanoparticles in vivo imaging in mice following intravenously injection 88. As compared to 
commercially available CT imaging agents, such as (Acepaque® ans Visipaque®, Amersham 
Health (now GE healthcare)), the gold nanoparticles were shown to have stronger CT signal as 
well as longer blood retention times allowing for extended imaging durations.  Improved contrast 
may allow enable non-invasive detection of small tumors (< 1 cm). 
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1.12.  Gold Nanostructures in Photothermal Therapy 
 
1.12.1.  Gold Nanoparticles 
Au NPs absorb light millions of times stronger than the organic dye molecules.  Nearly 
100% absorbed light is converted to heat via the nonradiative properties, as discussed previously 
(sections 1.3 and 1.4).  Au gold nanostructures also are photostable and biocompatible 92. These 
features make them novel agents for photothermal therapy, in which photon energy is converted 
to heat sufficient to induce cellular damage via thermal effects such as hyperthermia, coagulation 
and evaporation.  Phothermal therapy (PTT) using gold nanospheres can be achieved with pulsed 
or continuous-wave (cw) lasers in the visible range (500- 600 nm) which is coherent with the 
SPR absorption of these particles.   This therapy is suitable for hyperthermic treatment of 
shallow cancer such as skin cancer.  Lin and co-workers et al. reported the first extensive study 
of gold nanospheres with pulsed laser where selective and highly localized photothermolysis of 
targeted lumphocytes cells  was achieved 93.  Lumphocytes incubated with antibody-conjugated 
Au NPs were exposed to nanosecond laser pulses (Nd: YAG laser, 565 nm wavelength, 20 ns 
duration) showed cell death with 100 laser pulses at an energy of 0.5 J/cm2. In contrast, adjacent 
cells just a few micrometers away but without nanoparticles remained viable.  Since then, 
numerous studies have demonstrated the use of gold nanospheres in combination with laser 
irradiation (with excitation coherent with the SPR absorption) as a highly selective method of 
cell killing with broad applications in targeted cancer therapy 94, 95.  The localized cell damage is 
controllable from a few nanometers to tens of micrometers depending on the laser pulse duration 
and particle size.  The treatment using CW lasers is time consuming (minutes) compared to 
pulsed laser (single pulse time).  Another example of using CW lasers for PTT includes selective 
cancer cell killing and targeted macrophage destruction 96.   
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1.12.2.  Gold Nanorods and Photothermal Therapy (PTT) 
 The use of gold nanoparticles for PTT has been limited by the depth of penetration of 
visible light which has been shown to be effective only up to a few micrometers from the laser 
source.  In vivo therapy of tumors under skin and deeply seated within tissue, has led to the 
utilization of nanostructures with SPR absorption in the near infrared region (NIR) because of its 
deep penetration owing to minimal NIR absorption by hemoglobin and physiological 
components (including water) in tissues at this spectral region.  The advances in PTT therapy 
over the years have attributed to the emergence and use of gold nanorods (Au NRs) for 
photothermal therapy.  El-sayed et al first demonstrated the use of gold nanorods for in vitro cell 
therapy in which NRs conjugated to anti-EGRF antibodies specifically bind to ENT cancer cells.  
In the PTT treatment with Ti: Sapphire laser  800 nm,  it was found that  cancer cells required  
half the laser energy (10 W/cm2 for 4 min) to be photothermally damaged as compared to normal 
cells (20 W/cm2, 4 min) 97.  Extensive research in the use of gold nanorods conjugated to various 
types of targeting moieties (e.g. peptides, proteins, antibodies) is currently underway in which 
numerous reports have proven their potential applications using in vivo PTT models 15, 98.  Gold 
nanorods have become a preferred for PTT modality as compared to gold nanoshells due to their 
wide and tunable absorption profile which can be easily adjusted by changing the nanorod aspect 
(700-1200 nm) to match the excitation of the laser source. Additionally, the easy of surface 
functionalization using thiol chemistries have made them much more attractive to form stabile 
nanorod antibody suitable for in vivo applications.  In this thesis review, common the synthetic 
procedures for gold and iron oxide nanostructures that have been discussed by summarized. 
 
1.13. Synthesis of Gold and Iron Oxide  Nanostructures 
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1.13.1.  Size-controlled Growth of Au NPs 
Substantial research efforts have been devoted to the syntheses of monodisperse Au NPs, 
ranging of nanoparticles a few nanometers to hundred nanometers by various methods, as 
reviewed by several authors 99-101.  Au NPs have been prepared both by “top down” and bottom 
up strategies.  Top down method is where Au bulk is broken down in into smaller particles using 
a strong irradiative force, for example, ion irradiation in air 102 or arc discharge in water which 
generates Au NPs 103.  These Au NPs are typically used in suspension and require addition 
stabilization with surfactants in order to prepare stabile nanoparticles suitable for a wide range of 
applications.  However, the use of “top down” method has been limited because it is difficult to 
control size, shape, and the particle distribution.  The “bottom up” method refers to wet chemical 
processes used to prepared nanoparticles which include: chemical reduction of Au salts, 
electrochemical pathways, and decomposition of organometallic compounds.  Chemical 
reduction method is commonly preferred because it is simple and controllable; it has been used 
to prepare Au nanoparticles of various sizes and shapes.  Figure 1-10 depicts a general chemical 
reduction mechanism method used to prepare various gold nanostructures ranging from 
nanoparticles (one-dimensional), nanorods, nanobelts, and nanokite (multi-dimensional) 104.  
Many functional Au NPs are synthesized by a two-step procedure: (1) nucleation and (2) 
successive growth.  Initially, nucleating centers of Au NPs are formed by reduction reaction of 
Au precursors or salts.  Successive growth from the Au seed particles is performed under 
controlled and specific conditions of chemical concentration, surfactant, pH, temperature which 
leads to formation of the various types of Au nanostructures depicted on Figure 1-10:  (larger Au 
NPs, nanorods, nanocages, etc) which are largely dependent on the growth parameters and 
conditions.  
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A common method of preparing spherical Au NPs is by reduction Au precursor (HAuCl4) 
in the presence of citrate which has been used to synthesize a wide range of NPs sizes, from ~ 10 
to 150 nm. This procedure is modulated by changing the relative amounts of Au precursors to the 
amount of reducing reagents.   For example, in a typical synthetic reaction an aqueous solution of 
tetrachloroauric acid is heated to boiling point and then trisodium citrate is added into the 
solution. Citrate acts as both reducing and stabilizing agent, adsorbed to the particle surface.  The 
adsorption of citrate on the particles acts as particle stabilizer and significantly affects its size.   
In this stage, particle size decreases as the citrate/HAuCl4 ratio increases because of the 
stabilizing process of citrate.  Using a higher citrate concentration allows rapid and complete 
stabilization of Au NP, while lower citrate concentrations results in larger aggregated Au NPs 
due to incomplete citrate surface coverage 105.  
Citrate plays multiple roles when used for as particle synthesis and consequently 
increases the complexity of the particle preparation process.  As result of this complexity, recent 
synthetic efforts have used sodium borohydride, instead, as a reducing agent used to form small 
Au seeds.  Larger Au NPs are then prepared by successive growth using a small amount of Au 
seeds as nucleation centers in a solution of mildly reduced tetrachloroauric acid (HAuCl4) where 
ascorbic acid is used as a mildly reducing agent. Additionally, cetyltrimethylamonium bromide 
(CTAB) is now commonly used as a surfactant instead of citrate 106. 
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1.13.2. Gold Nanorods 
Non-spherical Au NPs of different shapes are prepared from the anisotropic growth of Au 
seed particles which is facilitated by the addition of surfactants such as cetytrimethylammonium 
bromide (CTAB), sodium dodecysulfonate (SDS) and poly(vinylpyrrolidone) (PVP) 107-109.  This 
thesis review will focus on the synthetic preparatory methods of gold nanorods and gold 
 
Figure 1-10: Illustration of Synthetic procedure involved in preparation of Gold nanostructures 
[103] 
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nanostars for which the applications have been discussed.   While there have been numerous 
synthetic methods for the preparation of gold nanorods such as high-temperature seedless 
synthesis 110 , synthesis by microwave irradiation 111 , pH-triggered synthesis 112, and by 
photochemical strategies 113, a two-step seed-mediated method in the presence of CTAB  remains 
the most facile and commonly  for the preparation of finely-tuned gold nanorods.  This method 
yields gold nanorods with controlled size and monodispersity that is dependent on the 
concentration of precursor salt, structure of seed particles, surfactant concentration, particles, 
temperature, pH and aging time 56, 114, 115.  A direct surfactant templating mechanism is the 
leading proposed mechanism for the rod formation in the presence of CTAB 116.  In brief, CTAB 
covers the seed particles to form a template with certain size which depends on CTAB 
concentration and over ionic strength of the solution.  However, CTAB binds preferentially to 
the {110} facet of Au seed particles and retards the crystal growth on this face. The growth of 
seed particles is controlled by the diffusion of Au atoms onto nucleating Au template where 
diffusing Au atoms are preferentially deposited on {100}, and not on {110} facet.  The rod 
aspect ratio is controlled by supplying Ag atoms (generated the reduction reduction of Ag ions) 
and preferentially deposited on the {110} facet fast than on the {100} facet. The seed particles, 
therefore, will favorably grow along {100} direction. Increasing Ag concentration results in 
more Ag deposition on the {110} facet will lead to the formation of Au nanorods with higher 
aspect ratio.  Over the years, this seed-mediated method has been shown to be facile.  It has been 
used to prepare rods of a wide variety of aspect ratios with absorbance ranging from 600 to 1200 
nm.  Modified synthetic method using binary surfactant mixture containing CTAB and 
benzyldimethylammoniumchloride (BDAC) has been proposed and used to prepared gold 
nanorods with larger aspect ratio ( > 5)56. 
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1.13.3.  Au Nanostars 
The use and synthesis of gold nanostars have garnered attention due to their strong 
scattering properties which have found various applications, most notably for surface enhanced 
resonance (SERs)-based imaging and detection of small molecules.  The most commonly 
reported preparatory method for Au nanostars is by seed-mediated method using 
poly(vinylpyrrolidone) (PVP) as a surfactant instead of CTAB used in Au NRs synthesis 117.  
PVP acts not only as a surfactant but also as a reducing agent and thus enables preparation of Au 
NPs from precursor without the addition of any other reducing agent.  PVP blocks the {111} 
facet of Au NPs and prevents growth along this direction.  For example, Yamamoto et al 
prepared star-shaped nanoplates of Au NPs using PVP as a single crystal of flat plate with {111} 
face and six symmetric horns extending in the [112] direction 54.  The amount of PVP used and 
water are the process variables that control the final particle shape where varying the amount of 
PVP can change the surface energy, crystallinity of PVP, and coverage of PVP on the initial Au 
nuclei.   As shown, Figure 1-10 summarizes the synthetic procedures for the preparation of all 
types of gold nanostructures, including intricate two-dimensional structures such as nanobelts, 
nanocages, and nanokits. 
 
1.14.  Synthesis of Iron Oxide Nanoparticles 
Superparamagnetic iron oxide nanoparticles (SPIONs) have been subjects of extensive 
research over the past decade owing to their promising uses as contrast agents in magnetic 
resonance imaging (MR) based imaging.  While there are numerous synthetic methods for the 
preparation of SPIONs (e.g. gas phase deposition and lithographic methods), wet chemical routes 
methods have proven to be the easiest, facile, and offer appreciable size control 118.  Initially, 
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SPIONs have been prepared by a simple acid-base reaction by adding a base to an aqueous 
mixture of Fe2+ and Fe3+ chloride at a 1:2 molar ratio resulting in a black precipitate of magnetite 
(Fe3O4).  The chemical reaction of Fe3O4 precipitation is given the overall reaction: 
 Fe  2 Fe  8 OH'  FeO8  4 H O                                 (1.3) 
According to the thermodynamics of this reaction, a complete precipitation of Fe3O4 should be 
expected between pH 9 and 14.  This method and  numerous variations of this procedure 119 have 
been used to prepare Fe3O4 nanoparticles soluble in aqueous medium and can allow rapid coating  
with biomolecules such as proteins.  However, SPIONs prepared using these methods are prone 
to aggregation which limited their potential in vivo applications.  Recent synthetic efforts to 
produce stabile and monodispersed SPIONs with narrow size distribution have been 
accomplished by organic-phase synthesis of thermal decomposition of iron precursors.  Seminal 
research using this method was first reported by Sun et al where 4-nm SPIONs coated with oleic 
acid were synthesized.  The preparation of SPIONs up to 20 nm is size were subsequently 
synthesized by seed-mediated method using smaller 4-nm SPIONs as nucleation seeds 120.  In 
brief, 4-nm SPIONs have been prepared by mixing iron precursor (Fe(acac)3), reducing agent 
(hexedecanethiol), and ligand molecule (oleic acid) in organic solvent ( phenyl ether).  The 
mixture containing iron precursor is then reduced by heating to 375oC for 1 hr which leads to 
reduction of brown iron ions, forming black SPIONs precipitate coated with oleic acid.   Figure 
1-11 shows TEM micrographs comparing the monodispersity of SPIONs resulting from different 
strategies.  The preparation of biocompatible SPIONs suitable for biological applications has 
been carried by particle surface modification using methods such as ligand exchange reaction 
and polymer coating.   
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1.15. Functionalization of Nanoparticles 
As synthesized, nanostructures are typically stabilized or coated with inert functional 
groups that do not allow the attachment of biomolecules.  Additionally, these function groups are 
cytotoxicity and limit uses of nanostructruees in biological systems. Consequently, prior 
functionalization is required in order to increase biocompatibility, reduce cytotoxicity, and to 
introduce useful functional groups on which the biomolecules can be anchored.  Various 
functionalization strategies used for the various types of nanostructures can be categorized into: 
ligand exchange reaction, phase transfers, and additional coating layers.  This review will 
summarize some of the most commonly used methods for gold nanoparticles and for iron oxide 
particles functionalization. 
 
 
Figure 1-11: Transmission electron microscopy (TEM) micrographs of SPIONs prepared 
by; a) acid-base reduction of iron precursor in aqueous solution; b) organic-phase thermal 
decomposition method which shows monodispersed SPIONs [117, 119]. 
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1.15.1. Gold Nanostructures 
Bare or surfactant-stabilized Au nanostructures are unstable and cytotoxic in 
physiological conditions and tend to aggregate forming large aggregates, which result in rapid 
clearance from the bloodstream.  The shortened blood half-life reduces the efficacy of gold-
based biomedical systems where longer organ contact time is required.  Fortunately, the use of 
the facile Au-thiol chemistries have made gold nanostructures easy to functionalize and attractive 
for various bio-applications.   Au nanostructures suitable for a wide variety of applications have 
been developed by attaching different functionalities and biomolecules onto the surface of Au 
NPs.  After functionalization, gold nanostructures have been shown to retain the desired 
reactivities, biocompatibily properties, and native optical properties.   Ligand-exchange reactions 
where molecules stabilizing the particles in the original first phase are replaced by other, more 
strongly binding ligands that improve particle stability and allow subsequent attachment of 
biomolecules.  Examples of the different functional groups that  have been reported  for gold 
functionalization include: thiol (-SH)121, hydroxyl (-OH) 122, phosphine (-PH2) 123, and amino (-
NH2) 124 groups with a wide array of long and short chain alkyl groups.  Thiol-containing ligands 
are predominant as the most effective functional group for Au NPs because of the strong Au-S 
covalent bond.  Some examples of the thiolated ligands reported in the literature include: 
alkythiol 125, thiol-terminated dendrimers 126, peptide 127, polypeptide 128, and their derivatives.  
Additionally, to improve the biocompatibility and stability of Au NPs, ligand molecules on the 
surface have been exchanged with thiolated polymeric molecules which increase their solubility 
in aqueous conditions.  Most commonly, thiolated polyethylene glycol moieties have been used 
as they provide “stealth” properties – a critical property for nanostructures used for in vivo 
applications. 
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An alternative approach to ligand-exchange functionalization strategy is reverse-phase 
transfer: a hydrophobic ligand molecule stabilizing the nanoparticles in organic phase is coated 
with amphiphilic molecules/ polymers, resulting in water-soluble particles.  For example 
phosphine-stabilized Au NPs 129 or oleic acid- coated Au NPs can be functionalized by reverse-
phase micelle formation using amphiphilic phospholipids or block copolymers forming micelle-
like particles that are less prone to destabilization in salt concentration130.  Some examples of 
amphiliphilic polymers that have been used include: carboxylated phosphoethanolamine-
polyethylene glycol (PL-PEG-COOH), thiolated phosphoethanolamine-co-polyethylene glycol 
(PL-PEG-SH), or aminated phosphoethanolamine-polyethylene glycol (PL-PEG-NH2) (Avanti 
Polar lipids).  For example, we have recently reported the use  PL-PEG-COOH to prepared 
monodispersed Au NPs that were subsequently attached to PHA synthase131.  
 
Figure 1-12: Au Nanoparticle core with different hydrophilic and hydrophobic ligand 
molecules used to prepare biocompatible nanoparticles suitable for bio-applications. 
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Other efforts have coated Au with thin layers of mesoporous silica that allow subsequent 
attachment of other molecules such as drugs, antibodies, and molecular dyes 132 . Figure 1-12 
illustrates some of derivatization strategies used to prepare biocompatible Au nanostructures.  It 
shows representative hydrophobic and hydrophilic ligand molecules that have been used to 
prepare stabile water soluble Au nanostructures as template for designing multifunctional probes 
with potential applications in therapy and as well for imaging. 
 
1.15.2.  Surface of coating of  SPIONs 
Surface coatings are critical integral component when designing SPIONs for potential 
biomedical applications.  Although not attracted magnetically, due to their superparamagnetic 
properties, SPIONs nanoparticles still have a significant tendency to agglomerate as a result of 
their high surface energy.  Colloidal electrostatic stabilization arising from repulsion of surface 
charges on the nanoparticles is typically inadequate to prevent aggregation in biological solutions 
due to the presence of salts or other electrolytes that may neutralize this charge.  In addition, 
particles used for in vivo are subject to various pressure change and plasma protein interactions.  
For example, it is has been shown that improperly functionalization SPIONs are rapidly adsorbed 
to plasma proteins (opsonized) and rapidly cleared through the liver kupfer cells which reduces 
the particle blood residence time. One of challenges is the use of particles for various biomedical 
applications is the is coating SPIONs with appropriate stealth moieties to achieve longer blood 
residence time as well as avoid reticuloendothelial (RES) particle clearance 133.  
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  There are a variety of natural and synthetic polymers have been evaluated for use as 
coatings on SPIONs.  One of the most widely utilized used polymer coatings on SPIONs 
intended for in vivo applications, has been the polysaccharide dextran 134.  For instance, 
Weissleder  et al have developed various formulations of dextran-coated SPIONs which have 
been evaluated extensively for a variety of MR imaging applications 135.  Poly(ethylene glycol) 
(PEG) is another widely used polymer for nanoparticle coating in biomedical applications 136 due 
to its antifouling nature that has been shown to reduce nanoparticle uptake by macrophages and 
extend  in vivo circulation time 137.   Other polymeric coatings that have been used include: poly 
(vinyl alcohol) (PVA), polyethylenimine (PEI), chitosan, phospholipids, and a combination of 
these polymers and are illustrated on Figure 1-13  The SPIONs coated with these polymers result 
 
Figure 1-13: Surface coating of SPIONs with a variety of different polymers that make 
SPIONs suitable for in vivo applications. 
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in different structures that depend on the hydrophobicity/hydrophilicity of the polymer chain 
which may also determine the hydrodynamic size of the particles in aqueous solution (see Figure 
1-13).  Polymeric coatings provide a steric barrier to prevent nanoparticle agglomeration and 
avoid opsonization. Additionally, it provides a means to attach biomolecules such as peptides 
and antibodies.  For example, we have recently prepared carboxyl-terminated 10-nm SPIONs by 
reverse-phase coating of oleic acid-stabilized SPIONs with carboxy-PEGylated phospholipids 
(PL-PEG, Avanti Polar lipids), resulting of SPIONs that can be easily attached to various 
molecules. 
 
 
1.16. Importance Consideration in Nanoparticles Design 
 As stated previously, a significant challenge associated with the application of 
nanomaterials systems is their behavior under physiological conditions.  The efficacy of many of 
these systems is often compromised due to recognition and clearance by the reticuloendothelial 
system (RES) prior to reaching target tissue, as well as the inability to overcome biological 
barriers, such as the vascular endothelium or the blood brain barrier 133.  The fate of these 
SPIONs upon intravenous administration is highly dependent on their size, morphology, charge, 
and surface chemistry.  These include particle properties such as size, shape, surface charge (zeta 
potential), solubility, surface modifications (including specific targeting agents), and route of 
administration.  There have been numerous reviews dwelling on the importance of these factors 
and how each can be rationally designed to influence bio-distribution 138.  When nanoparticles 
enter the bloodstream, they immediately encounter a complex environment of plasma proteins 
and immune cells. Nanoparticle uptake by the immune cells may occur both in the blood stream 
by monocytes, platelets, leukocytes, and dendritic cells and in tissues by resident phagocytes 
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(e.g., kupffer cells in liver, macrophages and B cells in spleen).  Nanoparticle uptake by immune 
cells may occur through various pathways and can be facilitated by the adsorption of plasma 
proteins to the particle’s surface.  This uptake may cause nanoparticles to be routed away from 
the site of its intended application and can greatly reduce the number of nanoparticles available 
to reach the target site, effectively reducing the efficacy of the nanoparticle-based system.  To 
this end, there are critical considerations to keep in mind when designing nanomaterials for in 
vivo applications that ensures that the nanoparticle-based probes can be efficacious at lower 
doses which would  lower costs and cause fewer deleterious effects 42.   
 
1.16.1. Size and Shape 
The translocation of nanostructures across biological barriers (e.g. plasma membrane) is 
critical in determining the potential and efficacy of nanomaterial-based systems when used in 
biomedical applications.  Nanostructures of various sizes, shapes, and chemical compositions 
have been designed for potential uses in difference areas spanning from their drug delivery uses 
to therapy applications.  The rate of particle uptake, clearances, and their biodistribution which 
ultimately determines the fate of nanoparticle carrier systems are to greatly depend on the size 
and geometrical shape of these nanostructures 139.   For instance, the particles in the range of 10-
200 nm have been shown to have longer blood half life compared to smaller particles (< 20 nm) 
which cannot escape RES capture and thus cleared rapidly from the bloodstream.  Additionally, 
larger nanostructures (> 500 nm) are known to be rapidly captured by macrophages which 
shorten the particle blood residence time.  Particle size is a critical factor that should be 
considered when designing nanomaterials for different uses.  Some application may be require 
designing particle systems where fast clearance is critical whereas other applications may require 
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longer blood residence time such as in time-release of therapeutics.  Particle size also affects the 
mechanism of bloodstream clearance where smaller particles ( sub 10nm ) are have been shown 
to occur through renal clearance while larger particles ( > 10 nm) occur through clearance by 
kupffer cells in liver. 
Particle shape has also been implicated as a critical factor that affects the rate of cellular 
uptake which would determine its success in the intended application.   Rod-shaped 
nanoparticles, owing to their larger longitudinal surface area, have been demonstrated to be taken 
up by cells at the rate higher than the rate of uptake of spherical nanoparticles of comparable 
size. This is because rod-shaped nanoparticles have larger contact area with the cell membrane 
receptors that increase the rate of particles receptor-mediated cell surface attachment and 
endocytosis 140. 
 
1.16.2. Surface Modifications 
Several studies have shown that biological responses to nanoparticles tend to scale with 
surface area rather than mass.  As particle become smaller, their surface areas shrink much more 
slowly than their volumes, causing nanoscale materials to have far greater surface-to-volume 
ratios than larger particles.  A larger surface-to-volume ratio also implies more proteins will bind 
a nanoparticle (relative to its mass) than a particle of larger size and that means the surface 
factors (such as charge and modification) can play a critical role.  Components of the 
nanoparticle corona, called opsonins, may be recognized and capture by the 
the reticuloendothelial system (RES) e.g. the macrophage cells in the liver and can lead to faster 
clearance.   The presence of opsonins on the particle surface creates a “molecular signature” 
which is recognized by immune cells and determines the route of particle internalization.  The 
route of internalization, then, may affect the eventual fate of the nanoparticle in the body (i.e. its 
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rate of clearance from the bloodstream, volume of distribution, organ disposition, and rate and 
route of clearance from the body).  The effect of this protein corona may have special 
significance for nanoparticles, due to the increased importance of surface effects for particles of 
this size.  Even for larger particles protein binding is established as one of the most important 
factors influencing bio-distribution.  In efforts to limit or avoid immune cells capture of the 
nanoparticle-based system, there are various types of surface modifications that are currently 
under studies.   
One common method of evading the RES capture is by modifying the particle corona 
with “stealth” molecules to minimize the molecular signatures.  One commonly used stealth 
molecule is polyethylene glycol (PEG).  Surface modification with PEG - a hydrophilic molecule 
which helps prevent protein adsorption to the corona- has been shown to increase the half life of 
particles by reducing protein-particle interaction (opsonization), and thus reducing the degree of 
macrophage capture.  There are also dextran-coated nanoparticles with longer blood half-life that 
have been FDA-approved for clinical applications.  
 
1.16.3. Surface Charge 
Along with size, surface charge (zeta potential) is a ubiquitous parameter that is 
important in designing nanostructures suitable for biomedical applications.  Particles may be of 
appropriate size to traverse a desired biological barrier but effects of surface charge may, 
nonetheless, limit their efficacy.  For each application, the particle surface charge should be 
rationally tuned to match the intended use.  For instance, it has been shown that positively 
charged nanoparticles perform better for gene DNA  delivery because of their ability to bind to 
negatively charged proteoglycans 141.  Nanostructures  intended for prolonged blood life 
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circulation  have been shown to be optimal when negatively charged or neutrally charged  
particles are used 138. 
 
1.16.4.  In vivo Barriers 
In designing NPs for potential biomedical applications, it is critically important the 
particles are appropriately designed to overcome the intrinsic biological barriers such as RES 
systems that would keep them from reaching the intended target site.  Biological barriers serve to  
protect the body against foreign entities, including injected therapeutics and contrast agents, but 
can restrict nanomaterials by blocking their movement, causing physical aggregation, or 
inducing a negative host response 142.  Upon intravascular administration, NPs immediately 
encounter blood, a high ionic strength, and heterogenous solution that can alter particles’ 
properties and can lead to aggregation.  Particles for cellular imaging or therapy should be 
designed to evade the RES system. 
 
1.16.5. Physicochemical Considerations 
NP pharmacokinetics and cellular uptake in vivo, including their ability to manage 
biological barriers, are largely related to NP physicochemical properties, including morphology, 
hydrodynamic size, charge, and other surface properties 143.  These properties are dictated by the 
types, structures, and orientations of the materials that comprise the SPIONs.  Typically, a 
SPION consists of a magnetically active core coated with a stabilizing shell to which targeting 
ligands and additional imaging modalities are anchored. Therapeutic agents can then be 
embedded in the shell structure or chemically bonded to its surface. At each stage of its design, 
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the size, charge, hydrophobicity, shape, and orientation of the NP's constituent materials must be 
considered with regards to overall NP physiochemical properties. 
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Chapter 2 
 
Gold hybrid nanoparticles for targeted phototherapy and cancer imaging 
 
Abstract: 
Gold and iron oxide hybrid nanoparticles (HNPs) synthesized by thermal decomposition 
technique are bio-functionalized with single chain antibody, scFv, that binds to the A33 antigen 
present on colorectal cancer cells.  The HNPs-scFv conjugates are stable in aqueous solution 
with magnetization value of 44 emu/g rate and exhibit strong optical absorbance at 800 nm.   
Here we test this material in targeting, imaging and selective thermal killing of colorectal cancer 
cells.  Cellular uptake studies showed that A33-expressing cells take up the A33scFv conjugated 
HNPs at a rate five-times higher than cells that do not express the A33 antigen.  Laser irradiation 
studies showed that approximately 53% of the A33-expressing cells exposed to targeted HNPs 
are killed after a six-minute laser treatment at 5.1 W cm-2 using a 808 nm continuous wave laser 
diode while < 5% of A33-nonexpressing cells are killed.  At a higher intensity, 31.5 W cm-2, the 
thermal destruction increases to 99% and 40% for A33-expressing cells and A33 non-expressing 
cells, respectively after 6-min exposure.  Flow cytometric analyses of the laser-irradiated A33 
antigen-expressing cells show that apoptosis-related cell death to be the primary of mode of cell 
death at 5.1 W cm-2 with increasing necrotic-related cell death at higher laser power.  These 
results suggest that this new class of bio-conjugated hybrid nanoparticles can potentially serve as 
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an effective antigen-targeted photothermal therapeutic agent for cancer treatment as well as a 
probe for magnetic resonance-based imaging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from: D.K. Kirui, D. A. Rey, and C. A. Batt.Gold hybrid nanoparticles for targeted 
phototherapy and cancer imaging. Nanotechnology 21, 105105 (2010)  (Copyright 2010 IOP science). 
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There has been a great deal of interest devoted to the development of nanomaterials for 
photothermal therapy that can be used in minimally-invasive selective cancer treatment.  This 
type of therapy utilizes the large absorption band of nanomaterials in the near infrared (NIR) 
region 1.  Absorption in the NIR region is desirable owing to the weak absorption by tissues 
which can penetrate the skin with less risk of thermal injury to normal tissues, and thus, can be 
used to treat specific cells targeted by the nanomaterials 1.  Nanomaterials that strongly absorb 
NIR irradiation include: gold spherical particles 1, 2, gold nanocages 3, gold nanorods 4, and 
single-walled carbon nanotubes 5 all of which have been demonstrated to have potential 
therapeutic applications.  These types of materials can convert absorbed photons into thermal 
energy, causing cell destruction as a result of electron-phonon and phonon-phonon processes 1 
and the use of these gold-nanostructured materials have shown promise as photothermal 
therapeutic agents both in vitro 1 and in vivo 6. 
The potential benefits of integrating nanomaterials with different properties (such as 
magnetization, fluorescence, and near-infrared absorption) into a single object of nanoscale 
dimensions can lead to the development of multifunctional nanomedical platforms for 
simultaneous targeting, imaging, and therapy administration 7, 8.  These efforts have spurred the 
developments of various types of hybrid nanoparticle systems such as hybrids of iron oxide- 
quantum dots 9, and various types of gold nanoparticle-iron oxide hybrids 10-12.  For example 
Kim and coworkers reported multifunctional nanoparticles that exhibit both magnetic and optical 
properties with potential use for simultaneous targeted phototherapy and imaging using magnetic 
resonance imaging (MRI) 2.  Iron oxide nanoparticles such as superparamagnetic iron oxide 
(SPIO) nanoparticles, have been extensively utilized as MRI contrast agents to image target 
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tissues in vivo in a highly specific manner 13-15.  The SPIO nanoparticles modified with tumor-
targeting ligands were used as in vivo MRI contrast agents 16 and to induce cell apoptosis via 
hyperthermia 17. 
For cancer targeting, high specificity is generally introduced by taking advantage of the 
physiological differences between malignant and normal cells.  Nanoparticles conjugated to 
cancer targeting agents have been used for site specific delivery of drugs and therapeutics 18.  
This has been shown to significantly reduce drug toxicity and localize therapeutic impact 19. 
Achieving specific targeting is particularly important when it comes to laser irradiation for 
medical applications.  It is critical to reduce the energy level to abide by medical safety standard 
and this has been demonstrated by the use of the targeting agents to reduce the laser power 
needed to achieve therapeutic effects in cancers.  Humanized single chain antibody (A33scFv) is 
one example of such targeting agent.  It is known to bind to a transmembrane glycoprotein, A33 
antigen, which is expressed in 95% of primary and metastatic human colorectal tumor cells 20, 
but is absent in most other normal tissues and tumor types 21.  A33 is not secreted or shed into 
the bloodstream and some colon cancer cell lines express large amounts of this antigen, binding 
almost 106 mAb molecules/cell 22.  Consequently, the A33 antigenic system is the focus of 
several clinical studies in patients with colon cancers 20, 22.  The A33scFv has recently been 
optimized and produced in our laboratory under the Cornell University/ Ludwig Institute for 
Cancer Research Partnership 23.  It has been recently conjugated to the surface of 5-nm gold 
nanoparticles encapsulated in novel diblock copolymers 24.   In this work, we utilized the 
clinically relevant A33scFv covalently-bound to HNPs to achieve specific targeting of A33-
expresssing colorectal cancer cells and to minimize damage to healthy surrounding cells. 
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Here, we report on novel dumbbell-like nanoparticles that have both magnetic and optical 
properties and are additionally conjugated to a targeting antigen, integrating therapeutic 
(photothermal therapy) and imaging functions (MRI and fluorescence) into a single nanoscale 
probe.  The dumbbell-like nanoparticles have several distinct advantages over previously 
reported materials used for photothermal therapy that individually lack one or more of the 
characteristics of our particles 1, 25.   
 
2. Experimental and Methods 
 
 2.1. Materials 
All of the chemicals were of reagent grade and were used without further purification. 
Iron(III) acetylacetonate ( ≥ 99.9%), 1-octadecene (90%), oleylamine, 1,2-tetradecanediol ( 
90%),  oleic acid ( technical grade, 90%), gold (III) chloride, 1,2,3,4-tetrahydronaphthalene ( 
reagent grade, 97%),  iron pentacarbonyl (≥ 99.9%), dimethyl sulfoxide (DMSO),  and  Albumin, 
Bovine (BSA) were purchased from Sigma-Aldrich; 1,2 Distearoyl-sn-glycero-3-
phosphoethanolamine-N-[Carboxyl (polyethylene glycol) 2000] ammonium salt (DSPEG-PEG 
COOH 2000) was purchased from Avanti Polar Lipids; N-hydroxylsulfosuccinimide (Sulfo-
NHS), 1-Ethyl-3-(3-dimethylaminopropyl carboiimide HCl (EDC) were purchased from Pierce 
Biotechnology; Alexa Fluor 488 and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell proliferation assay kit were purchased from Invitrogen; Annexin-V 
fluorescein isothiocyanate (FITC)/ propidium iodide (PI) detection kit and calcien AM stain from 
BD Biosciences, PharMingen; SW1222 cells (antigen expressing colorectal cancer) and non-
malignant cell lines HT29 cells were received as a gift from Ludwig Cancer institute of Cancer 
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Research, ( New York, NY); A33 single chain antibody was expressed in Pichia pastoris as 
previously reported 23. 
 
2.2. Nanoparticle Preparation 
The dumbbell-like Au-Fe3O4 nanoparticles were fabricated as previously described by Yu 
et al 26.  Briefly, 0.2 mmol gold (III) chloride solution in toluene was injected into a 4 mmol iron 
precursor, Fe(CO)5, in presence of 12 mmol oleic acid and 12 mmol oleylamine and then heated 
to reflux (~ 310oC) for 45 min.  The size of the Au nanoparticles was tuned by controlling the 
temperature at which gold (III) chloride solution was injected into the mixture or by controlling 
the Au (Cl)3/oleylamine ratio.  For example, injecting the Au precursor at 180oC led to the 
formation of 6 nm Au nanoparticles while the injection at 120oC has been previously shown to 
lead to 3 nm Au nanoparticles 27.  The reacted mixture was subsequently oxidized in air at room 
temperature for 1 h to ensure complete oxidation of Fe3O4 nanoparticles.  The particles were 
isolated by adding excess isopropanol followed by centrifugation for 5 min at 3000 rpm.  The 
oleic-capped nanoparticles were encapsulated with carboxy-PEGylated phospholipids (PL-PEG), 
resulting in stable water-soluble HNPs (see Supplementary Information).  The carboxyl- 
terminated HNPs nanoparticles were further modified by covalently attaching A33scFv single 
antibody 23 using EDC-NHS chemistry following the manufacturer’s protocols and then 
fluorescently-labeled with Alexa Fluor 488.  Bovine Serum albumin (BSA) was similarly 
immobilized on the particles and used as the non-targeted particle conjugate control (see 
Supplementary Information).  Particle purification to eliminate excess micelles, un-conjugated 
antibody and fluorophore were carried out in a size exclusion chromatography using FPLC 
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system (Superdex 200 size exclusion column on an AKTA Explorer FPLC, Amersham 
Biosciences, Piscataway, NJ). 
 
2.3. Particle characterization 
Particles were characterized by transmission electron microscopy (Philips, Tecnai F20, 
TEM) operating at 120kV and Dynamic light scattering (DLS) Zetasizer ZS system (Malvern, 
UK) to determine size and composition.  The particles were also characterized to determine the 
magnetic character using vibrating sample magnetometer (VSM, Lakeshore Model 7410) while 
magnetic relaxivity (r2) and  contrast agent (T2) values were determined using  a 3.0-T GE HDx 
imager (General Electric Healthcare, Waukesha, WI).   The optical properties were determined 
by obtaining an absorption spectrum using Shimadzu UV-3101 UV/Vis/NIR spectrophotometer 
in the range of 400 to 1000 nm.  Further, the fluorescently-labeled HNPs-antibody conjugates 
were characterized using spectrophotometer (Perkin Elmer, LSB-50) at 490/520 nm excitation 
and emission wavelength, respectively. 
 
2.4. Cell Culture 
Colorectal cancer cell lines (SW1222 and HT 29 cells) were used to demonstrate specific 
targeting and phototherapy using laser irradiation.  The cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin (P/S, 100 units/mL penicillin, and 100 µg/mL streptomycin).  For all 
studies, cell were grown overnight as monolayers at concentration of 10,000 cells per well at 37 
oC and 5% CO2 in a humidified incubator 28.  The cells were grown in black-walled 96-well 
65 
 
plates for toxicity assays and photothermal therapy assays and in glass 35-mm glass bottom 
culture dishes for confocal microscopy analyses.  
 
2.5. Cellular Uptake Assay 
Cells were grown in 35 mm glass-bottom flask overnight for particle uptake assay.  As a 
control, SW 1222 cells  expressing the A33 antigen receptor were treated using excess A33scFv 
in phosphate buffer (PBS, pH 7.4) for 4 hr to block the extracellular A33 antigen receptors. This 
was compared to the response of untreated SW 1222 cells.  After which the SW 1222 and HT 29 
cells were treated with equal concentrations of fluorescently-labeled HNPs particle conjugates 
(HNPs-scFv) and then incubated for various time durations before analyzing by confocal 
microscopy.  The cells were washed with PBS twice and fresh medium added.  Cellular uptake 
was quantified by measuring the fluorescence intensity of Alexa Fluor 488 with 490/520 nm 
excitation-emission filter. 
 
2.6. Photothermal Therapy 
Malignant colorectal cancer cell line, SW1222 cell line, which express A33 antigen and 
HT 29 cell line that do not express the antigen were used to study the phototherapy effect of the 
nanoparticles.  The cells were grown at concentration of 100,000 cells/well in a 96-well plate 
overnight.  The monolayers were treated with HNPs-A33scFv conjugates for 3 hr in fresh 
medium.  After which the cells were washed and fresh medium replenished before laser 
irradiation with a continuous wave 808-nm laser for 6 min.  To find the threshold NIR irradiation 
intensity for inducing photothermal destruction, the laser power was increased step-wise (n ~ 2.5 
W cm-2) while maintaining a fixed irradiation area of 4 mm in diameter.  Cell viability after laser 
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irradiation was assessed using a membrane-permeable dye calcein-AM used as a live cell stain.  
The dye permeates cell membranes and is digested by esterases inside the cytoplasm to produce 
a green fluorescent calcein dye.  Briefly, 40 µL of 10 µM of freshly prepared calcien AM 
solution was added and incubated for 1 h.  The cells were imaged using fluorescence microscope 
(Olympus BX50) and the number of viable cells quantified by measuring the fluorescence using 
a microplate reader on spectrophotometer (LS-50B) with 470 nm/ 520 nm excitation-emission 
filter. 
 
2.7. Flow cytometric apoptosis analysis after Photothermal Therapy 
To resolve the extent of laser phototherapeutic effect, cells irradiated with varying laser 
power intensities were double-stained with Annexin V-(FITC) and (PI) detection kit to determine 
the percent of apoptotic and necrotic cells.  In brief, cultured and laser treated SW1222 cells 
were washed with Annexin-V binding buffer and stained with Annexin-V (5 µL) and PI (5 µL) 
for 15 min at room temperature in the dark.  After the addition of 400 µL of binding buffer, cells 
were analyzed by FACScanCalibur flow cytometer using 488 nm and 533 filters for Annexin-V 
FITC and PI detection, respectively (Becton Dickinson). 
 
3. Results and Discussion 
 
3.1. Nanoparticle Synthesis, Functionalization and Characterization 
The hybrid gold nanoparticles synthesized by thermal decomposition of iron and gold 
precursors resulted in particles with an average aggregate size of 25 nm as characterized by TEM 
and DLS (Figure 2-1 (a, b)).  The TEM micrographs showed monodispersed dumbbell-like Au-
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Fe3O4 composed of 6 ± 2 nm Au and 18 ± 3 nm Fe3O4 nanoparticles.  The Au nanoparticles 
appear darker in color while the Fe3O4 appear lighter due to the higher electron density of gold. 
The DLS data showed oleic acid-capped particles with an average aggregate size of 28 ± 5 nm 
(Figure 2-1 (b)).  This is consistent with the TEM size measurements (6 nm Au and 18 nm 
Fe3O4 with a 1.8 nm monolayer of oleic acid and the chloroform solvent layer 0.64 nm).  
Subsequent functionalization with carboxy-PEGylated phospholipids (PL-PEG) increased its 
hydrodynamic aggregate size to 65 ± 5 nm (Figure 2-1  (c, d)).  The PL-PEG layer coating was 
invisible due to its low electron density compared to the core of HNPs and could not be 
accounted for in the TEM measurements and, thus, showed no increase in size (Figure 2-1  (c)).  
The resulting HNPs were water-soluble and stable for up to 6 months with no visible aggregation 
and much more stable than a previously reported functionalization strategy stable in aqueous 
solutions that aggregated in less than < 24 hr 29.  
 The potential use of HNPs for NIR photothermal therapy is dependent upon ability to 
absorb energy (light) in the NIR region.  Nanomaterials with high absorbance around 700-900 
nm have previously been shown to be ideal materials for NIR therapy 30-32.  The optical 
properties of the nanoparticles were characterized by obtaining a UV-Vis spectrum (Figure 2-1 
(e)).  The Au-Fe3O4 nanoparticles have an absorption peak at 525 nm and at 505 nm for 8-nm Au 
nanoparticles.  As compared to the single-component Fe3O4, the hybrid nanoparticles showed 
enhanced optical absorption properties in the NIR region.  The increase in the absorbance of Au-
Fe3O4 nanoparticles is due to the presence of Au in the particle composition which has been 
reported in several gold nanostructures used for NIR imaging 25.  The optical properties of these 
particles compares well to the gold nanoparticles UV-Vis spectra in the literature (peaks at 550 
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nm for core shell Au and 800 nm for  hollow Au nanoparticles) 25, 33.  In addition, the slight red 
shift of the Au-Fe3O4 has been attributed to the junction effect between Au and Fe 29.  
The potential use of HNPs for therapy as well as for magnetic resonance imaging also 
depends on their magnetic properties.  Generally, magnetic materials with superparamagnetic 
properties have been used as in vivo MRI contrast agents 34-36.  The field-dependent 
magnetization curve of the Au-Fe3O4 shows no hysteresis at room temperature (Figure 2-1 f), 
which is consistent with superparamagnetic behavior arising from the iron oxide (magnetite) 
nanoparticles.  The VSM measurements showed a magnetic moment of 44 for Au-Fe3O4 and 81 
emu/g for bare Fe3O4 nanoparticles.  These results compare well with previously reported 
literature values 12, 29.  To demonstrate the potential use as an enhanced MRI contrast agent, Au-
Fe3O4 was compared to bare Fe3O4 nanoparticles of an equivalent iron concentration.  MR 
images were obtained using a clinical 3.0-T MR system as described elsewhere (Supplemental 
Information).  The hybrid Au-Fe3O4 show a MR contrast with a r2 relaxivity value of 49.2 mM-
1s-1 while Fe3O4 exhibited stronger MR contrast with a relaxivity value of 69.0 mM-1s-1 (Figure 
2-2).  The significant decrease in the relaxivity value Au-Fe3O4 is attributed to the weakly 
magnetic contribution from the Au nanoparticles.  These properties make the HNPs potential 
MRI T2 contrast agents. 
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Figure 2-1: Particle characterization of Au-Fe3O4 of ; (a, b) TEM and DLS data of ‘as  
synthesized’ oleic-capped particle size with average of 25 nm;  (c, d) PL-PEG coated 
particles with average size 65 nm; (e) optical properties of HNPs with strong absorption 
at 600-800 nm;  (f)  Superparamagnetic properties with 40 emu/mg magnetic moment. 
Scale bar: 100 nm TEM 
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 The use of nanoparticles in vitro and in vivo requires that they are biocompatible.  The 
cytotoxic behavior of HNPs- and targeted HNPs-A33scFv conjugates on SW 1222 cells were 
examined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.  
As expected, the HNPs were reasonably nontoxic and biocompatible up to 100 µg particle 
concentration, whereas HNPs-A33 scFv conjugates show a dose-dependent toxicity.  Thus, no 
obvious cytotoxicity was observed at low doses up to 100 µg HNPs, while higher doses 
exhibited some toxicity (Figure 2-3). 
 
3.2. Confocal Imaging and Cellular Uptake 
The HNPs-scFv were fluorescently labeled with Alexa Fluor 488 and in turn used to 
demonstrate cellular particle uptake in SW 1222 cells.  The particle conjugates showed a slight 
red shift from an emission maximum of 520 nm for an un-conjugated Alexa Fluor 488 to 525 nm 
after conjugation to scFv or BSA (Figure 2-S1 (a-b) in the Supplementary Information).  
Further, the labeled particles of HNPs-scFv and HNPs-BSA showed to have equal conjugation 
efficiency which is necessary if they are to be used for comparative cellular uptake experiments 
(Figure S1 in the Supplementary Information).  They can also potentially be used for in vivo 
fluorescence imaging to monitor the effects of therapeutics 37.  The un-conjugated HNPs showed 
no fluorescence, confirming that the fluorescence is due to presence of Alexa Fluor 488 
(Supplementary information).  The applicability of  scFv to target and enhance therapeutic 
/particle uptake was demonstrated using confocal laser scanning microscope to image cells 
incubated with fluorescently-labeled HNPs-scFv or HNPs-BSA conjugates.  SW 1222 cells used 
as a control for receptor-mediated endocytosis were pretreated with excess free A33 scFv 
molecules (non-fluorescent, 100 times the number of scFv on particle) before incubation with 
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HNPs-scFv conjugates. This was necessary to block the extracellular A33 antigen receptors for 
which HNPs-A33 scFv conjugates could bind and be endocytosed.  Figure 2-4 (a-f) show 
bright-field and dark-field images obtained after 5-hr incubation where endocytosed particles 
appear green (HNPs-Alexa 488).  The results show that there is enhanced particle uptake of 
HNPs-scFv in A33 antigen expressing cells (SW 1222 cells) as compared to the uptake in SW 
1222 cells with blocked receptors or in HT 29 cells.  A time-course study of particle uptake up to 
15 h shows a time-dependent increase in the particle uptake for A33scFv single chain conjugated 
particles in cells expressing the A33 antigen cells while the particle uptake for non-A33 antigen 
cells is diminished (Figure 2-4 (g)).  At 15 hr, there is a 5-fold preferential particle uptake of 
HNPs-scFv in SW1222 cells with unblocked receptors as compared with cells with blocked 
receptors are cells that do not express A33 antigen receptors (Figure 2-4).  The preferential 
uptake of HNPs-scFv is attributable to receptor-mediated endocytosis which can be used to 
enhance particle uptake in A33-expressing colorectal cancer cells while limiting the uptake in 
non-antigen expressing cells.  The use of targeting agent such as the A33scFv antibody is crucial 
in reducing amount of therapeutics such as the amount the energy laser power to below medical 
safety standard needed to achieve therapeutic effects in cancers 1, 25.  It also provides a targeting 
mechanism for in vivo imaging as well as for drug delivery 9, 38. 
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Figure 2-2 : (a) Plot of spin-spin relaxation rate (R2) against Fe concentration for Au-Fe3O4 and 
bare Fe3O4 nanoparticles; (b) T2-weighted MR images of the PL-PEG-coated nanoparticles at 
various concentrations in water illustrating the detection limit to be lower than 31 µg/mL. Error 
bars represent variability in R2 values (n = 3). 
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3.4. In vitro phototherapy  
As shown in Figure 2-1 e, HNPs showed strong absorption in the NIR region and can 
potentially be used for therapeutic applications of cancer cells using NIR irradiation.  To 
demonstrate the photothermal effect in vitro, the SW 1222 and HT 29 cell lines were treated with 
HNPs-scFv conjugates and laser irradiated at varying intensities.  The proportion of viable cells 
as a function irradiation intensity for both cell lines were quantified by measuring the 
fluorescence intensity of calcien AM staining of cell death are visualized in fluorescence 
microscopy images.  Figure 2-5 show fluorescent images of NIR-irradiated cells after calcien 
AM staining where the presence of green fluorescence indicate live cells and regions devoid of 
fluorescence indicate dead cells.  After laser exposure at 5.1 W cm-2 for 6 min, the cell viability 
of SW 1222 cells decreased to nearly 53% while the viability of HT 29 cells remained almost 
unchanged (96%), indicating that the targeted HNPs-scFv conjugates are potent photothermal 
absorbers in cells that express A33 antigen (Figure 2-5 (b, g)).  At higher laser power intensities, 
the proportion of viable SW 1222 cells decreases more dramatically than the HT29 cells as is 
shown by the widening area devoid of fluorescence for SW 1222 cells (see Figure 2-5 (a-e)).  
Increased photothermal destruction was observed with increasing laser intensity i.e. the 
proportion of viable SW 1222 cells decreased to 32%, 11%, and 1% for laser intensities of 7.9, 
31.5, and 100 W cm-2.  In contrast, the control HT 29 cells that do not express A33 showed no 
significant decrease in cell viability at low laser intensity (98%, 96% and 90% for 3.2, 5.1 and 
7.9 W cm-2, respectively) and exhibited normal morphology after 6-min laser exposure.  The 
fluorescent images show no observable cell damage and appear indistinguishable from the 
images of non-irradiated cells (Figure 2-5 (f-h)).  Significant decrease in cell viability was 
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observed at 31.5 W cm-2 with 65% viability and 28% for 100 W cm-2 (Figure 2-5 (i, j)).  At this 
dosage, the laser power is high enough to cause photodestruction in a nonspecific fashion, even 
in the absence of the light-absorbing nanoparticles.  
The conclusion from this study was that use of A33scFv as a targeting agent leads to 
preferential particle uptake and that phothermal-active particles when irradiated with NIR 
irradiation result in photodestruction of SW 1222 cells at much less power (5.1 W cm-2) than in 
cells that do not express A33 antigen (31.5 W cm-2).  This allows for highly localized treatment 
of cells that express a known and targeted biomarker achieved by the antigenic nature of the cells 
and not by the positioning of the laser irradiation.  This system also could allow for broader 
application of laser illumination without adverse effects to untreated tissue thus allowing for 
greater assurance of complete irradiation of targeted areas. 
The threshold laser power for the selective destruction of A33 antigen-expressing cells 
(SW1222 cells) using HNPs-scFv is approximated to be 5.1 W cm-2.  This value compares well 
to the 7.0 W cm-2 threshold power intensity reported for the use of  transferrin-conjugated gold 
nanoparticles to selectively destroy breast cancer cells 1.  Gadolinium-based paramagnetic gold 
nanostructures with magnetic susceptibility and potential MRI agent have a reported 3.1 W cm-2 
threshold laser power for photodestruction of SKB3-expressing breast cancer cells 25.  Silica-
gold core-shell type gold nanoshells with 35.0 W cm-2 threshold laser power have also been 
reported 39.  While the potency of the hybrid Au-Fe3O4 compares favorably to other materials 
previously used for photothermal therapy, our HNPs can potentially be used for dual therapy and 
imaging via magnetic resonance imaging. 
 
3.5. Flow Cytometric Analysis of Photothermally-treated cells 
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Flow Cytometric (FACS) analysis was performed to measure the percentage of live, 
apoptotic, and necrotic cells. The effect of laser irradiation on cell death was investigated by 
varying laser intensity with a fixed concentration of 0.5 mg of HNPs-scFv. The degree of 
apoptosis and necrosis was then examined by measuring the binding of Annexin-V FITC and 
inclusion/exclusion of PI using FACSCalibur flow cytometer (Becton Dickinson).  Data were 
analyzed using the WINMDI software (Purdue University), employing a uniform analysis gate 
set on the core population of the cultured cells so that events of extreme forward or side scatter 
were excluded. The cytograms in Figure 2-6 show the bivariate PI/Annexin-V analysis of SW 
1222 cells after photothermal therapy at varying laser power.  Viable cells are negative for both 
PI and Annexin-V (Q3), apoptosis cells are PI negative and Annexin-V positive (Q2), while 
necrotic cells are positive both PI and Annexin -V (Q1). After 6-min laser irradiation at 5.1 W 
cm-2, 3.2% of the cell populations were apoptotic. With increasing laser power, the proportion of 
these cells increased to 7.0% at 7.9, 29.5% at 31.5, and 46.2% at 100 W cm-2.  The proportion of 
dead cells attributable to necrosis-related cell death were 22.5% for 5.1 W cm-2 and increased to 
37.6% at 7.9, 56.4% for 31.5 W cm-2, and 52.7% at 100 W cm-2 (Figure 2-6 (a-d)).  It seems that 
cell death was dominated by late apoptosis-related death at various laser intensities while the 
proportion of the necrosis-related cell death increased at higher laser power (31.5 and 100 W cm-
2).  Non-irradiated cells of equal density and grown under similar conditions were used as 
control.  The flow cytometric analysis revealed that < 1% cells were apoptotic or necrotic cells 
with the vast majority being live cells with negative PI/Annexin-V (Figure 2-6 e).  Our findings 
support other photothermal studies using anti-HER2 gadolinium-gold nanostructures targeting 
breast cancer cells that reported a similar observation where higher laser intensity to led increase 
in the necrotic cells 25.  This study confirmed the conclusion reached from our photothermal 
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study that using targeted particles increases preferential particle uptake in cells, which 
consequently reduces the amount of laser power required to reach threshold therapeutic levels.  
This study also provided more insight on the mechanism of cell death. 
 
 
 
  
 
Figure 2-3: Cell viability of SW 1222 cells after incubating in increasing concentration 
particle conjugates as determined by MTT assay of: (a) HNPs- A33scFv, (b) HNPs-
BSA. The results show a dose-dependent toxicity where there is significant cytoxicity at 
higher particle concentration. Error bars represent absorbance variability measured at 
570 nm where n = 3. 
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Figure 2-4: Particles uptake colorectal cancer cells as analyzed by confocal microscopy 
images; (a-d) SW1222 colorectal cancer cells with;  (a, b) HNPs- A33scFv; (c, d) HNPs- 
BSA, blocked receptors; (e, f) HT 29 cells with HNPs- A33scFv for  5hr; scale bar:10 
µm. g) time- course cellular uptake of HNPs conjugates. Error bars represent variability in 
image fluorescence (n = 5). 
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Figure 2-5: Cells incubated with HNPs-scFv and then irradiated by 800-nm laser for 6 min 
at different power densities. The first row shows SW 1222 cells while the second row 
shows HT 29 cells. Each column shows cells treated at a specific laser intensity where 3.2 
W cm-2 (a, f), 5.1 W cm-2 (b, g), 7.9 W cm-2 (c, h), 31.2 W cm-2 (d, i) and 100 W cm-2 (e, j). 
Viable cells appear green from calcien AM staining while dark areas devoid of 
fluorescence are cells destroyed from photothermal irradiation. Scale bar 10 µm for all 
images. 
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Figure 2-6: Flow cytometric analysis to determine death modes of SW 1222 colorectal 
cancer cells after NIR irradiation at varying laser intensities: (a) Untreated cells,  (b) 
5.2, (c) 7.9, (d) 31.5, (e) 100 W cm-2, and. Cells are double-stained with Annexin V-
FITC and propidium iodide (PI) to detect early apoptosis and necrosis (late stage 
apoptosis), respectively. Late apoptosis-related cell death is observed across the board 
with increasing necrosis-related cell death with increasing laser power. 
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4. Conclusion 
 
In summary, this work reports the preparation of multifunctional gold-iron oxide 
nanoparticles for targeting, imaging and laser photothermal therapy of cancer cells using laser 
irradiation at 800 nm.  The hybrid nanoparticles are functionalized with carboxyl-terminated 
phospholipid and then conjugated with A33scFv single chain antibody to target A33 antigen that 
are over-expressed on the surface of SW1222 colorectal cancer cells.  Our preliminary results 
showed that the presence of the targeting antibody (scFv) can facilitate preferential cellular 
particle uptake.  The photothermal studies with the immunotargeted hybrid nanoparticles show 
that they strongly absorb at 808 nm, with a photothermal cell damage power density threshold of 
~ 5.1 W cm-2.  This threshold for selective destruction of cancer is substantially lower than those 
reported for gold nanoshells (35 W cm-2) 39 and comparable to paramagnetic gold nanostructures 
(3.1 W cm-2) 25.  Further flow cytometric analysis of photothermally treated cells show that at 
lower power densities, the primary of model of cell death is by apoptosis-related cell death while 
the necrotic-related cell death becomes prevalent at higher laser densities (31.5 and 100 W cm-2).  
The results also demonstrate that the nanoparticle conjugates are potential multifunctional probes 
for cancer diagnosis and therapy.  In vivo studies will be carried out to examine the applicability 
of the multifunctional nanoparticles in targeting, imaging and therapy of cancer cells.  The 
imaging can be carried out using MR imaging and scattering-based imaging techniques including 
two-photon photoluminescence imaging 16, 40. 
 
 
 
81 
 
Acknowledgments 
 
We thank John Grazul (Cornell Center for Material Research) and Carol Bayles 
(Nanobiotechnology Center) for their assistance in performing TEM and fluorescence 
microscopy. The authors acknowledge the financial support from Sloan foundation and the 
Ludwig Institute for Cancer Research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
REFERENCES 
 
1. Li, J. L.; Wang, L.; Liu, X. Y.; Zhang, Z. P.; Guo, H. C.; Liu, W. M.; Tang, S. H., In vitro 
cancer cell imaging and therapy  using transferrin-conjugated  gold nanoparticles. Cancer 
Letters 2009, 274, 319-326. 
 
2. Kim, J.; Park, S.; Lee, J. E.; Jin, S. M.; Lee, J. H.; Lee, I. S.; Yang, I.; Kim, J.-S.; Kim, S. 
K.; Hyeon, T., Designed Fabrication of Multifunctional Magnetic Gold Nanoshells and 
their Application to Magnetic Resonance  Imaging and Photothermal Therapy. Angew. 
Chem Int 2006, 45, 7754-7758. 
 
3. Chen, J.; Wang, D.; Jiefeng, X.; Au, L.; Siekkinen, A.; Warsen, A.; Li, Z.-Y.; Zhang, H.; 
Xia, Y.; Li, X., Immuno Gold Nanocages with Tailored Optical Properties for Targeted 
Photothermal Destruction of Cancer Cells. Nano Lett. 2007, 5, 1318-1322. 
 
4. Kuo, W. S.; Wu, C. M.; Yang, Z. S.; Chen, S. Y.; Chen, C. Y.; Huang, W. M.; Sun, C. 
K.; Yeh, C. S., Biocompatible bacteria@Au composites for application in the 
photothermal destruction of cancer cells. Chem Commun 2008, 4430-32. 
 
5. Kam, N. W.; O'Connell, M.; Wisdom, J. A.; Dai, H., Carbon nanotubes as 
multifunctional biological transporters and near-infrared agents for selective cancer cell 
destruction. Proc. Natl. Acad. Sci. USA 2005. 
 
6. O'Neal, D. P.; Hirsch, L. R.; Halas, N. J.; Payne, J. D.; West, J. L., Photo-thermal tumor 
ablation in mice using near-infrared absorbing nanoparticles. Cancer Lett 2004, 209, 171-
6. 
 
7. Wang, L.; Bao, J.; Li, Y.; Huang, Y., Multifunctional Nanoparticles Displaying 
Magnetization anfd Near-IR absorption. Angew. Chem. Int. 2008, 120, (13), 2473-76. 
 
8. Park, H.; Yang, J.; Seo, S.; Kim, K.; Suh, J.; Kim, D.; Haam, S.; Yoo, K.-H., 
Multifunctional Nanoparticles for photothermally controlled drug delivery and magnetic 
resonance Imaging Enhancement. Angew. Chem. Int. 2008, 4, (2), 192-96. 
 
9. Park, J. H.; Maltzahn, G. V.; Sangeeta, B. H.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J., 
Micellar Hybrid Nanoparticles for Simultaneous Magnetofluorescent Imaging and Drug 
Delivery. Angew. Chem. Int. Ed. 2008, 47, 1-6. 
 
10. Drake, P.; Cho, H. J.; Shih, P. S.; Kao, C.-H.; Lee, K.-F.; Kuo, C. H., Gd-doped iron-
oxide nanoparticles for tumour therapy via magnetic field hyperthermia. J. Mater. Chem. 
2007, 17, 4914-4918. 
 
11. Wang, L.; Park, H. Y.; Lim, S. I.; Schadt, M. J.; Mott, D.; Luo, J.; Wang, X.; Zhong, C., 
Core@Shell nanomaterials: gold-coates magnetic nanoparticles. J Mater Chem 2008, 18, 
2629-35. 
 
83 
 
12. Wang, L.; Maye, M. W.; Fan, Q.; Rendeng, Q.; Zhong, C., Iron oxide-gold core-shell 
nanoparticles and thin film assembly. J Mater Chem 2005, 15, 1821-32. 
 
13. Josephson, L.; Kircher, M. F.; Mahmood, U.; Tang, Y.; Weissleder, R., Near-Infrared 
Fluorescent Nanoparticles as Combined MR/Optical Imaging Probes. Bioconjugate 
Chemistry 2002, 13, (3), 554-560. 
 
14. Medorova, Z.; Pham, W.; Kim, Y.; Dai, G.; Moore, A., In vivo imaging of tumor 
response to therapy using a dual-modality imaging strategy. Int. J. Cancer 2006, 118, 
2796-802. 
 
15. Veiseh, O.; Sun, C.; Gunn, J.; Kohler, N.; Gabikian, P.; Lee, D.; Bhattarai, N.; 
Ellenbogen, R.; Sze, R.; Hallahan, A.; Olson, J.; Zhang, M., Optical and MRI 
Multifunctional Nanoprobe for Targeting Gliomas. Nano Lett. 2005, 5, (6), 1003-1008. 
 
16. Khemtong, C.; Kessinger, C. W.; Ren, J.; Bey, E. A.; Yang, S.; Guthi, J. S.; Boothman, 
D. A.; Gao, J., In vivo off-Resonance Saturation  Magnetic Resonance Imaging of 
Targeted Superparamagnetic Nanoparticles. Cancer Res 2009, 69, (4), 1651-55. 
 
17. Prasad, N. K.; Rathinasamy, K.; Panda, D.; Bahadur, D., Mechanism of cell death 
induced by magnetic hyperthermia with nanoparticles of Mnx Fe2O3 synthesized by a 
single step process. J. Mater. Chem. 2007, 17, 5042-5051. 
 
18. Arbab, A. S.; Bashaw, L. A.; Miller, B. R.; Jordan, E. K.; Lewis, B. K.; H, K., 
Characterization of biophysical and metabolic properties of cells labeled with 
superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR 
imaging. Radiology 2003, 229, (3), 838-46. 
 
19. Glennie, M. J.; van de Winkel, J. G., Renaissance of cancer therapeutic antibodies. Drug 
Discovery Today 2003, 8, 503-5. 
 
20. Deckert, P. M.; Renner, C.; Cohen, L. S.; Jungbluth, A.; Ritter, G.; Welt, S., A33scFv-
cytosine deaminase:a  recombinant protein construct for antibody-directed enzyme-pro-
drug therapy. J. Cancer 2003, 88, 937-939. 
 
21. Ackerman, M.; Chalouni, C.; Schmidt, M.; Raman, V.; Ritter, G.; Old, L.; Mellman, I.; 
Wittrup, K., A33 antigen displays persistent surface expression. Cancer Immunology, 
Immunotherapy 2008, 57, (7), 1017-1027. 
 
22. Daghighian, F.; Barendswaard, E.; Welt, S.; Humm, J.; Scott, A.; Willingham, M. C.; 
McGuffie, E.; Old, L. J.; Larson, S. M., Enhancement of Radiation Dose to the Nucleus 
by Vesicular Internalization of Iodine-125-Labeled A33 Monoclonal Antibody. J Nucl 
Med 1996, 37, (6), 1052-1057. 
 
84 
 
23. Damasceno, L.; Pla, I.; Chang, H. J.; Cohen, L.; Ritter, G.; Old, L. J.; Batt, C. A., An 
optimized fermentation process for high-level production of a single-chain antibody 
fragment in Pichia pastoris. Protein Express  Purif. 2004, 37, 18-26. 
 
24. Hong, Y. C.; Sinoj, A.; Juana, M.; Soazig, C. D.; Kahli, S.; Il, K.; Carl, A. B., 
Encapsulation of Single Small Gold Nanoparticles by Diblock Copolymers. Chem Phys 
Chem 2008, 9, (3), 388-392. 
 
25. Lim, Y. T.; Cho, M. Y.; Lee, J. M.; Chung, B. H., Paramagnetic gold nanostructures for 
dual bioimaging and phototherapy of cancer cells. Chem Commun 2008, 4930-4932. 
 
26. Yu, H.; Chen, M.; Rice, P. M.; Wang, S. X.; White, W. R. L.; Sun, S., Dumbbell-like 
Bifunctional  Au-Fe3O4 Nanoparticles. Nano Lett. 2005, 5, (2), 379-382. 
 
27. Shi, W.; Zeng, H.; Sahoo, Y.; Ohulchanskyy, T. Y.; Ding, Y.; Wang, Z. L.; Prasad, P. N., 
A General Approach to Binary and Ternary Hybrid Nanocrystals. Nano Lett. 2006, 6, (4), 
875-881. 
 
28. Cortez, C.; Crook, T. E.; Johnson, A. P. R.; Radt, B.; Cody, S. H.; Caruso, F., Targeting 
and Uptake of Multilayered Particles for Colorectal Cancer cells. Adv Mater 1998, 18, 
1998-2003. 
 
29. Xu, C.; Xie, J.; Wang, C.; Kohler, N.; Walsh, E. G.; Morgan, J.; Chin, Y. E.; Sun, S., Au-
Fe3O4 Dumbbell Nanoparticles as Dual-Functionalal Probes Angew. Chem. Int. 2008, 
47, 173-176. 
 
30. Terentyuk, G. S.; Maslyakova, G. N.; Suleymanova, L. V.; Khlebtsov, N. G.; Khlebtsov, 
B. N.; Akchurin, G. G.; Maksimova, I. L.; Tuchin, V. V., Laser-induced tissue 
hyperthermia mediated by gold nanoparticles: toward cancer phototherapy. Journal of 
Biomedical Optics 2009, 14, (2), 021016-9. 
 
31. Murphy, C. J.; Gole, A. M.; Stone, J. W.; Sisco, P. N.; Alkilany, A. M.; Goldsmith, E. C.; 
Baxter, S. C., Gold Nanoparticles in Biology: Beyond Toxicity to Cellular Imaging. 
Accounts of Chemical Research 2008, 41, (12), 1721-1730. 
 
32. Niidome, T.; Yamagata, M.; Okamoto, Y.; Akiyama, Y.; Takahashi, H.; Kawano, T.; 
Katayama, Y.; Niidome, Y., PEG-modified gold nanorods with a stealth character for in 
vivo applications. Journal of Controlled Release 2006, 114, (3), 343-347. 
 
33. Larson, T. A.; Bankson, J.; Aaron, J.; Sokolov, K., Hybrid plasmonic magnetic 
nanoparticles as molecular specific agents for MRI imaging and photothermal therapy of 
cancer cells Nanotechnology 2007, 18, 325-333. 
 
34. Sun, S.; Zeng, H., Size-Controlled Synthesis of Magnetite Nanoparticles. J. Am. Chem. 
Soc 2002, 124, 8204-8205. 
 
85 
 
35. Jun, Y. H., YM; Choi, JS; Suh, JS; Cheon, J, Nanoscale Size Effect of Magnetic 
Nanocrystals and Their Utilization for Cancer Diagnosis via Magnetic Resonance 
Imaging. JACS 2005, 127, 5732-5733. 
 
36. Lee, J. H., YM; Jun, JW; Jang, JT; Cheon, J, Artificially engineered magnetic 
nanoparticles for ultra-sensitive molecular imaging; Nature medicine. Nature Medicine 
2007, 13, (1), 95-99. 
 
37. Dubertret, B.; Skourides, P.; Norris, D. J.; Noireaux, V.; Brivanlou, A. H.; Libchaber, A., 
In Vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles. Science 2002, 
298, 1759-1761. 
 
38. Welt, S.; Ritter, G.; Williams, C.; Cohen, L. S.; John, M.; Jungbluth, A.; Old, E. A., 
Phase I Study Anticolon Cancer Humanized Antibody A33. Clin Cancer Res 2003, 9, 
1338-1346. 
 
39. Hirsch, L. R.; Stafford, R. J.; Bankson, J. A.; Sershen, S. R.; Rivera, B.; Price, R. E.; 
Hazle, J. D.; Halas, N. J.; West, J. L., Nanoshell-mediated near-infrared thermal therapy 
of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. U. S.A 2003, 100, 
(23), 13549-13554. 
 
40. Park, J.; Estrada, A.; Sharp, K.; Sang, K.; Schwartz, J. A.; Smith, D. K.; Coleman, C.; 
Payne, J. D.; Korgel, B. A.; Dunn, A. K.; Tunnell, J. W., Two-photon-induced 
photoluminescence imaging of tumors using near-infrared excited gold nanoshells. Opt. 
Express 2008, 16, 1590-1599. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
Supplementary Information 
Gold Hybrid Nanoparticles for Targeted Phototherapy and Cancer Imaging 
 
 
Experimental Section 
Synthesis and Functionalization of Au-Fe3O4 hybrid nanoparticles (HNPs): Gold-iron 
oxide hybrid nanoparticles capped with oleic acid were synthesized by a previously reported 
procedure 1.  The surface HNPs nanoparticles were then functionalized with carboxyl  group-
containing phospholipid by coating with (1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-
[carboxy(Polyethylene Glycol) 2000  (PL-PEG COOH) 2.  Briefly, 17 mg of oleic acid-capped 
as-synthesized nanoparticle powder was suspended in 1mL chloroform with 5.5x10-6 moles of 
carboxyl-terminated PEG phospholipids (PL PEG COOH).  The chloroform was evaporated to 
dryness at room temperature and the residue heated to 80oC.  The particles were rehydrated in 
1mL of borate buffer (pH = 5.5) and then spun at 500,000 x g in an ultracentrifuge to eliminate 
empty micelles. The resuspended water-soluble HNPs were sonicated in a bath sonicator 
(Branson Sonifier 250, Branson Ultrasonics) for 30 minutes and were subsequently bio-
functionalized. 
Bio-functionalization of HNPs with A33 single chain antibody (A33scFv): The PL-PEG-
coated HNPs were then subsequently functionalized to attach single chain antibody as well as 
bovine serum albumin using EDC-NHS chemistry (1-Ethyl-3-(3-dimethylaminopropyl 
carboiimide HCl and N-hydroxylsulfosuccinimide). Briefly, 50 µL of 5 mg mL-1 HNPs-PL-PEG 
were  dispersed  in borate buffer (pH = 5.5) and then reacted with 40 mg EDC and 20 mg NHS 
for 20 min at room temperature.  Excess EDC and NHS were removed by using a size exclusion 
chromatography FPLC system (Superdex 200 size exclusion column on an AKTA Explorer 
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FPLC, Amersham Biosciences, Piscataway, NJ) eluted with 50 mM sodium borate buffer (pH 
5.5) and concentrated by centrifugation (3 000 rpm, 10 min) using a 30,000 MWCO filter 
(Millipore).  The NHS-ester activated HNPs were reacted with 2 mL of 1 mg mL-1 A33 scFv at 
4o C for 2 hr.  The conjugates were again purified by size exclusion chromatography FPLC 
system eluting with 50 mM phosphate-buffer saline (pH 7.4).   
 Fluorescent-labeling of HNPs-scFv: The HNPs-scFv conjugates were then reacted with 
amine-reactive Alexa Fluor® 488 carboxylic acid, tetrafluorophenyl (TFP) ester following 
manufacturer’s protocol (Invitrogen).  Briefly, 100 µL of 3.1 mg mL-1 of HNPs-scFv were added 
into 1 mL of 10 mM of bicarbonate solution (pH 8.1) to which excess amine-reactive Alexa 
Fluor (TFP) 488 was added and stirred at 4o C for 3 hr.  The fluorescently-labeled HNPs-scFv 
conjugates were also purified using size exclusion chromatography FPLC system eluted using 
phosphate-buffer saline (pH 7.4). The labeled HNPs-scFv were concentrated to 1 mg mL-1 by 
centrifugation and subsequently used to perform cellular uptake experiments. The fluorescence 
of HNPs-scFv and HNPs-BSA conjugates were measured using spectrophotometer (LS-B 50, 
Perkin Elmer, 490/520 excitation-emission wavelengths). The successful antibody 
immobilization was determined by measuring the fluorescence of the nanoparticle conjugates. 
The presence of fluorescence in purified nanoparticle conjugates indicates that the A33scFv was 
successfully immobilized on the particles. This is because amine-reactive Alexa Fluor 488 would 
not react directly with the carboxyl-terminated nanoparticles, but would react via amines groups 
on the antibody which were covalently linked to the A33 scFv antibody via EDC-NHS 
chemistry.  
Magnetic Resonance Imaging (MRI) measurement: To determine the potential 
application of HNPs particles for MR contrast imaging, serial dilution of particles were prepared 
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and the T2-weighted value measured using a 3T GE HDx imager (General Electric Healthcare, 
Waukesha, WI). A transmit-receive knee coil array was used for data acquisition, T2-weighted 
fast-spin-echo sequences with the following parameters were used: repetition rate (TR) = 2400 
ms, echo time (TE) = 80 ns, slick thickness = 0.5 mm, field of view = 140 x 140 mm, echo train 
length = 13.  
Magnetic nanoparticles are known to shorten the spin-spin relaxation time (T2) of water 
resulting in a decrease in the MR signal intensity.  The MR signal intensity decreased with 
increasing HNPs concentration because of higher concentration of Fe3O4 nanoparticles. 
Nanoparticles Cytotoxicity and cell viability Assay: In vitro cytotoxicity was evaluated 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Briefly, 10,000 
cells/well were seeded in black-walled 96-well culture plates in a final volume of 100 µL.  After 
attachment for 24 h, cells were incubated with nanoparticle conjugates at various concentrations 
(0, 30, 60, 90, 120, 150 µg HNPs) for 12 h before adding 50 µl of MTT (5 mg mL-1 in PBS) 
solution to each well for an additional 4 h.  The reaction was stopped by removal of MTT, and 
formazan crystals were solubilized in 100 µl dimethyl sulfoxide (DMSO) in each well.  
Absorbance at 570 nm was recorded using a Model 680 Microplate Reader (Bio-Rad, Bath, UK) 
and then correlated to cell viable using a beer law via a standard curve. 
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Figure 2-S1 show fluorescence spectra of Alexa 488 labeled-particle conjugates. The 
fluorescence of HNPs-A33scFv and HNPs-BSA conjugates are represented on Figure 2-S1 (a, 
b) in which the emission maximum is shifted ~ 5 nm higher compared to un-conjugated dye 
(Figure 2-S1 (c)).  The HNPs-BSA-Alexa 488 conjugates that were treated and reacted in a 
similar fashion (Figure 2-S1 (b)) have equal fluorescence intensity, suggesting equivalent 
conjugation efficiency. 
 
Figure 2-S1: Fluorescence spectra of particle conjugates obtained at 490/ 520 
excitation-emission wavelength of Alexa Fluor 488-labeled conjugates; (a) HNPs-BSA, 
(b) HNPs-A33scFv,(c) Alexa 488, and (d) HNPs only. The fluorescently labeled 
particles show an emission peak while non-fluorescent HNPs do not have an emission 
peak. 
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Chapter 3 
Polyacrylic acid-derived Gold Nanorods for Cellular Targeting and Photothermal Therapy  
 
Abstract 
 The modification and control of surface chemistry on gold nanorods (GNRs) is a critical 
step in the production of functional GNRs for use in a myriad of applications.  The popular 
cetyltrimethyl ammonium bromide (CTAB)-capped GNR synthesis produces stabile aqueous 
suspensions of GNRs having a net positive surface charge and trimethyl ammonium surface 
groups.  However, CTAB-capped GNRs are inert to traditional coupling chemistries, and 
typically require GNR ligand exchange in order to change the GNR surface groups to more 
functional moieties (e.g., carboxylates, amines, thiols).  Further, CTAB removal and ligand 
exchange often presents problems associated with GNR precipitation.  Here, we report a single-
step, layer-by-layer procedure to functionalize CTAB-capped GNRs with functional carboxylic 
acid surface groups via electrostatic self-assembly using polyacrylic acid (PAA).  This approach 
allowed for consistent biomolecule-GNR coupling using standard carboxyl-amine conjugation 
chemistries.  The current study focuses on cancer targeting biomolecule-GNR conjugates and 
selective photothermal destruction of cancer cells by GNR-mediated hyperthermia and near-
infrared light.  Gold nanorods were conjugated to a single chain antibody (A33scFv) selective for 
colorectal carcinoma cells and used as probes to target, visualize and demonstrate photothermal 
therapy of colorectal carcinoma cells.  Selective targeting and GNR uptake in antigen-expressing 
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human colorectal carcinoma (SW 1222) cells were observed using fluorescence microscopy.  
Selective photothermal therapy is demonstrated using SW 1222 cells, where > 62 % cell death 
was observed after cells are treated with targeted A33scFv-GNRs and an 808-nm diode laser. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from: D.K. Kirui, S. Krishnan, A.D. Strickland and C. A. Batt.Gold 
Polyacrylic acid-derived Gold Nanorods for Cellular Targeting and Photothermal Therapy. 
Macromolecular Bioscience 11 (000-000) (2011)  (Copyright 2011 Wiley). 
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Gold nanorods (GNRs) are nanoscale materials that possess interesting optical properties 
and unique application potentials particularly in photothermal therapy,1, 2 biosensing,3 molecular 
imaging,4-6 and in gene delivery,7 for cancer therapy.  These various potential applications 
require that the nanorods be functionalized to attach different biochemical groups.  However, this 
is a very challenging issue that typically involves multistep processes and can lead to shape 
change and self-assembly based aggregation.  As synthesized, nanorods are coated with a 
cationic surfactant cetyltrimethyl ammonium bromide (CTAB) stabilizer that does not provide 
useful chemical moieties for successive conjugation to attach biomolecules.  Previous 
conjugation strategies have involved exchanging CTAB for other molecules with useful 
functional groups.  A common example is the use of thiolated bifunctional small molecules such 
as mercaptopropionic acid and/or mercaptohexanoic acid and other homofunctionalized thiol 
molecules (e.g poly(ethylene glycol) (PEG)-thiols) chemisorbed on the nanorod surfaces 8 to 
displace CTAB from the surface.  While thiolated nanorods have good colloidal stability in 
buffered solutions,9 they are prone to detach from the particle surface in the presence of other 
thiols, or during chromatographic purification steps.  Additionally, thiols are reactive to some 
conjugation reagents (e.g., maleamide).  The instability of thiol groups have been shown to 
increase particles’ rapid clearance in blood, making them less desirable for in vivo applications 
that require long blood half-life.10  Gold nanorods are also commonly functionalized by applying 
a thin layer of mesoporous silica coat on nanorods and then chemically modifying the silica 
surface with another silane molecule (e.g. aminopropyltrimethoxysilane) for conjugation to 
molecular targets.  Silica-coated nanorods have been shown to have good colloidal stability; 
however its syntheses require the use of intermediate coatings such as poly (vinylpyrrolidone) 
and polystyrene sulfonate to facilitate silica coating.11  Additionally, obtaining a smooth silica 
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thickness is critically dependent on amount of CTAB on the nanorods, amount of base added, 
and ethanol or methanol/water ratio used.12, 13  This process is often tedious and time-consuming 
resulting in nanorods that are prone to aggregation and have limited uses in biomedical 
applications.  
Another commonly used method is Layer-by-layer (LBL) electrostatic adsorption of 
polyelectrolytes on positively-charged CTAB surface on GNRs.14  Layer-by-layer coating 
involves  applying a layer of negatively-charged poly-styrene sulfonate (PSS) over CTAB layer 
and then subsequently coating with positively-charged polyallylamine hydrochloride (PAH) 
layer.11  This coating alters the surface charge on GNRs in order to achieve good colloid stability 
and/or to enhance cellular uptake.  For example, Chen et al recently prepared PAH-PSS-GNRs 
with a net positive surface charge that could stain HeLa cells due to electrostatic interaction.15  
While coating GNRs with these polyelectrolytes have been shown to enhance biocompability 
and increase cellular uptake, they have been immobilized through time-consuming, multistep 
processes and have not been used for covalent attachment of targeting agents that are critical to 
achieve specificity required for cellular applications. 
 In this report, we outline a novel, simple layer-by-layer method for direct coating of 
CTAB-stabilized gold nanorods with polyacrylic acid (PAA) without intermediary coating step 
or no further polymerization step (Scheme 3-1).  Additionally, the coating strategy allows the 
covalent attachment of targeting molecules such as single chain antibodies without further 
modifications.  We hypothesized that CTAB-capped nanorods can be coated in a single-step with 
a thin layer of PAA coating resulting in rods with peripheral carboxyl groups for facile 
attachment of targeting agents such as A33scFv.  Photothermal therapy application of targeted 
A33-GNRs was demonstrated in colorectal cancer cells using a continuous wave 808-nm laser 
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treatment.  The cationic CTAB adsorbed to the nanorods can provide strong positive charges to 
which a layer of negatively-charged PAA can form stable water-soluble nanorods with carboxyl 
functional groups on the surface.  The carboxyl functional groups provide critical anchors for 
targeting agents and other biomolecules.  Cytotoxicity of the resultant PAA-coated GNRs were  
demonstrated using a  human colon adenocarcinoma, SW 1222 cell line, known to express A33 
receptors on the plasma membrane 16 and assessed viability after 24 h of incubation with 
nanorods using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  
Gold nanorods were then conjugated to A33 single chain antibody (A33scFv) to form A33scFv-
GNRs, labeled with fluorescein (FITC), and subsequently used to demonstrate potential 
application for targeting, cell labeling, and for selective photothermal therapy of antigen-
expressing cells.   
 
1. Experimental Methods 
 
1.1. Chemicals and Materials. 
  Gold (III) chloride (≥ 99.9%), silver nitrate (99.99%), L-ascorbic acid (99%), 
cetyltrimethyl ammonium bromide (CTAB, 99+ %), benzylhexadecyldimethylammonium 
chloride (BDAC), sodium borohydride (96%), fluorescein (FITC), and poly (acrylic acid) (Mv = 
420,000) were purchased from Sigma-Aldrich.  N-hydroxylsulfosuccinimide (Sulfo-NHS), 1-
Ethyl-3-(3-dimethylaminopropyl carboiimide HCl (EDC) were purchased from Pierce 
Biotechnology, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell 
proliferation assay kit, blocker solution, alkaline phosphatase chromogenic solution(BCIP/NBT) 
were purchased from Invitrogen; calcien AM stain purchased from BD Biosciences; protein L-
peroxidase was purchased from Sigma-Aldrich; and nitrocellulose membrane, 0.2 µm, was 
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purchased from Whatman.  A33 single chain antibody was expressed and purified as previously 
reported 17. 
 
1.2. Preparation of Au Seeds. 
 A CTAB solution (1 mL, 0.20 M) was mixed with HAuCl4 (1mL, 0.5 mM) under 
stirring, to which 120 µL of freshly prepared, ice-cold NaBH4 (0.01 M) was added, leading to a 
brownish-yellow solution. The obtained solution was stirred for another 2 min and was kept at 
25o C and was used as the seed solution.  
 
1.3. Preparation of Au NRs.  
 Growth solution was prepared by mixing together 50 mL  of 0.20 M CTAB and 0.15 
M BDAC, 2.8 mL of 4 mM AgNO3, 5 mL of 15 mM HAuCl4 and 45 mL of Milli-Q water in a 
250 mL flask.  After gentle mixing and equilibration in a 27-30o C oil bath, approximately 1 mL 
of ascorbic acid (80 mM) was slowly added drop-wise until the mixture became colorless.  After 
this color change, ascorbic acid solution was added drop-wise to give a final volume of 1.25 mL.  
The final step was the addition of 120 µL of the seed solution to the growth solution at 27-30oC.  
The colorless solution gradually became purple within 10-20 minutes and was allowed to 
proceed for 2 h.  The solution was centrifuged at 10 000 rpm for 15 min to remove excess CTAB 
and BDAC surfactant.  It was further re-suspended and centrifuged twice to remove excess 
CTAB and then re-dispersed in a final volume of 20 mL Milli-Q water.  
 
1.4. Surface modification of Au GNRs.  
 CTAB bilayer is dynamic in nature and can desorb resulting in the apparent toxicity of 
gold nanorods.  Moreover, the desorption of the surfactant from the bilayer will decrease the 
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effective nanorod surface charge and thus may result in irreversible nanonorod aggregation;18 
hence, it is important to mask the CTAB layer for potential biomedical applications.19  In this 
work, surface modification of gold nanorods was coated with polyacrylic acid using the 
following protocol.  In brief, 1 mL of GNRs solution was diluted to 10 mL with Milli-Q water.  
To this solution, 100 µL of 2 µg/mL polyacrylic acid (Mw = 420,000) prepared in a 6 mM NaCl 
solution (which was sonicated previously for 30 min) was added drop-wise and the resulting 
solution was stirred vigorously for 6 h.  The PAA-coated GNRs were separated by centrifugation 
in a test tube twice to remove excess polyelectrolyte and then redispersed in 2 mL of PBS buffer 
(pH 7.4).  The colloidal stability of PAA-coated GNRs was compared to the stability of CTAB-
capped nanorods after repeated centrifugation and redispersion in buffer solutions and in buffer-
ethanol mixture. 
 
1.5. Functionalization of Poly(acrylic) acid-coated Nanorods.  
 The carboxyl-terminated PAA-coated nanorods were modified by covalently attaching 
A33scFv single antibody 17 using EDC-NHS chemistry following the manufactures protocols 
and then fluorescently-labeled with amine-reactive fluorescein (FITC). Particle purification to 
eliminate excess un-conjugated antibody and fluorescein were carried out in a size exclusion 
chromatography using FPLC system (Superdex 200 size exclusion column on an AKTA 
Explorer FPLC, Amersham Biosciences, Piscataway, NJ). 
 
1.6. Dot-blot immunoassay analyses.   
 A33scFv-GNRs conjugates were analyzed using a colorimetric dot-blot immunoassay 
to determine the presence and retention of A33scFv native conformation after the attachment of 
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GNR.  This method is useful for screening antibody reactivity against specific antigens and is 
employed in the production of antibodies, antibody purification, or for routine diagnosis of 
pathological conditions.20  In brief, 20 µL of A33scFv-GNRs (1 mg mL-1), 20 µL of GNRs (1 mg 
mL-1), and 5 µL of A33scFv (0.6 mg mL-1) were spotted on a nitrocellulose membrane and 
allowed to dry for 1 min.  The membrane was immersed in Milli-Q water for 5 min and 
developed in blocker solution following manufacturer’s protocol (Invitrogen).  The reactivity of 
the conjugates were tested against a 5-mL solution of a protein L-peroxidase conjugate (100 µg 
mL-1), where protein L is known to bind to the Fab region of the antibody.  Next, the membrane 
was incubated in an alkaline phosphatase chromogenic solution (BCIP/NBT, 5 mL), and an 
intense purple color develops in response to peroxidase catalysis.  
 
1.7. Cytotoxicity and Cellular uptake Studies.  
 We examined the potential cytotoxicity of PAA-coated nanorods using a colorimetric 
MTT cell viability assay while cellular uptake was examined using fluorescent-based confocal 
microscopy analysis.  Human colorectal SW1222 cancer cell line were cultured at 37°C in a 
humidified atmosphere containing 5% CO2 and grown continuously in Dulbecco’s modified 
Eagle (DMEM) medium (Invitrogen) containing 10% fetal bovine serum (Sigma) and 1% 
penicillin-streptomycin (Invitrogen) and used for both cytotoxicity and cellular uptake studies.  
In a cytotoxicity experiment,  a 100 µL  suspension of SW 1222 cells (106 cells mL-1) was plated 
onto 96-well black-walled plates, grown for 12 h, then treated with an aliquot of increasing 
PAA-GNRs concentration and maintained at 37oC for 7 h  with periodic monitoring.  Medium 
containing gold nanorods not taken up by the cells was discarded; fresh media was replenished 
and 10 µL of MTT assay component A was added followed by the addition 100 µL of 
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component B 18 h later.  The absorbance of the resultant cell suspension was determined (λ = 
595 nm) by using a microplate absorbance reader (Tecan GENios, MTX lab systems, Virginia) 
and correlated to cell density using a pre-determined standard curve.  The absorbance of cell 
suspensions treated with PAA-GNRs were compared to the untreated wells and its cell viability 
deduced.  For cellular uptake studies, human colorectal cancer cells (SW 1222 and HT 29) were 
seeded overnight in a 35-mm glass bottom flask at density of 104 cells in a humidified 
incubator.21  Cells designated for non-targeted cellular uptake were subsequently treated with 
excess A33scFv in phosphate buffer (PBS, pH 7.4) for 4 h to block the extracellular A33 antigen 
receptors and was used as a control.  The seeded cells were treated with 60 µL of 2 mM FITC-
labeled A33scFv-GNRs for 6 h after which nanorods not taken up were discarded, washed three 
times with PBS, and replenished with fresh medium.  To allow live-cell visualization, 20 µL of 
FM 4-64® cell labeling dye (20 µg mL-1, Invitrogen) was added and then further incubated in a 
37oC humidified incubator for 30 min.  The cellular uptake was visualized by the fluorescence 
intensity from fluorescein using confocal microscope (Zeiss).  
 
1.8. Photothermal therapy. 
  The potential application of GNRs for targeted photothermal therapy was investigated 
by measuring the temperature rise of PAA-GNRs solution (100 µg mL-1, PBS) irradiated using 
808-nm continuous wave (cw) laser (5.1 W cm-2) for 10 min.  Next, malignant colorectal cancer 
cell line, SW 1222 cell line, which express A33 antigen was used to study the photothermal 
therapy effect of targeted nanorods using a HT 29 cells as a control. The cells were grown at 
concentration of 100,000 cells/well in 35-mm glass bottom culture plates overnight.  The 
monolayers were treated with A33scFv-GNRs conjugates for 5 h in fresh medium.  After which 
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the cells were washed and fresh medium replenished before laser irradiation with a 808-nm laser 
for 6 min.  To find the threshold NIR irradiation intensity for inducing photothermal destruction, 
the laser power was increased step-wise (n ~ 2.5 W cm-2) while maintaining a fixed irradiation 
area of 4 mm in diameter.   Cell viability after laser irradiation was assessed using a membrane-
permeable dye calcein-AM used as a live cell stain.  The dye permeates cell membranes and is 
digested by esterases inside the cytoplasm to produce a green fluorescent calcein dye.  Briefly, 
40 µL of 10 µM of freshly prepared calcien AM solution was added and incubated for 1 h.  The 
cells were imaged using fluorescence microscope (Olympus BX50) with a green filter.  
Quantitative analysis of cell death was performed by measuring fluorescence of detached cells 
using a spectrophotometer (LS-50B) with 470 nm/ 520 nm excitation-emission filter. 
 
1.9. Instrumentation.  
 The characterization of gold nanorods was carried out by using different experimental 
techniques. Absorption UV-visible spectra were measured with a Shimadzu spectrometer in a 
quartz cell with 1 cm path length.  Fluorescence spectra were measured with a LS-50B 
spectrometer (Perkin Elmer) also in a quartz cell with 1 cm path length.  The nanorod solution 
was dried on carbon formvar-coated grids and analyzed in a transmission electron microscopic 
(TEM, FEI Tecnai G2 F20) with a field-emission gun operating at 120 kV.  Dynamic light 
scattering (DLS) studies and surface charge measurements of gold nanorods before and after 
polyacrylic acid coating were determined using Malvern Zetasizer Nano ZS (Malvern 
Instruments).  Attenuated total reflectance Fourier transform infrared (ATR-FTIR, Bruker 
Optics, Vertex 80v) was used to analyze the adsorption of PAA on the nanorod surface.  Samples 
for analysis were prepared by carefully dispersing 100 µL (1 mg mL-1) of nanorod solution onto 
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a silicon oxide chip, and allowing it to dry in a dessicator for 24 h.  Live cell imaging for cellular 
uptake studies was carried out using LS-510 confocal microscope (Zeiss). 
 
 
 
 
 
 
 
Scheme 3-1: Schematic representation of Layer-by-layer PAA-coating procedure of gold nanorods 
using polyacrylic acid and subsequent bio-functionalization to prepare molecular probes for cellular 
labeling. 
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2. Results and Discussion 
Gold Nanorod Synthesis and Characterization. Gold nanorods were synthesized by a 
seed-mediated growth method using CTAB and BDAC surfactants, as described in the 
Experimental Section. The polymer coating of the CTAB-stabilized gold nanorods and 
successive bio-conjugation scheme are shown in Scheme 3-1.  The seed-mediated synthesis 
resulted in gold nanorods with an average aspect ratio of  5-6 (length 66 ± 5 and width 11 ± 3 
nm), which is consistent with literature reports.5, 14, 22  Before surface modification and 
conjugation reactions, the structural and optical properties of CTAB-stabilized gold nanorods 
were confirmed by transmission electron microscopy (TEM), dynamic light scattering (DLS) and 
by UV−vis spectroscopy.  TEM micrographs and DLS size distribution data showed fairly 
uniform gold nanorods (Figure 3-2 (a, b)).  CTAB-stabilized nanorods are positively charged, 
and their mutual repulsion prevents aggregation and as a result remained stable in the original, 
high-CTAB content solution for over 3 months.  However, the presence of CTAB poses major 
obstacles in utilizing gold nanorods for biological applications.  First, CTAB is a cationic 
detergent and shows high cytotoxity at the concentrations used for rod synthesis (~ 0.2 M).23, 24 
The cytotoxicity has been attributed to the excess CTAB in solution, and not from the fraction of 
CTAB bound to the nanonorods.  We assumed that through strong electrostatic cationic nanorod-
bound CTAB and consequently would reduce cytotoxicity associated with time-dependent 
desorption of the CTAB surfacant.  More importantly, the carboxyl-groups on the polymer chain 
would provide critical functionality to anchor biomolecules required for various applications.  In 
fact, after incubating the rods with PAA for 6 h, TEM analysis showed monodispersed rods 
coated with a thin layer (~ 3 nm) of PAA which is shown with uranyl acetate negative staining 
(Figure 3-2 (d)).   
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Figure 3-2 : TEM images of as-synthesized CTAB-coated NRs (A); CTAB-coated NRs stained 
with uranyl acetate showing no apparent surface coating (B); PAA-coated NRs (C); PAA-coated 
NRs stained with uranyl acetate showing a 3-nm layer of polyacrylate coating (D); DLS size 
distribution data of as-synthesized NRs (E); and PAA-coated NRs (F). 
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The uranyl acetate stained images are shown on Figure 3-2 (b, d).  Polyacrylate coating 
is visible on a sample of PAA-coated rods (Figure 3-2 d), but not on Figure 3-2 (b) which is a 
sample of as-synthesized rods.  Furthermore, as expected the DLS analysis showed an increase in 
average hydrodynamic diameter (60 nm) with narrow distribution (Figure 3-2 (f)).  The DLS 
size increase as compared to uncoated nanorods takes into account the size of the PAA layer and 
the timed average diameter of PAA-coated nanorods in solution over the course of the DLS 
acquisition period.  Further FT-IR surface analyses confirmed the adsorption of PAA on the 
nanorod surface.  Figure 3-3 displays the FTIR spectra of the surface chemistry of these PAA-
coated GNRs and the appropriate controls.  The characteristic peaks located at 1721 cm -1 are 
unique for vibration mode of the carbonyl (C=O) double bond, 1454 and 1414 cm -1  are 
attributed to C-H2 scissoring, and the bands at 1270 and 1178 cm -1 are caused by vibration of the 
C-O bond which are all known  IR signatures for polyacrylate.25  The presence of these peaks on 
PAA-GNRs and their absence on CTAB-GNRs samples confirmed the successful incorporation 
of PAA on the rod surface (Figure 3-3 (b, c)).   
Absorption spectra of gold nanorods at different stages of functionalization are shown in 
Figure 3-4.  The UV−visible spectra show the transverse and longitudinal plasmon bands of 
nanorods at 500−550 and 800−900 nm, respectively.  The SPR band of as-prepared gold 
nanorods is observed at 825 nm (Figure 3-4 (a)).  It is clear from the figure that there is a red 
shift in the longitudinal band after PAA functionalization to (λmax = 850 nm), about ~25 nm 
increase with no peak broadening.  This suggests that the coating resulted in insignificant 
nanorod aggregation which is corroborated by the TEM images previously discussed.  The 
increase in the λmax after PAA coating is consistent with changes in local dielectric function from 
the attachment of PAA.  It is known that the absorption and scattering properties of metal 
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nanoparticles are strongly determined by the local dielectric function.26  Therefore, the red shift 
in the peak maxima is probably due to the change in the local refractive index around the CTAB-
coated nanorods from water to that of PAA.  These observations are consistent with the previous 
reports on coating of gold nanorods with different polyelectrolytes.22, 27  The stability of the 
PAA-capped Au GNRs in PBS buffer solution (pH 7.4) was monitored over a 30-day period.  
The plasmon spectra of PAA-GNRs at 15 and 30 days after surface coating are shown in Figure 
3-4(b), and indicate no significant spectral changes or shift in absorbance due to time-dependent 
aggregation, and thus, good colloidal stability of the PAA-capped GNRs. 
The presence and the stability of PAA coating on the nanorods surface was further 
analyzed by measuring Zeta (ζ) potential before and after functionalization.  As expected, 
CTAB-stabilized nanorods showed a positive charge (+53.2 mV) on the surface due to the 
presence of cationic quaternary ammonium groups from adsorbed CTAB, whereas PAA-coated 
nanorods showed a negative charge (-64.2 mV) surface charge due to the presence of anionic 
COO- groups. The stability and potential desorption of PAA from the nanorod surface under 
physiological conditions was investigated by monitoring changes in Zeta (ζ) potential over 1-
week period.  The results showed insignificant variations in ζ, suggesting that the adsorbed PAA 
layer is stabile and can withstand physiological conditions.  Further zeta potential measurements 
showed that the PAA nanorods conjugated with A33 single chain antibody to form A33scFv-
GNRs and subsequently labeled with amine-reactive fluorescein resulted in nanorod probes with 
a higher surface potential (-25.4 mV).  The higher surface charge is probably due reduction in the 
number of surface COO- groups due to covalent attachment of A33scFv.   
 CTAB cytotoxicity is well documented and poses challenges to the use of gold nanorods 
for biological applications.22, 28  CTAB-coated gold nanorods can kill cells at sufficiently high 
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concentration primarily due to free CTAB (desorbed or a fraction remaining from nanorod 
synthesis).  In this work, we expected that the PAA coating of the surfactant bilayer would 
reduce the toxicity of these nanorods because surfactant desorption would be retarded, and 
excess CTAB from rod synthesis can be removed with successive washing.  To investigate our 
hypothesis, we compared the toxicity of gold nanorod solutions before and after applying the 
PAA coating using a standard colorimetric assay (e.g., MTT assay ) 29 on the SW 1222 cell line, 
which is a convenient method for evaluating proliferation and cell death in response to external 
factors.  We found that coating the surfactant bilayer with PAA reduced the cytotoxicity and 
rendered the PAA-coated nanorods biologically nontoxic within the concentration of ~200 
µg/mL.  CTAB-capped nanorods concentration of ~ 200 µg/mL exhibited marked cytotoxicity 
(Figure 3-5).  Similar results have been reported for nanorods coated with other polyelectrolytes 
such as PSS and PAH.15, 19  The reduced cytotoxicity have been explained by the retardation 
effect30 in which applied polyelectrolyte overcoat reduces the amount of quaternary ammonium 
surfactant desorbed over time which would ultimately lead to cell death as previously described. 
 The use of PAH and PSS polyelectrolytes as intermediary surface coatings to passivate or 
alter surface charge prior to application of a permanent coating such as mesoporous silica coating 
is widely reported in the literature.14, 15  However, previous reports on the use of these 
polyelectrolytes have involved multistep processes and have not demonstrated covalent 
attachment of biomolecules that are necessary for achieving specific molecular targeting.  We 
expected that using PAA would provide robust colloidal stability as well as allow facile the 
attachment of various biomolecules through its carboxyl groups.  We tested the colloidal stability 
of PAA-coated nanorods after several rounds of buffer exchanges, increases in salt concentration 
and centrifugation steps then compared it to CTAB-stabilized nanorods.  It was found that the  
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Figure 3-3 : ATR-FTIR spectra of dry Au GNRs solution showing the adsorption of PAA on the 
nanorod surface; (A) absorbance of dried PAA; (B) PAA-GNRs showing PAA peaks indicated with 
arrows; (C) as-synthesized Au GNRs coated with CTAB.  
  
108 
 
 
PAA-coated nanorods retained its stability whereas CTAB-stabilized nanorods aggregated in 
each step likely due to the removal of free CTAB in solution, which aids in nanorod stabilization 
(not shown).  These observations confirm previously discussed time-dependent zeta potential 
measurements in which solutions of PAA-coated nanorods showed insignificant changes in zeta 
potential over a 1-week period.  These findings proved that PAA-coated nanorods are robust 
with potential uses in various biomedical applications.  One of the potential applications of these 
carboxylated nanorods is for cellular targeting and labeling.   
In order to prove that these nanorods can be used to target and discriminately label 
antigen-expressing cells, we have functionalized the PAA-coated nanorods with targeting 
antibody specific to colorectal carcinoma cells, labeled the conjugates with fluorescein, and then 
demonstrated their applicability in vitro.  Covalent attachment of single chain antibody using 
EDC-NHS chemistry and successive fluorescein (FITC)-labeling were performed and used to 
demonstrate cellular labeling.  The presence of A33scFv in the antibody-nanorod conjugates was 
confirmed using a dot blot assay (Figure 3-6 (a)).  A solution of A33scFv–GNRs conjugates 
spotted onto nitrocellulose paper developed an intense purple color, which is a colorimetric 
indicator of the presence of A33scFv in the purified nanorods conjugates; this color change did 
not occur for purified PAA-GNRs or CTAB-stabilized GNRs.  The intense purple color shown in 
Figure 3-6 (a) suggests that successful EDC-NHS coupling chemistry and efficient binding of 
protein L to the blotted nanorod conjugates.  Further, this suggests that the antibody native 
conformation and active site is unaltered and is useful for cellular targeting applications.  
Furthermore, colloidal stability of A33scFv-GNRs conjugates was confirmed by obtaining a Uv-
Vis absorbance spectrum which showed no further shift with the peak maxima at λmax = 850 nm, 
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suggesting that the covalent attachment of A33 antibody did not alter the spectroscopic 
properties of GNRs.  Following covalent A33scFv attachment, A33scFv-GNRs conjugates were 
fluorescently labeled with FITC and then confirmed by measuring its fluorescence (Figure 3-6 
(b)).  The A33-GNRs conjugates showed an excitation at λmax 525 nm compared to the 
fluorescence of un-conjugated FITC (λmax = 520 nm).  
 Selective targeting of surface cell receptors using peptides, aptamers, and antibodies have 
been shown to be critical and has been successfully used to achieve tumor targeted drug delivery, 
31
 detection and imaging,32 and efficient photothermal therapy.1, 33  In this work, we evaluated 
specific targeting, preferential nanorod cellular uptake, and the potential use of A33scFv-GNRs 
for photothermal therapy using human colorectal cancer (SW 1222) cell line with A33 antigen 
surface expression.  Under confocal microscopy, colorectal cancer SW 1222 cells incubated with 
fluorescently-labeled A33scFv-GNRs conjugates Figure 3-7 (a, b)) exhibit a strong internalized 
green fluorescence color, which suggests successful binding to A33 surface antigen and 
subsequent internalization.  As a control, SW 1222 cells pre-treated with free A33scFv and 
subsequently incubated with fluorescently-labeled A33scFv-GNRs did not exhibit fluorescence 
Figure 3-7 (c-d)), which suggests that free A33scFv can block the binding of A33scFv-GNRs in 
A33 antigen expressed on the tumor cells.  Furthermore, incubation of the HT 29 cell line, a 
human colon adenocarcinoma epithelial cell line with low expression of A33 receptors on the 
plasma membrane, with fluorescently-labeled A33scFv-GNRs showed very weak fluorescence 
(Figure 3-7 (e-f)).  Together, these results suggest that A33scFv-GNRs can specifically target 
and can lead to selective uptake in colorectal SW 1222 cells.  
 Gold nanorods are also attractive molecular probes for photothermal therapy application 
used to induce cell death via hyperthermia. They possess strong absorption in the near-infrared 
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region and can be used in combination with laser irradiation to achieve selective cell killing.   
The heating capacity of A33scFv-GNRs was determined by irradiation with 808-nm NIR laser.  
Figure 3-8 (a) show a heating curve of A33-GNRs solution (100 µL, 100 µg mL-1) where +35oC 
temperature increase after 10 min of irradiation was observed which is consistent with other 
reported literature values.34  This result suggested nanorods as efficient thermal converters that 
can be used for selective photothermal therapy to induce cancer cell death via hyperthermia.  
Hyperthermia conditions are reached between 42-43oC which causes cell death by direct damage 
to DNA.35  Next, we demonstrated selective photothermal therapy in vitro using antigen-
expressing SW 1222 cell line that were initially treated with A33-GNRs and then irradiated with 
808-nm near-infrared laser (5.1 W cm-2).  Figure 3-8 (b, c) show fluorescent images of SW 1222 
cells treated with A33-GNRs followed by laser irradiation and then stained with calcien AM. 
The presence of green fluorescence indicates live cells and regions devoid of fluorescence 
indicate dead cells.  After laser exposure at 5.1 W cm-2 for 5 min, approximately 62 % of the SW 
1222 cells were killed, while the viability of HT 29  cells remained almost unchanged (98 %), 
indicating that the targeted A33-GNRs conjugates are potent photothermal absorbers in cells that 
express A33 antigen.    
 
3. Conclusion 
In this paper, we report on a facile layer-by-layer method of functionalizing gold 
nanorods in order to reduce cytotoxicity of GNRs that are synthesized by surfactant-mediated 
method.  This single-step coating procedure results in carboxylated nanorods with good colloidal 
stability, which obviates the need for multistep, time-consuming functionalization strategies 
widely reported in the literature. We have also demonstrated that the coating strategy produces 
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polyacrylate-coated nanorods that provide anchors for biomolecule conjugations using simple 
covalent chemistries.  The polyacrylate coating strategy also produces GNRs that are non-
cytotoxic as tested in vitro at relatively high concentrations (~200 µg/mL) and are therefore 
suitable for bio-applications.  
Biomolecules can be attached as needed to these as-synthesized GNRs for a wide variety 
of bio-applications. PAA coating allowed facile attachment of single chain antibodies and 
subsequent fluorescent labeling needed for the fabrication of selective molecular probes for cell 
labeling and imaging.  Further we demonstrated differential of antibody-coated GNRs uptake in 
antigen-expressing human colorectal carcinoma cells compared to the control cell lines.  
Experiments showed effective photothermal therapy of colorectal cancer cells when treated with 
Plasmon resonant A33scFv-GNRs and irradiated with NIR laser for 5 min.  The proposed PAA 
coating protocol can also be extended to conjugate DNA/RNA, proteins, enzymes to monitor cell 
interactions in living cells as well as to fabricate probes for in vivo diagnostics. The nanorods 
showed good colloidal stability and optimal near-infrared optical absorption with broad in vivo 
applications in imaging and as therapeutic agents. 
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Figure 3-4:  Stability of PAA-GNRs over time.  UV-vis absorption spectra of as-synthesized gold nanorods 
(A), PAA-coated gold nanorods (B), A33scFv-GNRs prepared from reaction of PAA-coated gold nanorods 
with A33scFv. 
  
113 
 
 
 
 
 
0 40 80 120 160 200
0
10
20
30
40
50
60
70
80
90
100
110
Ce
ll 
vi
a
bi
lit
y 
(%
)
PAA-GNRs( µg/mL)
 PAA-GNRs
 CTAB-GNRs
Figure 3-5: Cell viability of SW 1222 cells after incubation with increasing concentration 
particle conjugates as determined by MTT assay of: (A) PAA-GNRs, (B) CTAB-GNRs. The 
results show a dose-dependent toxicity with significantly higher cytotoxicity for cells 
incubated with CTAB-GNRs at higher particle concentration. Error bars represent absorbance 
variability measured at 570 nm where n = 3. 
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Figure 3-6: Characterization of antibody-conjugated and fluorescently labeled PAA-coated 
GNRs, (A) Dot Blot assay on nitrocellulose membrane confirming the presence of A33scFv 
in purified A33-GNRs conjugates (i) show intense purple colored arising from HRP-
peroxidase, (ii) positive control (A33scFv), and (iii) negative control showing less intense 
corresponding to the native GNRs color; (B) Fluorescence of FITC-labeled GNRs antibody 
conjugates with the corresponding  positive and negative control; (C) image of fluorescently-
labeled GNRs under UV-light. 
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 Figure 3-7: Effect of A33 targeting on uptake of PAA-GNRs.  Gold nanorods uptake in 
colorectal carcinoma cells as analyzed by confocal microscopy. (a, b) antigen-expressing SW 
1222 cells incubated with A33-GNRs; (c-d) SW1222 cells are incubated with excess A33scFv to  
block surface receptors and then incubated with A33scFv-GNRs; (e-f) non-antigen expressing 
HT 29 cell line incubated with A33scFv-GNRs for 5 h; green fluorescence: FITC; red 
fluorescence: FM 4-64® cell labeling dye; scale bar: 20 µm.  
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Figure 3-8:  GNRs-assisted photothermal therapy of colorectal carcinoma cells using 808-nm 
NIR laser treatment. (A) Graph shows 35oC temperature increase in a A33scFv-GNRs solution 
( 100 µL ,100 µg/mL ) when irradiation 808-nm laser; (B) SW 1222 cells incubated with 
A33scFv-GNRs (C) SW 1222 cells pretreated with excess A33scFv before addition of 
A33scFv-GNRs; (D) HT 29 cells incubated with A33scFv-GNRs followed by laser irradiation. 
Nanorod incubation lasted for 5 h and laser treatments performed at 5.1 W cm-2 power density. 
Viable cells appear green from calcien AM staining while dark areas devoid of fluorescence are 
cells destroyed from photothermal therapy irradiation. Scale bar 50 µm for all images. 
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Chapter 4 
 
Targeted near-IR hybrid magnetic nanoparticles for in vivo Cancer therapy 
and Imaging  
 
Abstract: 
 
The potential of gold-iron oxide hybrid nanoparticles (HNPs) conjugated to A33 single chain 
antibody used in combination with 808-nm laser irradiation for selective therapy and non-
invasive in vivo imaging of human colorectal cancer cells in subcutaneous xenograft tumor 
model is demonstrated.  Laser-activated photothermal therapy represents a new, minimally 
invasive technology with potential uses for selective ablation of malignant tumors.  Tumor 
xenograft models of human colorectal carcinoma cells are used to demonstrate particle 
localization following systemic injection and to show effective photothermal treatment using 
near-IR laser irradiation (808 nm, 5 W cm-1 ) during a 14-day  therapy duration.  Dumbbell-like 
gold-iron oxide (6-18 nm) nanoparticles (HNPs) were conjugated with A33 targeting single 
chain antibody (A33scFv) and shown to selectively accumulate in SW 1222 tumors as compared 
to their accumulation in non-A33 expressing (HT 29) tumors cells.  Particle localization in A33-
expressing tumors was observed 12 h post-injection while particle clearance occurred after 24 h 
after injection.  Subsequent photothermal treatment of antigen-expressing tumor cells showing 
over 65% necrotized cell population, corrupt extracellular matrix and cytoplasmic acidophilia 
after seven courses of laser treatment (as compared to untreated group).  Cell killing was shown 
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using histological assessment by hematoxylin and eosin (H&E) staining where scar-like structure 
containing collagen bundles were observed for samples treated with HNPs
 
plus laser irradiation.  
In contrast, there was no difference in the size or tumor histology in control groups, indicating 
the laser treatment alone was incapable of causing significant cell killing.  In addition, 
systemically injected HNPs were shown to be effective T2 magnetic resonance (MR) imaging 
contrast agents where localized particles were detected in the targeted xenograft tumors.  These 
finding suggest that the new class of bio-conjugated hybrid nanoparticles (HNPs) exhibit great 
potential for dual applications in both therapy applications as well for non-invasive in vivo 
detection using MR imaging.   
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University. 
 
Current hyperthermic techniques for cancer tumor therapy 1, 2  possess low spatial 
selectivity in the heating of tumors which causes unintended harm to surrounding healthy tissues.  
To circumvent this problem, there has been a great interest in the use of gold nanostructures as 
local heating agents to induce cell death of the targeted cells by hyperthermia.  Interest in the use 
of gold nanostructures for photothermal ablation originates from their surface Plasmon resonance 
(SPR) effect, a strong enhancement of absorption and scattering of light in resonant with the SPR 
frequency.  These types of materials can convert absorbed photons into thermal energy in a 
picosecond time scale, causing cell destruction as a result of electron-phonon and phonon-
phonon processes 3.  One of the potential applications is to selectively cause thermal heating of 
biomolecules, cells or tissues and thus cause heat-induced damage of the surrounding materials 
or cells.  This photothermal destruction can be used for disease treatment or cancer therapy.  
Gold nanoparticles with different shapes and structures, such as gold spherical particles 4, 5, gold 
nanocages 6, gold nanorods 7, and single-walled carbon nanotubes 8 have shown promise as 
photothermal therapeutic agents both in vitro 5 and in vivo 9. 
 While gold nanoparticles offer distinct optical properties with potential photothermal 
therapy applications, magnetic iron oxide nanoparticles on the other hand exhibit 
superparamagnetic properties and have been utilized to make noninvasive molecular probes for 
disease detection and diagnosis.  Magnetic nanoparticles have been employed as magnetic 
resonance imaging (MRI) T2 contrast agents to provide valuable anatomical information 
regarding clinical behavior of a disease and treatment response to certain therapeutic modalities 
10
.  Additionally, iron oxide nanoparticles have been used for thermotherapy of cancer cells using 
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external magnetic field to induce hyperthermia and to aid in magnetic-guided drug delivery 11, 12.  
Combining the magnetic property of iron oxide nanoparticle and the optimal properties of the 
gold nanoparticle to make a single multifunctional device for both therapy and diagnostics 
(theranostics) applications has recently garnered great interest.  Multifunctional gold-iron hybrid 
nanoparticles can potentially be used for multimodal imaging, (MRI and CT imaging) 12, 
therapeutic combinations such as drug delivery and photothermal therapy, and image-guided, 
minimally invasive intervention 13. 
The potential benefits of integrating nanomaterials with a variety of novel properties 
(such as strong plasmonic behavior, and magnetization) into a single object of nanoscale 
dimensions have spurred great interest in the development of multifunctional nanomedical 
platforms for simultaneous targeting, imaging, and therapy administration 14, 15.  These efforts 
have led to the developments of various types of hybrid nanoparticle systems such as hybrids of 
iron oxide- quantum dots 16, and various types of gold nanoparticle-iron oxide hybrids 17-19.  For 
example Kim and coworkers reported multifunctional nanoparticles that exhibit both magnetic 
and optical properties with potential use for simultaneous targeted phototherapy and imaging 
using magnetic resonance imaging (MRI) 4.  Iron oxide nanoparticles such as superparamagnetic 
iron oxide (SPIO) nanoparticles have been extensively utilized as MRI contrast agents to image 
target tissues in vivo in a highly specific manner 20-22. The SPIO nanoparticles modified with 
tumor-targeting ligands were used as in vivo MRI contrast agents 23 as well as to induce cell 
apoptosis via hyperthermia 24.  Recently, we reported on the use of novel gold hybrid 
nanoparticles for targeted photothermal therapy and magnetic-based imaging of colorectal cancer 
model in vitro 25.  
124 
 
Motivated by the efficacy of these gold hybrid nanoparticles to selectively kill cells in an  
in vitro model, we report on our investigation of systemically delivery of targeted HNPs, 
application a near-infrared irradiation, activating capability of HNPs and resulting tumor 
response (as measured by histology and tumor size reduction) using subcutaneous  colorectal 
cancer tumor murine model.  Furthermore, we evaluated the oncological efficacy and benign 
tissue ablation capabilities of this technology as well as their applicability for non-invasive MR 
imaging detection.  To increase the uptake/accumulation in antigen-expressing cells, the HNPs 
were conjugated to a humanized single chain antibody (A33scFv) to target a A33 antigen 
expressed in 95% of primary and metastatic human colorectal tumor cells 26, but is absent in 
most other normal tissues and tumor types 27.  A33scFv, recently produced in our laboratory, has 
been shown to bind to a transmembrane glycoprotein, A33 antigen expressed in colorectal cancer 
cells 28.  Advantages of using A33 antigen as localization targets because  it is not secreted or 
shed into the bloodstream and some colon cancer cell lines express large amounts of this antigen, 
binding almost 106 mAb molecules/cell 29.  Consequently, the A33 antigenic system has been the 
focus of several clinical studies in patients with colon cancers 26, 29.   
We have demonstrated particle targeting and localization in subcutaneous (s.c.) human 
colorectal tumor xenografts using fluorescently-labeled HNPs-A33scFv conjugates.  Alexa 
Fluor® 750, a near-IR dye, was conjugated through the amino-terminal fragment of A33scFv to 
make stabile HNPs-A33scFv conjugates suitable for in vivo near-IR fluorescence imaging.  
Following particle localization, subsequent laser treatment resulted in effective cell killing as 
observed by the reduction of tumor volume (in positive control) and confirmed by histological 
assessment which showed cell damage after seven-course therapy.   Targeted HNPs were also 
detected in the SW1222 tumor xenograft by MR imaging suggesting the potential uses of these 
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hybrid nanoparticles for therapy applications as well for non-invasive imaging diagnostic 
applications. 
 
 
1. Experimental and Methods 
1.1. Materials 
All of the chemicals were of reagent grade and were used without further purification.  N-
hydroxylsulfosuccinimide (Sulfo-NHS), and 1-Ethyl-3-(3-dimethylaminopropyl carboiimide HCl 
(EDC) were purchased from Pierce Biotechnology; Alexa Fluor® 750 succinimidyl ester was 
purchased from Invitrogen; Matrigel from BD Biosciences( Bedford, MA); SW1222 cells 
(antigen expressing colorectal cancer cell line) and non-malignant cell lines HT 29 cells were 
received as a gift from Ludwig Cancer institute of Cancer Research, New York, NY; A33 single 
chain antibody was expressed in Pichia pastoris as previously reported 30.  Six to eight-week old 
immunocompromised Balb/c nude mice were purchased from Charles River international 
(Wilmington, Massachusetts).  
  
1.2. Nanoparticle preparation and Conjugation 
The dumbbell-like Au-Fe3O4 (HNPs) nanoparticles were fabricated as previously 
described by Yu et al 31. The oleic-capped nanoparticles were encapsulated with carboxy-
PEGylated phospholipids (PL-PEG, Avanti Polar lipids), resulting in stabile water-soluble HNPs 
that we have recently reported 25.  Briefly, the carboxyl-terminated dumbbell-like nanoparticles 
were covalently attached to single antibody (A33scFv) 30 using EDC-NHS chemistry following 
the manufacturer’s protocols.  To study the in vivo specific targeting as well as nanoparticle 
tumor localization, HNPs-A33scFv conjugates were further labeled with amine-reactive Alexa 
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Fluor® 750, a commonly used near-IR fluorescent dye.  Briefly, a 1 mL of purified HNPs-
A33scFv conjugates (1mg mL-1, 50 mM PBS) was reacted with 100 µg of Alexa Fluor® 750 in 
borate buffer (pH 8.5) and allowed to react for 3 h at room temperature.  Particle purification to 
eliminate excess fluorophore was carried out using size exclusion chromatography using FPLC 
system (Superdex 200 size exclusion column on an AKTA Explorer FPLC, Amersham 
Biosciences, Piscataway, NJ).  HNPs-scFv conjugates were subsequently concentrated to 1 mg 
mL-1 by centrifugation using a 30 kDa microfilter where absorbance measurement (at λ600) was 
used as a means of monitoring concentration change where absorbance is correlated to particle 
concentration by beer’s law. 
The formation of fluorescently-labeled HNPs-scFv conjugates was confirmed by 
obtaining a fluorescence spectra using SLM Aminco spectrofluorometer (SPF-500C, SLM 
instruments, Inc.).  The fluorescent spectrum was compared to the un-conjugated HNPs or the 
fluorophore alone.  To test the potential applicability of HNPs as thermal heating agents to 
generate heat and cause cellular hyperthermia, serial dilutions of HNPs-scFv conjugates were 
tested by irradiation with near-IR 808-nm laser and the change in temperature recorded using a 
Neoplix thermocouple (Neoptix Corp., Woodland Hills, CA). 
 
1.3. Cell Culture and inoculation of mice with tumor cells  
SW 1222 and HT 29 human carcinoma colorectal  cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin (P/S, 100 units/mL penicillin, and 100 µg/mL streptomycin) in a 5% CO2 
humidified atmosphere.   Prior to use, the cells were trypsinized, counted, and resuspended in 
100 µL PBS and 100 µL of Matrigel (BD Bioscience, Bedford, MA).  Balb/c nude mice 6-10 
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weeks of age were subcutaneously (s.c.) injected in the hand left and right flanks with 5 x 106 
cells SW 1222 (200 µL)  and HT 29 cells, respectively.  Tumors were allowed to grown to about 
6-7 mm in diameter before particle injection, imaging, and phothermal therapy treatment.  All 
animal experiments were conducted in accordance with the Guidelines for the Care and Use of 
Research Animals established by Institutional Animal Care and Use Committee (IACUC) of 
Cornell University (Ithaca, NY) and in compliance with Federal and New York State regulations.  
 
1.4.  Intratumoral nanoparticles accumulation and Imaging 
To assess the intratumoral active accumulation of HNPs-scFv conjugates, Balb/c tumor- 
bearing mice were anaesthetized with isoflurane and injected with fluorescently-labeled HNPs-
scFv conjugates (1 mg mL-1, 200 µL) through the tail vein.  Particle localization due to active 
antibody targeting was monitored using Olympus OV100 fluorescence microscope imaging 
system (Olympus) equipped with a near-infrared CCD camera.  At various time intervals, the 
fluorescence intensity from HNPs-scFv conjugates was acquired up to 72-h post-injection.  At 
specific time points, mice samples with localized fluorescence on the antigen-expressing 
xenograft were sacrificed and tumors were prepared for histology staining and assessment.  The 
localization of particles in xenograft tumors was confirmed by Prussian blue tissue staining 
which stains for the presence of iron.  
 
1.5.  In vivo near-infrared Photothermal therapy treatment  
Nude mice were subcutaneously inoculated with 5 x 106 SW 1222 cells in the rear right 
flanks were allowed  to grown for about 21 days before the experiment.  When tumors had 
grown to 6-10 mm in diameter, mice were randomly allocated into three groups I, II, and III (n = 
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3).  Each of the mice in group I were systemically injected with 200 µL of HNPs-A33scFv 
conjugates (1 mg mL-1) and allowed to localize in the tumors before therapy application.  Mice 
in group II were used as control and were untreated with neither laser nor particles whereas 
group III were injected with saline buffer and treated with laser using the same laser settings as 
used in group I treatment.  Mice were anesthetized with injection of 300 µL of 2.5% 
tribromoethanol (20 µL/g Avertin, Sigma-Aldrich) solution that kept the animal anesthetized for 
about 30 min.  To explore hematologic effects of laser therapy, each of group were exposed to 
therapeutic tumor irradiation protocol under anesthesia (∼ 5 W/cm2, 6 mm dia., 30 min) for a 
total of seven rounds of therapy in the course of a 14-day period.  As positive controls( group I), 
tumor-bearing mice injected with HNPs-scFv conjugates (1 mg mL-1, 200 µL) and allowed 12 h 
to localize in the tumor prior to laser treatment.  Negative control tumor xenografts were injected 
with 200 µL of saline buffer (PBS) followed by laser treatment (group III) or treated with laser 
without prior administration of HNPs or PBS (group II).  The tumor reduction resulting from 
application laser over the course of 14-day period was compared to the reduction in tumors 
where laser only was applied or were untreated.   
The laser settings and the duration of treatment were obtained through a set of 
experiments that involved localized (intratumoral) HNPs injection at tumor site followed by 
application of incremental laser power over two rounds of laser therapy.  These experiments 
were necessary to determine the power dosage and duration required for effective therapy in 
tumors with localized HNPs but causes minimal damage to tumors without HNPs.  As positive 
control, 15 µL of HNPs (PBS, pH = 7.4) were injected into tumor bed and irradiated within 2 
min of injection with laser powers starting at 3 W cm-2 (increments ~ 1.5 W cm-2 in 6 mm dia.).  
Control tumor sites were injected with 15 µL of 50 mM PBS and then irradiated with the same 
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power settings used in the positive control.  Histological analyses and comparison of tumors 
from positive controls with HNPs versus the tumors injected with saline buffer were used to 
determine the optimal laser irradiation and settings for therapy following intravenous particle 
injection and subsequent localization.  
 
1.6.  Laser Treatment Protocol 
For intravenously injected HNPs, laser treatments were performed ca. 12 hours post-
injection to allow particle localization and intratumoral penetration of HNPs-scFv conjugates.  
Before laser activation the skin at the tumor site was swabbed with polyethylene glycol as an 
index matching agent to maximize laser penetration. A near-IR 808-nm laser (built in-house) was 
calibrated before each use.  At day 0 the near-IR laser was aimed at the tumor bed for 20 minutes 
using a 200 x laser fiber passed through a standard focusing lens.  The treatment was 
administrated for a total of seven courses (every 48 h for 14 days) after intravenous injection and 
localization of HNPs-scFv conjugates or appropriate controls. 
 
1.7.  Histological Examination 
Histological analyses of xenograft tumors were performed to confirm the presence of 
HNPs localized in the tumors resulting from the use A33scFv as an active targeting agent and 
also to analyze the dose-dependent of applied laser therapy.  After intratumoral localization, as 
observed by optimal near-IR fluorescence imaging, xenograft tumors were harvested and 
prepared for Perl’s Prussian blue staining for iron detection. Xenograft tumors harvested before 
HNPs injection were used as control for Perl’s Prussian blue staining.  Following tumor 
resection, the xenograft samples were fixed overnight in 4% paraformaldehyde solution. Tissue 
130 
 
samples were sliced into 5-µm thick sections and then incubated with 2% potassium ferrocyanide 
in 6% hydrochloric acid for 30 min.  For Perl’s Prussian blue staining, cells were fixed with 4% 
paraformaldehyde, followed by incubation in freshly prepared solution of 2% potassium 
ferrocyanide in 2% HCl for 20 min and counterstaining with 1% neutral red.  Images of the 
tissue sections were acquired using BX60 Olympus microscope. 
 Histological assessment of tumor samples to assess the efficacy of photothermal therapy 
was performed by hematoxylin and eosin (H & E) staining.  Xenograft tumor tissues were 
collected from tumor-bearing mice before or at the end of in vivo therapy experiments.  The 
samples were sliced into 10 µm sections, fixed in 4% paraformaldehyde, and stained with H & E.  
The morphological changes resulting from therapy were evaluated by light microscopy using 
BX60 Olympus microscope.  To quantify the level of presence of HNPs in  xenograft tumors, 
three different regions of interest (ROI) with 0.50 mm2 area were sampled  on the acquired 
microscopy images with Prussian blue staining (Figure 4-5) and H &E stained images (Figure 
4-7).  Specific colors (blue for presence of iron in Perl’s Prussian staining; blue for endothelium, 
red for nucleus for H&E stained cells) were extracted and intensities measured using ImageJ 
1.41 (NIH).  
 
1.8.  MR Imaging of Intravenously-injected HNPs 
To demonstrate the potential use of HNPs as MRI T2 contrast agents, 200 µL HNPs-
A33scFv (1 mg mL-1) conjugates were intravenously injected allowed for 12 h to circulate and 
localize at the tumor sites before acquisition of magnetic susceptibility measurements.  The mice 
were euthanized by intraperitoneal injection of 2.5% tribromoethanol (20 µL/g Avertin), 
trancardially perfused with 50 mM PBS (pH = 7.4), and fixed in 4% paraformaldehyde.  
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Prepared mice were scanned on a 7T scanner (Bruker BioSpin, Biospec 70/30 USR) with 3D 
FLASH sequence.  Imaging parameters were as follows: TEs (echo time) 5 ms, 6 ms, 30 ms, 35 
ms; TR (repetition time) 35 ms; excitation pulse angle 15°; matrix size 150 x 150 x 100; voxel 
size 200 µm3 isotropic; NEX 1. A 3D Fourier transform was applied to the raw k-space data to 
reconstruct the images.  The T2 contrast capability of HNPscFv conjugates in xenograft tumors 
were quantified by comparing the contrast of SW1222 tumors (right flank) and HT-29 (left 
flank).  3-D tumor segmentation and T2* quantification was performed using (ITK SNAP 2.0) 
program and the standard error represent (n = 3) for each group.  
 
 
Statistical Analysis 
Three mice per each group were used for comparison using an analysis of variance.  
Differences between experimental groups were considered to be statistically significant at p < 
0.05.  All values were expressed as arithmetic means ± s.d. (standard deviation).  Data were 
expressed as mean ± standard deviation of n smaller than triplicates, and analyzed for statistical 
significant. Unpaired student’s t-test was used to determine statistical significance (Figure 4-6).  
One-way ANOVA was used to compare variations in the mean tumor sizes at different treatment 
timepoints in the various treatment groups (Figure 4-7). 
 
2. Results and Discussion 
2.1.  Nanoparticle Conjugation and Characterization 
We have previously reported the synthesis and functionalization of 6-18 nm gold-iron 
oxide hybrid nanoparticles (HNPs) resulting in stabile, biocompatible nanoparticles (Figure 4-1 
(a)).  The HNPs showed enhanced optical absorbance in the near-IR region as compared to 
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homofunctional iron oxide nanoparticles of comparable size which suggests that they can be 
used for photothermal therapy (Figure 4-1 (b)).  To prepare nanoprobes for targeted delivery, 
the carboxylated HNPs were conjugated to A33scFv and were subsequently tested using an in 
vitro human colorectal cancer model for specific targeting and photothermal therapy.  We further 
demonstrated HNPs as potential multifunctional nanoparticle platform for magnetic resonance 
imaging as well as thermal agent for phototherapy therapy 25.  Here, we have prepared HNPs-
scFv conjugates with the goal of testing the probes for localized targeting and photothermal 
therapy using colorectal cancer xenograft tumors.  First, the HNPs were labeled with near-IR 
fluorophore through the reaction of amino-terminal antibody with Alexa Fluor® 750 
succinimidyl ester resulting in stabile nanoparticle-antibody conjugates with good optical 
fluorescence properties (Figure 4-2 (a)).  The fluorescently-labeled HNPs-scFv conjugates 
showed an emission fluorescence peak at (λmax = 750 nm) whereas the un-conjugated HNPs 
showed no fluorescence.   
 
 
2.2. Photothermal Conversion of NIR irradiation into  heat 
Since the ultimate the goal is to use localized HNPs conjugates to cause heat-induced cell 
death, we have tested the ability of HNPs to convert laser energy into thermal energy by 
irradiating serial dilutions of HNPs-scFv conjugates with 808-nm continuous-wave diode laser.  
Solutions of HNPs-scFv conjugates (100 µL of 0, 0.5, 0.2, and 0.1 mg mL-1 HNPs) were 
irradiated and changes in temperature recorded using a thermocouple (Neoplix, Woodland Hills, 
CA).  Figure 4-2 (b) shows the temperature change of an aqueous solution containing HNPs as a 
function of exposure time.   It can be seen that the HNPs are various concentrations rapidly 
converts laser energy into heat,  due to electron-phonon and phonon-phonon process 5.  Laser 
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exposure of 0.5 mg mL-1  aqueous solution of HNPs  to the NIR laser light (5.0 W/cm2) for 10 
min elevated the temperature of the solution from 25 to 54 °C (an increase of 29 °C).  Under the 
same conditions, minimal temperature change was observed in saline buffer (PBS).  The 
magnitude of the increase in the temperature of the aqueous solution of HNPs decreased with 
decreasing HNPs concentration (Figure 4-2 (b)).  This temperature increase suggests HNPs as 
thermal agents that can be used for selective photothermal therapy to induce cancer cell death via 
hyperthermia which is attained when the temperature is between 42-45oC and can cause cell 
death by direct damage to DNA 32.  In comparison to our recent report on  photothermal 
applications using gold nanorods (NRs) 33, the new HNPs displayed similar photothermal 
conversion efficiency.  For example, the temperature of an aqueous solution of 11 by 66 nm gold 
NRs increased by 35 °C over a period of 10 min at an output power of 5.1 W/cm2.  Similar 
nanoparticle-assisted temperature heating has observed for gold nanorods 34, carbon nanotubes 35 
as well as for graphene nanoparticles 36.  
 
2.3.  Intratumoral particle accumulation 
  Most nanoparticles between the sizes of 10-200 nm are expected to accumulate in 
tumors by enhanced permeation and retention (EPR) effect because of leaky tumor vasculature 
and highly permeable blood vessels of tumors resulting from the rapid growth and porous 
angiogenesis.  This property has been used to passively and preferentially localize nanoparticles 
and therapeutics with a number of therapeutics based on EPR effect are already been FDA-
approved for clinically applications 37.  Additionally, tumors are characterized by dysfunctional 
lymphatic drainage that helps the retention of nanoparticles in tumor long enough to allow local  
therapy application and eventual nanoparticle disintegration 38.  Besides using passive targeting 
134 
 
as means of concentrating nanoparticles in the tumor site, active research focuses on using active 
targeting agents such as antibodies for more efficacious therapeutic delivery systems.  In this 
report, we have used specific A33scFv targeting to achieve preferential in subcutaneous 
colorectal tumors that express A33 surface antigen.  The intratumor accumulation was 
demonstrated using near-IR fluorescence imaging in live animals.  The fluorescence images 
obtained at different time point after intravenous injection of fluorescently-labeled HNPs-scFv 
conjugates (200 µg in PBS, pH = 7.4) are presented in Figure 4-3 (a).  Initially after injection, 
majority of fluorescence (HNPs) were observed in the liver potentially due of macrophage 
capture and clearance of these particles. Significant cell surface labeling and particle localization, 
as evidenced by increased fluorescence intensity, in the antigen-expressing SW 1222 tumor 
xenograft (right flank) was observed 12-hr post-injection. In contrast, there was minimal 
fluorescence (particle accumulation) in the non-antigen subcutaneous HT29 tumors (left flank).  
Gradual particle localization was observed where optimal particle accumulation, as inferred by 
fluorescence intensity, was achieved at ca. 12 hr post-injection while particle clearance was 
observed at 36 hr where majority of the excreted particles appeared in the bladder.  Whole body 
imaging of HNPs localized to SW 1222 xenograft over the time course of 30 min to 72 h 
postinjection showed that the peak accumulation occurred at 12 hr post-injection which was 
followed by gradual decrease over 36 hours and complete clearance after 72 hours (Figure 4-3 
(b)). 
 
2.4. MR Imaging of mice 
The potential use of HNPs as contrast agent for non-invasive MR imaging was 
demonstrated by performing MR images of xenograft mice intravenously injected with HNPs-
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scFv conjugates.  The mice were sacrificed and transcardially perfused with 4% 
paraformaldehyde solution in preparation for MR imaging.  Next, T2 contrast capability between 
subcutaneous antigen-expressing SW1222 xenograft tumors (right flank) which was compared to 
the contrast in a control HT29 xenograft tumor (left flank).   Figure 4-4 (a) show T2* contrast 
images of systemically delivered nanoparticles after 12 h post-injection.  The SW1222 tumors 
appeared darker in comparison to the contrast of HT-29 tumor (left flank) or tumor-bearing mice 
before particle administration.   This is attributed to the localization of HNPs in the targeted 
tumors which reduces the T2* magnitude and can potentially serve as effective in vivo MRI 
agents.    In contrast, there was no apparent MRI signal change in the tumors of mice receiving 
non targeted HNPs.  Notably, signal reductions were also seen in the liver and bladder as can be 
seen on the MR micrographs where they appeared much darker than the other organs (Figure 4-
4).  The presence of HNPs in the liver is due to macrophage particle capture which was 
particularly notable shortly after systemic injection (fluorescence) while particle clearance led to 
the deposition of HNPs in the bladder.  3-D quantitative analyses of the T2* tumor volume 
showed ~50% reduction in the SW1222 xenograft tumor fluorescent brightness as compared to 
the brightness of HT 29 xenograft (Figure 4-4 (b)).  The MR results showing the presence of 
HNPs in positive SW 1222 xenograft further corroborated earlier particle localization data using 
optical imaging. 
 Following tumor resection, the presence of HNPs in targeted SW 1222 subcutenous 
tumors was further confirmed by direct staining of iron with Perl’s Prussian blue staining.  
Prussian blue staining demonstrated iron-containing sites as blue spots in the cytoplasm.  Tumors 
obtained before and after intravenous injection were prepared, stained with Prussian blue and 
then compared to each other.  The presence of blue stains in SW1222 tumors cells would 
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confirm that the localization of HNPs and fluorescently-labeled HNPs-scFv conjugates 
previously observed by live animal imaging.  Figure 4-5 (a) show representative micrographs of 
s.c. SW1222 tumors where there were visible and notable blue stains for tumors harvested 12 
hours post-injection.  In comparison, very few blue stains were observed for tumors harvested 
before nanoparticle intravenous injection. This is potentially due to the presence of endogenous 
iron in blood.  Similar observation was made for subcutaneous (s.c.) HT29 tumors harvested 
following intravenous particle injection. The amount of blue stains as by quantified with ImageJ 
program (NIH) showed that over half of the tumor populations were labeled with HNPs as 
compared to the control (Figure 4-5 (b)).  Previous reported literature duration for particle 
accumulation after intravenous injection have ranged from 30 min for rapidly cleared particles to 
72 h for particles with longer blood half-life which may vary depending upon particle properties 
such as size, charge, and functionalization 39.   
  
2.5. Tumor growth suppression: direct intratumor injection 
After observing effective particle homing to human colorectal SW1222 tumors using 
A33scFv targeting, we subsequently investigated photothermal therapy conditions/settings for 
tumor growth suppression by laser treatment.  To inform the development of near-IR radiation 
doses needed to destroy tumors, groups of three mice were initially used to determine the optimal 
conditions such as laser power and treatment duration for near infrared nanoparticle-assisted 
therapy of SW 1222 tumor xenografts.  For each group, 15 µL of HNPs-A33scFv conjugates (1 
mg mL-1, PBS = 7.4) were directly administered at three sites within the tumor interstitium (bed) 
and subsequently irradiated with increasing laser power doses with varying time periods. For 
control experiment, a group injected with 15 µL PBS and exposed to laser treatment.   Each of 
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this group was treated with increasing laser power and time duration over an extended period and 
before tumors were harvested and histological studies were performed to determine the effective 
of laser treatment.   For these studies, it was determined that ca. 30 min of irradiation at 5 W/cm2  
with seven courses (14 days) of treatment would be needed to cause cell damage to xenograft 
tumors with injected HNPs with minimal damage to  control xenograft tumors.  
 
2.6. Photothermal therapy in mice 
A major hurdle, of cancer therapy is to kill cancer cells without injury to normal or cells, 
tissues, or organs.  We have shown that laser irradiation can induce hyperthermic cytotoxicity 
with following intratumorally injected HNPs while causing limited harm to the xenograft tumors 
without HNPs conjugates.  Further, we have demonstrated the localization of HNPs-scFv 
conjugates after ca. 12 h post-injection using A33scFv as a targeting agent.  Next, once particle 
localization was confirmed by fluorescence microscopy, photothermal therapy was performed 
every 48 h for 14 days (seven-course treatment) with xenograft tumors exposed to  laser 
treatment as demonstrated on  Figure 4-6 (a).  Mice from each group were euthanized and tumor 
excised for further analyses where the largest tumors from each group are shown.  Figure 4-6 (b) 
show representative micrographs of tumors harvested after 14 days from the different groups, (I) 
tumors treated with targeted HNPs plus laser, (II) tumors from untreated group, and (III) tumors 
treated with laser only.  From the tumor physical appearance, the control group (I) with targeted 
HNPs laser treated were the smallest in size, while the tumors treated with laser only appeared 
insignificantly smaller than non-treated tumors (control groups- II or III).  
The effectiveness of photothermal therapy was further quantified by measuring the 
changes in the tumor volumes over the course of laser treatment.  Tumor volume was calculated 
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using the equation, ab2/2, where a represents the longer dimension and b represents the shorter 
dimension of the tumor.  Mean values of tumor volumes in each group during treatment are 
shown in Figure 4-6 (c); error bars correspond to 95% confidence intervals (n = 3 mice per 
group).  From these observations, the tumor volumes of the treatment group (I) after seven-
course treatment were significantly smaller than either the group treatment with the untreated 
group (II) or laser only (III).  It is also worth noting that in the first four courses of treatment, the 
tumors in group (III) were a little smaller than those of control group II (untreated).  However 
following subsequent rounds of laser treatment, the tumors of the laser irradiation group (III) 
grew to almost equal size to those in the control group II.   The tumor inhibition effect in the 
control group (I) is obvious and confirms the efficacious nanoparticle-assisted therapy using 808-
nm laser.   The smaller tumor size for control group (III) at the on-set of therapy application may 
be due to nonspecific heat stimulation resulting from laser irradiation. 
Histological analyses of tumor tissues harvested before and after laser therapy were 
conducted to investigate the cellular effect of laser irradiation combined with targeted particle 
therapy.  Tumors excised from representative xenograft mice were prepared and analyzed by H 
& E staining. Tissue staining showed healthy, well-vascularized tissues with no apparent cell 
damage.  After the first course of laser treatment (day 1), the tissue morphology remained 
unchanged with no significant cell damage (Figure 4-7).  It was after four courses of treatment 
(day 8), when substantial cell damage (nucleus damage) showing necrotized cells, initial stage of 
cytoplasmic acidophilia and nucleus shrinkage was observed.  This cell thermonecrosis of cells 
was progressively increased until the seventh treatment (day 14) where bundle-like tissues 
without cells were observed (Figure 4-7).  After 14-day therapy, histological examination 
confirmed that the combination of HNPs administered by either intratumoral (i.t.) or i.v. 
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injection followed by laser treatment caused significantly greater  cell necrotic,  corruption of 
cytoplasm and extracellular matrix than did PBS with laser treatment, or untreated group (Figure 
4-7 (a-f)).  In the positive control  group (I) treated with HNPs plus the laser, common features 
of thermonecrosis such as loss of nucleus, cell shrinkage, and coagulation were found in the 
tumor tissues where ∼ 65% of the tumor tissues were necrotized as was quantified by 
proportional of cells with intact nucleus( ImageJ, NIH).   In control group (III) treated with PBS 
plus laser, there was only a baseline fraction of necrosis in tumor tissue (< 5%) and there was 
little pyknosis or karyolysis, confirming the benign nature of laser treatment in the absence of 
heat-inducing HNPs agents (Figure 4-7).  Tissue extracted from mice with intratumoral HNPs 
injection plus laser treatment showed that almost all of the tumor tissue was necrotized, 
exhibiting pyknosis, karyolysis, cytoplasmic acidophilia, and degradation and corruption of 
tumor extracellular matrix. This set of experiment was critical in establishing the laser required 
for effective therapy following i.v. HNPs injection. Thus, selective in vivo photothermal 
destruction of the tumors mediated by HNPs was confirmed.  
It has been assumed that, in photothermal therapy, optical irradiation is absorbed and 
transformed into heat, inducing thermal denaturing of proteins (and DNAs) in the cell and 
coagulation of tissue and, consequently, causing irreversible damage to the targeted tissue 40 .  As 
can be seen in Figure 4-7, in the sample of the treatment group, extensive cellular injury was 
observed and the vessels were injured.  Various mechanisms account for heat-induced cell death.  
Specifically, heating up to 39 to 45oC may lead to the acceleration of biological reactions 
accompanied by the production of shock-heating proteins 41.  The heating process influences 
DNA polymerase, ligation enzyme and non-histone protein, which blocks DNA synthesis or 
RNA synthesis 42.  Heat also affects the physical properties of the membrane, especially 
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permeability and fluidity 43.  Heat-induced cell injury was also viewed as a systemic effect, 
including membrane blebbing, depolymerization of cytoskeletal filaments, thermal inactivation 
of membrane proteins and mitochondria, or increased production of heat.  
 
3. Conclusion 
In this report we have demonstrated targeting and localization of HNPs following 
intravenous injection where A33scFv has been proven to be an effective agent for active 
targeting. Next, the localized HNPs were used to demonstrate the photothermal therapy effect of 
HNPs upon near-IR irradiation to destroy solid subcutaneous colorectal tumors.  Histological 
analyses (H&E) revealed healthy and well-vascularized tumor xenografts before laser therapy.  
Particle localization was observed by near-IR fluorescence imaging at 12 h post-injection and 
confirmed by Perl’s Prussian tissue staining.  Following, laser therapy, ~65% necrotized cells 
were observed for control group treated with HNPs plus laser.  Laser therapy of tumors with 
were localized, thermal energy was generated from the optically excited HNPs enough to destroy 
tumors cells in a non-invasive manner.  Success of this site-specific cell killing relies on targeted 
delivery HNPs-A33scFv constructs into tumor xenografts as well as HNPs-mediated 
photothermal effect.  Additionally, we also showed that the HNPs would be an efficient non-
invasive MRI imaging in which the HNPs localization were observed in T2* magnitude and 
resulted in ~ 50% image darkening.  In summary, HNPs can act as an efficient photothermal 
therapy agent capable of inducing cell death and for non-invasive MR imaging. The combination 
of small size, strong absorption in the NIR region, and integration of the superparamagnetic iron 
oxide nanoaparticles into a single device makes HNPs ideally suited for theranostic applications 
(i.e., MR image-guided PTA therapy).  HNPs-scFv showed high uptake in SW 1222 human 
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colorectal xenografts as a result of enhanced permeability and retention effects and active 
targeting A33cFv.   
We believe our findings motivate future investigation into the long-term bio-distribution 
of HNPs, more extensive analysis of their potential toxicity in vivo, and the development of 
methods for detecting low concentrations of HNPs in whole animals to remotely quantify i.v. 
tumor targeting. Methods for actively targeting NRs to tumors, particularly to vascular epitopes, 
could potentially enhance their specificity for tumors or direct their additional accumulation in 
premalignant lesions and metastatic lymphatics. Finally, we provide clear evidence that the 
application of quantitative biodistribution-based modeling to the in vivo testing of nanomaterials 
can provide insight into their function and direct procedural optimization. 
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Figure 4-1:  Properties of HNPs functionalized with carboxylated phospholipids (DSPEG-COOH). 
(a)   TEM image showing the hybrid nanoparticles ( 6-18 nm) Au-Fe nanoparticles; (b) Zetasizer 
measurement showing average hydrodynamic particle size ca. 60 nm after functionalization ; (c) 
UV-vis-NIR spectra comparing the absorbance of HNPs-PEG to homofunctional Fe3O4 
nanoparticle.  
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Figure 4-2: HNPs fluorescence and temperature response properties. (a) Fluorescently-labeled HNPs 
showing appropriate emission at (em= λ750 )suggesting successful labeling; (b) Temperature change 
curves of the HNPs solution and the saline buffer exposed to the 808-nm laser at a power density of 5 
W/cm2.  Concentration-dependent temperature rise was noted for the HNPs solution, in marked 
contrast to the PBS temperature which showed little change during the laser irradiation. Temperature 
change curves of the HNPs-PEG solution and the water exposed to the 808 nm laser at a power 
density of 5.1 W/cm2. Rapid raise of temperature was noted for the HNPs-PEG solution, in marked 
contrast to the water temperature which showed little change during the laser irradiation. 
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Figure 4-3:  Tumor xenograft animal after intravenous injection with Alexa 750-labeled 
HNPs conjugates.   Time dependent images showing near-infrared fluorescence of murine 
model with subcutaneous tumors with SW 1222 cells (right flank) and HT 29 cells (left 
flank).  Images acquired after systemical injection of fluorescently-labeled HNPs-A33scFv 
labeled with near- infrared dye, Alexa Fluor 750. Images collected time intervals post 
injection (A) 5 min, (B) 30 min, (C) 90 min, (D) 24 hr, (E) 36 hr, and (F) intratumoral 
local injection of 20 µL of HNPs-A33scFv. The intratumoral particle accumulation is 
evident after 12 h while particles clearance was significant at 36 h post injection. 
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Figure 4-4:  In vivo T2 magnitude images of HNPs distribution in mice at 12 h after 
intravenous injection of HNPs-A33scFv conjugates.  The contrast enhancement of HNPs is 
shown on mice- bearing SW 1222 cells (right flank), HT 29 (left flank) colorectal cancer cells. 
Antigen-expressing tumor (right flank) appears darker due to the T2 enhancement compared to 
the tumor (hind left flank) as is shown on MR orientations (sagittal (i), coronal (ii), and axial 
(iii)). Dark spots are identified by T2 mapping as the accumulation of HNPs was indicated with 
crosshair; (b) tumor brightness as quantified using ITK-SNAP is where positive SW1222 
xenograft appeared 50% less bright compared to control (HT29 cells). 
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Figure 4-5:   Perl’s Prussian blue staining and histological analyses of SW1222 tumor xenografts 
before and after particle-injection. (a) Tissues after injection and localization of HNPs, blue 
stains signify the presence of HNPs-scFv resulting from active targeting localization (b) Tissues 
harvested after photothermal therapy, showing the presence of HNPs at reducing levels of iron 
due to clearance; (c) tissue harvested before systemic injection indicating the absence of blue 
stain or HNPs in tissue (control); (d) Comparative amounts of iron in the targeted tumor 
xenografts of SW1222 and HT29 cells as quantified by ImageJ (NIH). Scale bar 100 µm. 
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Figure 4-6 :  In vivo photothermal therapy application and effect of 808-nm laser on 
subcutaneous tumor xenografts. (a) Tumors on hind flanks treated with 808-nm laser after 
swapping with index matching polyethylene glycol solution; (b) representative tumor sizes 
harvested after 14 days post-irradiation of mice treated with HNPs plus NIR laser (group II), or 
untreated control (group II), or PBS plus NIR laser (group III); (c) time-dependent tumor growth 
curves of SW1222 tumor cell xenografts.  The tumor size was calculated as ab2/2 (a represents 
the longer dimension and b represents the shorter dimension of the tumor) where they were 
measured 24 hr after irradiation and continued for the duration of the therapy. The results are 
presented as the arithmetic means with standard deviations of tumor volumes in each group (n = 
3).  Error bars represent 95% confidence level (n = 3 mice per group). Asterisks indicate 
statistical significance relative to the untreated control (p = 0.006). Only HNPs plus NIR treated 
group (I) shows significant suppression of tumor growth compared with other experimental 
groups (n = 3). , p < 0.05, one-way ANOVA. 
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 Figure 4-7: Histological assessment of tumor tissues before and after photothermal therapy 
showing cell damage by H&E staining. (a) tumor harvested before therapy (day 1), showing 
healthy cells with well-defined nucleus, cytoplasm and extracellular matrix; (b) tissues from 
control  group II (untreated at end of therapy), showing healthy cells with apoptotic/necrotic 
cells possibly resulting from hypoxia; (c) xenograft samples from group I (HNPs plus laser) 
after third round of therapy,  showing nucleus shrinkage and slight corruption of extracellular 
matrix; (d) group I tumors after fourth treatment that show necrotized cells, initial stage of 
cytoplasmic acidophilia and nucleus shrinkage; (e) group I  after seven rounds of therapy 
showing over 65% necrotic cells as compared to untreated group, corruption of extracellular 
matrix and cytoplasmic acidophilia; (f) tissues from intratumoral plus laser treatment (two 
rounds), showing almost total cell necrosis, pyknosis,  and karyolysis with bundle-like 
structure left behind. Scale bar: 100 µm. 
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 In summary, the thesis has demonstrated rational design and utility of iron oxide and 
gold nanostructures for therapy and diagnostics (theranostic) applications.   We have shown the 
rational design of hybrid nanoparticles with both strong magnetic as well as optical properties 
that can be used to make a single device with multiple applications.  The most upstream research 
effort in this thesis, thus far, touched on investigation that ensured that the molecular targeting 
capabilities of colorectal cancer cells using A33 single chain antibody.  Cell culture experiments 
were initially used to validate A33scFv targeting capabilities which were followed by in vitro 
demonstration of photothermal therapy (Chapter 2).  More recently, we have also shown 
effective photothermal treatment in nude mice using subcutaneously grown colorectal cancer 
xenografts following successful particle localization after systemic injection (Chapter 4).  While 
these are significant results by their own, here are some further thoughts/ideas that would make 
this novel technology viable for future translational research.  In Chapter 4, particle localization 
in antigen-expressing SW 1222 xenograft tumors was confirmed by live-animal fluorescence 
imaging and by histological assessment of stained tissue samples after euthanizing the animal 
and tumor resection.  To fully understand the fate of particles and the potential in vivo toxicity, 
more studies are needed. 
To understand the fate of particles in vivo, bio-distribution studies are needed to 
investigate the time-dependent particle duration and half-life in blood and in the various organs.  
This study would be critical in addressing dosage and toxicity issues associated with the use of 
HNPs for therapy and diagnostics. In a typical experiment, xenograft mice tumors that are 
systemically injected with HNPs are sacrificed and the tissues samples of the following organs: 
kidney, liver, and bladder, spleen, and tumor samples are recovered and prepared for analyses.  
The organs are digested and appropriately prepared in order to extract embedded nanoparticles 
155 
 
whose concentration may be subsequently be determined by inductively coupled plasma mass 
spectrometry (ICP Mass Spec).  For example Vergoni al and coworkers 1 determined the 
concentration of nanoparticles following targeted and systemic injection of nanoparticles in 
murine models.Similar preparatory protocol would be used to characterize the bio-distribution 
properties of HNPs.  One major drawback to using ICP Mass Spec as analytical method to 
determine the amount of HNPs is that physiological in vivo systems (e.g. mice) already have 
high iron (Iron-56) content, the most naturally-occuring abundant iron isotope.  Consequently, 
the detection of localized or systemically-injected HNPs would be made more difficult because 
of a larger background noise from the endogenous Iron-56 already in blood and would introduce 
experimental error to the bio-distribution experiments.  This problem would be circumvented by 
synthesizing HNPs from a precursor of Iron-58, which is one of least abundant isotope also 
absent in the in vivo system.  The quantification of Iron-58 isotope recovered from blood samples 
or tissue samples can be performed using ICP-Mass Spec with detection limits as low as part per 
billion (ppb). 
 Another facile method that can used to study in vivo bio-distribution is positron emission 
tomography (PET) nuclear imaging technique.  Both the hybrid particles as well as gold 
nanorods possess peripheral carboxyl functional groups that can be used to attach radiolabeled 
with a positron-emitting tracer. Similar PET-based methods have been used to study bio-
distribution of quantum dots (QDs) in mice where dextran-coated QDs were labeled with 64Cu  
and subsequently used for in vivo PET imaging 2.  Other nuclear radiolabels such as Yttrium-90 
and Indium-111 labeled biomolecules have been frequently used for various bio-distribution and 
bio-stability studies 3-5.  For instance,  McDevitt et al. recently reported on the preparation of 
soluble Yttrium-86-labeled carbon nanotubes (CNTs) and subsequent PET imaging 6.  The 86Y-
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CNT constructs were synthesized from amine-functionalized, water-soluble CNT by covalently 
attaching multiple choices of DOTA chelates and then radiolabeling with the positron-emitting 
metal-ion, yttrium-86.  Using similar preparatory protocol, the carboxyl-terminated nanoparticles 
can be attached the PET tracers and used to study biodistribution  in vivo.  
We have reported our work in the rational design and the eventual in vivo hybrid 
nanoparticles (HNPs) application in Chapters 2 and 4.  In Chapter 3, we have begun the 
rational design of gold nanorods for potential in vivo photothermal therapy.  The one advantage 
of moving towards the use of gold nanorods for photothermal therapy is their strong near-IR 
absorption which would be ideal for in vivo phototherapy application.  We have shown effective 
photothermal therapy in targeted colorectal carcinoma cells in vitro.  Going forward, establishing 
xenograft models that can be used to validate their application in vivo is a rational next step. 
Once, in vivo localization as well as therapy application is validated, an interesting course of 
experimentation is making hybrid gold nanorods-iron oxide nanoparticles for potential 
theranostic applications.  In this work, gold nanorods can be designed to allow the attachment of 
smaller iron oxide nanoparticles, resulting in nanorods coated with small beads of iron oxide, 
forming multifunctional platforms.  These hybrid gold and iron nanostructures would be more 
efficient in photothermal therapy uses (higher NIR absorption) as well as stronger MR 
capabilities (owing to aggregation of iron oxide NPs around the gold NR structure).  In vivo 
particles localization as well as biodistribution studies can be performed in nude mice where the 
gold nanorod-iron oxide attached to targeting agents and/or radioisotopes used to study effects 
effects of targeting and the associated cytotoxicity. 
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Iron oxide nanoparticles and gold nanostructures (NPs and NRs) have been implicated for 
a myriad of other biomedical applications.  Beyond the scope of what have been discussed 
above, the nanostructures hold great potential for research and applications in the following areas 
  
I.  Particle-assisted heat induced therapeutic release 
We have demonstrated the use of hybrid nanoparticles as well as the use of gold nanorods 
for laser-assisted for photothermal therapy. These nanostructures act as local heating agents 
where near-IR irradiation (suitable for in vivo penetration) is used to induce cell death by 
hyperthermia.  Similar concept could be extended to the use of these nanostructures as a means 
for controllable or time-dependent drug release. In this case, temperature release would result in 
the degradation of temperature-sensitive drug capsule, resulting in controlled release of its 
content.  For example, a recent study showed the use of phothermal laser irradiation to 
controllably release a model drug (rhodamine) from a temperature-sensitive poly (lactic-co-
glycolic acid) (PLGA).  The polymer was conjugated to hybrid nanoparticles (Manganese/gold 
nanoparticles) and used for photothermal-triggered drug release as well for non-invasive MR 
imaging 7.  In much the same way, it is envisioned that the hybrid nanoparticles (HNPs) we have 
reported in this thesis can be conjugated to polymeric drug delivery system that disintegrates at 
higher temperature.  Once the hybrid nanoparticles have been targeted to select cells, laser 
irradiation can be used as an external remote to trigger drug release. 
 
II. Magnetic-driven Therapeutic Delivery and release 
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Another potential application of hybrid nanoparticles is for externally-guided therapeutic 
delivery to treatment of disease such as lung cancer.  We have demonstrated the 
superparamagnetic character of HNPs (Chapters 2 and 3) and this means that they respond to a 
magnetic field.  Superparamagnetic nanoparticles have recently been suggested and incorporated 
into drug delivery systems (DDS) to make ‘nanomagnetosols’ that can be remotely-guided using 
strong magnetic field 8.  For example, this DSS have become valuable tool in the delivery of 
aerosolized therapeutics. One example where this strategy has become prevalent in the delivery 
of aerosol used to treat lung cancer. In this particular application, aerosols encapsulated along 
with magnetic nanoparticles are targeted by an external magnetic before they are releasing its 
content where the DSS are disintegrated by heating with alternating magnetic field.  We envision 
that the hybrid particles reported in this thesis may also form valuable tool for a similar 
therapeutic application.  Again, using the hybrid particles provides an added advantage because 
they can also be used for diagnosis or imaging (MRI or CT imaging) following therapeutic 
delivery.   
 
III. Magnetic thermotherapy and  Imaging applications 
While we have reported the use of hybrid nanoparticles for multimodal laser-assisted cell 
therapy and as well for non-invasive MR imaging, these particles can be adapted for applications 
using other therapy and imaging modalities.  Depending on the availability of the therapy and 
imaging modality, the gold- iron oxide hybrid nanoparticles can potentially be used to induce 
cell death using external magnetic field.   In this case, iron oxide nanoparticle is used to generate 
heat using external magnetic fields 9. The localized temperature causes hyperthermia and the 
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leads to cell death.  Magnetic thermotherapy using iron oxide nanoparticles has been investigated  
for the treatment of prostate cancer 10, multiple sclerosis 9, for multimodal treatment of  
multiforme glioblastoma 11.  Once therapy applications are completed, the particles can be used 
for non-invasive visualization or MR imaging to monitor the efficacy of therapy applications. 
We envisioned that the hybrid nanoparticles, due to their strong magnetic properties, may be 
adapted for uses in thermotherapy applications. It may involve modifying the particle corona to 
allow attachment of targeting moieties that would increase cell-specific selectivity.     
 
IV. Thermotherapy and X-ray (CT) Imaging Applications 
The other imaging modality that has gained more interest for biomedical imaging is X- 
ray based computed tomography (CT) imaging.  CT imaging is one of the most useful diagnostic 
tools in hospitals today in terms of availability, efficiency, and cost.  Hybrid nanoparticles are 
partly composed of gold nanoparticle cores which are an ideal material for CT contrast agents 
because they possess high electron density.  In cases where MR imaging modality is too costly, 
the hybrid nanoparticles can be alternatively used as CT imaging agents due to presence of gold 
nanoparticle core.  CT distinguishes between different tissues based on the fact that different 
tissues provide different degrees of X-ray attenuation, where the attenuation coefficient is 
determined by the atomic number and electron density of the tissue; the higher the atomic 
number and electron density, the higher the attenuation coefficient.  Currently, it is not molecular 
imaging modality since relevant targeted and molecular specific contrast agents have yet to be 
approved for clinical use.  Present CT contrast agents are predominantly based on iodine 
containing molecules, which are effective in absorbing X-rays; however they are nonspecific 
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because they cannot be conjugated to biological components or cancer markers and allow only 
very short imaging times due to rapid clearance by the kidneys 12. 
 
V. Tissue regeneration Applications 
Due to the magnetic properties, hybrid nanoparticles can potentially be used for tissue 
regeneration applications. Magnetic-based nanoparticles have garnered as potential interest 
materials to enhance tissue regeneration of various types of cells.  For instance, iron oxide 
nanoparticles have been investigation for the treatment of osteoporosis which caused by 
reduction of bone mass and increases risk of bone fractures. Osteoporosis affects approximately 
44 million Americans  and osteoporosis-related bone fracture cost over $19 million yearly 13.  As 
a novel therapy method, recent research efforts have involved using magnetic nanoparticles 
coated with hydroxyapatite (HA) and to concentrate/ localize HA which is essential for bone 
regeneration 14. The magnetic NPs are used for magnetic-driven concentration in which an 
external magnetic field is placed in close proximity to the osteoporositic tissue.  
 
VI. Particle-assisted Photodynamic therapy 
 Nanostructures such as hybrid nanoparticles (HNPs) can also be used for photodynamic 
therapy (PDT) of diseased cells or tissues.  Photodynamic therapy (PDT) is a method of clinical 
treatment whereby diseased cells and tissues are destroyed by a combination of light and special 
drugs called photosensitizers (PS).  Additionally, the presence of adequate molecular oxygen in 
the tissue is also required 15.  In this thesis, we have demonstrated the use of both iron oxide-gold 
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nanoparticles for laser assisted photothermal therapy in which hybrid particles act as local 
heating agents.  In future research, the use particles may be extended to include uses for a novel 
therapy application - photodynamic therapy application.  Photodynamic therapy 16.  
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APPENDIX 1 
 
ADDITIONAL MOLECULAR STRUCTURES AND TEM MICROGRAPHS 
 
A.1. Molecular Structures of molecules for conjugation 
In order to make water-soluble nanoparticles that are suitable for in vivo applications, we 
have used functionalized poly (glycol ethylene) PEG phospholipids, which are amphiphilic in 
nature, to coat oleic acid-stabilized nanoparticles. The formation of these water-soluble particles 
involves hydrophobic-hydrophobic interaction between the oleic acid stabilizing the particle and 
the phospholipid moiety on the amphiphilic copolymer which ultimately lead to the formation of 
the reverse-phase micelles, which contain the hydrophilic layer on the peripheral ends.  In 
subsequent text, the molecular structures a number of PEG phospholipids and the formation of 
water-soluble will be shown. We prepared water-soluble nanoparticles by reverse-phase micelle 
formation using PEG-carboxyl phospholipid (DSPE-PEG (2000) carboxylic Acid, Avanti Polar 
lipids) as the capping agent.  Figure A1.1 shows a representative molecular structure of a 
PEG2000 phospholipid that was used to fabricate carboxyl-terminated nanoparticles described in 
 
Figure A1.1: Functionalized PEG-carboxyl phosphopholipid (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (ammonium salt) ) .  Molecular 
Formula C134H267N2O57P, Molecular weight = 2847.779 g mol-1. 
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Chapters 2 and 4.  By using this functionalization strategy, the resulting particles were 
aggregate-free, stable, and contain amine-reactive moieties which allowed facile attachment of 
biomolecules through lysine residues.  
There are other derivatives of functionalized phospholipids that are commercially 
available that allows facile attachment of molecules using simple chemistries.  For example, we 
have used amine-terminated PEG phospholipid (DSPE-PEG (2000) Amine, Avanti lipids) 
instead of carboxyl-terminated to prepare aminated nanoparticles that are reactive to carboxylic 
acid moieties (Figure A1.2).  Other functionalities that are available through Avanti lipids 
include: Maleimide, biotin, folate, and cyanur-terminated PEG phospholipids 1.  
 
 The surface charge on the nanoparticles is one of the critical consideration that affect 
particle bio-distribution, cellular uptake, circulation, and blood half-life.  To modulate the zeta 
potential or surface charge, we have used mPEG2000 (PEG 2000 PE, Avanti Lipids) as a 
component in mixture of functionalized phospholipids (Figure A1.3).  Compared to PEG-COOH 
(negatively charge) and PEG-NH2 (positively charged), mPEG2000 are neutrally charged and 
can be used as mixtures of functionalized phospholipids to control surface charge.  For instance, 
 
Figure A1.2: Functionalized PEG- amino phospholipid (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine -N-[amino(polyethylene glycol)-2000] (ammonium salt)). Molecular 
Formula C132H266N3O54P; Molecular weight 2788.790  g mol-1. 
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we have prepared particles with negligible surface charge by mixing mPEG and PEG-COOH 
phospholipids in the mol ratios of 7:3 where 1: 2.5 mol ratios of particles to total phospholipid 
concentrations were used.   
 
Anot 
 
 
 
 
 
 
A.1.2. Reverse-phase Encapsulation of Oleic acid-coated Nanoparticles 
The preparation of micelle-like particles using the phospholipids which has been 
described previously involved reverse-phase encapsulation of oleic acid-coated nanoparticles 
(suspended in chloroform). The particles were mixed with phospholipid PEG-COOH, and the 
mixture was sonicated, dried by evaporation, and eventually rehydrated in water.   
Figure A1.4 shows schematic representation of this process. Additionally, the Figure 
depicts the interactions and forces that stabilize the particles and the peripheral functional groups 
that are used for the attachment of other molecules e.g. antibodies, fluorophores, and 
chemotherapeutics.  
 
 
 
 
Figure A1.3: PEG phospholipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (ammonium salt)). Molecular formula = C133H267N2O55P; 
Molecular weight = 2803.789 g mol-1.  
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Figure A1.4:  Encapsulation of nanoparticles using phospholipids PEG-COOH to form stabile, 
water soluble particles. (A) Schematic showing reverse-phase encapsulation of Fe3O4 in 
amphiphilic copolymers to form micelle-like particles, (B) Fe3O4-stabilized by oleic acid or oleate 
which form hydrophobic particles soluble in chloroform (CHCl3), (C) Water-soluble NPs with 
carboxyl groups which allows facile attachment of biomolecules. 
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A.1.3. Transmission Electron Microscopy Images of Hybrid Nanoparticles 
 
 We have prepared hybrid Au-Fe3O4 nanoparticles for potential uses in therapy and 
imaging (theranostics) applications. We have demonstrated in vitro therapy and imaging 
applications (Chapter 2) and more recently we have further demonstrated their in vivo 
theranostic applications (Chapter 4). Below are TEM and high resolution (HR-TEM) that 
revealed the formation of peanut-shaped as well as dumbbell-like particles with dual magnetic as 
well as optical properties.   
 
 
 
Figure A1.5: Transmission electron microscopy (TEM) images of dumbbell-like particles.  Particles 
preparation was reported previously in Chapters 3 and 4.  (A) TEM micrographs showing monodispersed 
Au-Fe3O4 NPs; (B), (C) High resolution(HR) TEM micrographs showing variations of Au: Fe3O4 ratios.  
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